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1 Zusammenfassung 
Viele hochaktive Zytostatika sind zurzeit für die systematische chemotherapeutische 
Anwendung nicht einsetzbar, weil ihr Eintritt ins Gehirn durch die Blut-Hirn-Schranke 
(BHS) blockiert wird.  Die Entwicklung einer Möglichkeit zum Transport dieser Stoffe über 
diese Schranke würde das Potenzial einer systemischen Chemotherapie bedeutend erhöhen. 
 
Chemotherapie von Glioblastomen mit Doxorobicin beladenen Nanopartikeln 
In früheren Studien wurde gezeigt, dass die Überlebenszeiten von Ratten mit ins Gehirn 
transplantierten 101/8 Glioblastomen durch mit Polysorbat 80 überzogenen Doxorubicin-
Nanopartikel signifikant verlängert werden können.  Ziel der vorliegenden Studie war es, die 
Effizienz dieser Doxorubicin-beladenen Nanopartikel mit morphometrischen, histologischen 
und immunohistologischen Methoden zu untersuchen, um so die Tiere weniger zu belasten 
als das in Letalitätsstudien erfolgt.  Das 101/8 Glioblastom wurde dazu intrakranial 
männlichen Wistar-Ratten implantiert.  Die Ratten wurden randomisiert in drei Gruppen 
geteilt: die erste Gruppe erhielt keine Behandlung (Kontrolle, n = 20),  die zweite Gruppe 
wurde mit Doxorubicin-Lösung (Dox-sol, n = 18) und die dritte Gruppe mit Polysorbat 80-
überzogenen Doxorubicin-Nanopartikeln (Dox-NP + PS 80, n = 18) behandelt. 
Die Versuchstiere erhielten die Doxorubicin-haltige Zubereitung an den Tagen 2, 5 und 8 
nach Tumorimplantation als Injektion in die Schwanzvene.  Die Dosierung wurde an das 
Körpergewicht der Tiere angepasst und betrug 3 × 1,5 mg/kg Doxorubicin. 
Die Tiere der Kontrollgruppe wurden an den Tagen 6, 8, 10, 12, und 14 nach der 
Tumorimplantation getötet und ihre Gehirne entnommen.  Die Gehirne der Ratten, die die 
Doxorubicin-Zubereitungen erhielten, wurden an den Tagen 10, 14, und 18 nach der 
Implantation entnommen.  Die Rattenhirne wurden histologisch auf folgende Merkmale hin 
untersucht: Tumorgröße, Zellproliferation, Gefäßdichte, Expression des sauren 
Gliafaserproteins (GFAP, Glial Fibrillary Acidic Protein), Expression des vaskulären 
endothelialen Wachstumsfaktors (VEGF, Vascular Endothelia Growth Factor), Häufigkeit 
und Ausmaß des nekrotischen Areals und mikrovaskuläre Proliferation. 
Die Tumore zeigten die Zeichen von Malignität wie z.B.  Invasion in das Gehirngewebe und 
rasche mitotische Aktivität.  Die Tumorproliferation blieb auf hohem Niveau stabil.   
   Zusammenfassung 
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Insgesamt war der Tumor durch ein reproduzierbares Wachstumsmuster gekennzeichnet und 
in seiner  Entwicklung einem menschlichen Glioblastom vergleichbar und durch eine diffuse 
Infiltration des Gehirn charakterisiert.  Das umliegende Gehirngewebe wies an den Grenzen 
des soliden Tumors keine Zeichen von Verkapselung auf. Somit erfüllt das 101/8 
Glioblastom dementsprechend Kriterien für ein zuverlässiges, menschlichen Tumoren 
adäquates Glioblastom-Modell. 
Dox-NP + PS 80 zeigten im Vergleich zu Dox-sol und der Kontrollgruppe eine deutliche 
Antitumoraktivität, wie eine verkleinerte Tumorgröße, niedrige Proliferationsraten und 
kleine nekrotische Flächen.  Diese Ergebnisse korrelierten mit einer vorherigen 
Letalitätsstudie (Steiniger 2004) bei der im gleichen Glioblastom-Modell mehr als 20% der 
Tiere, die mit diesen Nanopartikeln behandelt wurden, eine Langzeitremission zeigten.  Der 
Behandlungseffekt mit den Nanopartikeln im Vergleich zur Behandlung mit Doxorubicin-
Lösung oder der unbehandelten Kontrollgruppe wurde durch verminderte Gefäßdichte, 
Abnahme der VEGF-Expression und durch das Fehlen von mikrovaskulärer Proliferation 
aufgezeigt.  Die drastische Wirkung von Dox-NP + PS 80 auf die Vaskularisierung ist 
vermutlich auf die zytotoxische und darüber hinaus auf eine anti-angiogenetische oder 
Wirkung von Doxorubicin zurückzuführen. 
 
Verkapselung von schlecht wasserlöslichen Arzneistoffen in Poly(butylcyanoacrylat)-
Nanopartikel (PBCA-NP) 
Die Entwicklung von parenteralen Zubereitungen mit schlecht wasserlöslichen Arzneistoffen 
stellt eine große Herausforderung dar.  In diesen Präparaten wurden die Arzneistoffe bisher 
meist in nichtwässrigen, organischen Lösungsmitteln gelöst.  Diese Lösungen wurden meist, 
aber nicht immer, unmittelbar vor der Anwendung mit wässrigen Medien verdünnt (Strickley 
2004).  Die meisten dieser Vehikel sind nicht innert und können während der Therapie eine 
Vielzahl von Nebenwirkungen oder Arzneistoffwechselwirkungen hervorrufen.   
Die Nanopartikeltechnologie stellt eine vielversprechende Methode dar, den 
Arzneistoffgehalt in einem wässrigen Medium zu erhöhen und damit die in-vivo-Effizienz zu 
optimieren.  Dementsprechend wurde in diesem Teil der vorliegenden Studie die Effizienz 
dieser Methode unter Verwendung von Poly(butylcyanoacrylat)-Nanopartikeln und den 
beiden hydrophoben Arzneistoffen Loperamid und Paclitaxel untersucht.  Für diesen Zweck   Zusammenfassung 
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wurde das Standardprotokoll für die Herstellung von Nanopartikeln so modifiziert, dass 
Arzneistoff-beladene Nanopartikel in einem Gemisch aus wässrigem Medium und 10% (v/v) 
organischem Lösungsmittel durch anionische Emulsionspolymerisation von 
Butylcyanoacrylat (BCA) hergestellt und das Lösungsmittel später entfernt werden konnte.  
Das Lösungsmittel wurde je nach Arzneistofflöslichkeit ausgewählt.  Die Nanopartikel 
wurden mit Dextran 70.000, Poloxamer 188 oder 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamin-N-[methoxy(polyethylene  glycol)-5000]-Natrium-Salz (PEG-PE) 
stabilisiert.  Das Polymerisationsmedium bestand aus einer Stabilisator-Tensid-Mischung in 
0,01 N HCl und einem geeigneten organischen Lösungsmittel im Verhältnis 1:9.  Die 
Anwesenheit von organischen Lösungsmitteln im Polymerisationsmedium beeinflusste die 
physikochemischen Eigenschaften von unbeladenen Nanopartikeln nicht.  Es konnte gezeigt 
werden, dass sich in Anwesenheit von Dichlormethan, Methanol oder Ethanol die Effizienz 
der Einbettung von Loperamid in Nanopartikel bis zu 80% erhöhte.  Die Loperamid-
beladenen Nanopartikel wurden zusätzlich mit 1% Polysorbat 80 überzogen. 
Wie in den Veröffentlichungen von Alyautdin et al. (Alyautdin 1997) beschrieben, wurde 
diese Zubereitung mit und ohne Coating Mäusen injiziert und der analgetische Effekt mittels 
des Tail-Flick-Tests bestimmt.  Als Kontrolle wurde eine Loperamidlösung verwendet.  Der 
Arzneistoff Loperamid gehört zur Klasse der Opioide, besitzt aber wegen der Effluxaktivität 
der Pgp-Pumpe keine Gehirngängigkeit und keine zentral-analgetischen Effekt.  Wie 
erwartet wies die Loperamidlösung deshalb dementsprechend keinen derartigen Effekt auf.  
Im Gegensatz dazu erzeugten die Polysorbat 80-überzogenen Loperamid-Nanopartikel und 
auch die nicht-überzogenen Loperamid-Nanopartikel einen deutlichen analgetischen Effekt.  
Unsere Ergebnisse zeigten darüber hinaus, dass auch Poloxamer 188 einen Transport von 
Arzneistoffen über die BHS ermöglicht. 
Die Beladung von PBCA-NP mit Paclitaxel war auch in Anwesenheit eines 
Stabilisatorgemisches aus Dextran und Poloxamer 188 relativ niedrig (~ 25%).  Der 
Höchstwert der Beladung wurde in Anwesenheit von PEG-PE (~ 45%) erreicht, und die 
Effizienz der Verkapselung konnte bis auf 55 µg/mg PBCA-NP gesteigert werden.  Dieses 
Ergebnis korreliert mit den Ergebnissen von Mitra and Lin et al. (Mitra and Lin 2003).  Es 
wurde vermutet, dass dies auf die bessere Löslichkeit von Paclitaxel durch Einschluss in 
PEG-PE-Mizellen und/oder die Affinität dieser Mizellen zur Nanopartikelmatrix   Zusammenfassung 
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zurückzuführen ist.  Paclitaxel ist ein Pgp-Substrat, weswegen die Penetration ins ZNS nach 
einer systemischen Applikation für die Therapie nicht ausreichend ist.  Das Ziel war es zu 
untersuchen, ob mit Polysorbat 80- oder Poloxamer 188 (F68)-überzogene Nanopartikel es 
ermöglichen, Paclitaxel über die BHS zu transportieren.  Deshalb wurde die 
Antitumoreffizienz von drei Paclitaxel-Zubereitungen ebenfalls in den 101/8 Gehirntumor-
tragenden Ratten untersucht.  Die verwendeten Formulierungen waren Paclitaxel-beladene 
PBCA-Nanopartikel (PXL-NP), mit Polysorbat 80 überzogene PXL-NP (PXL-NP + PS 80) 
und mit Poloxamer 188 überzogene PXL-NP (PXL-NP + F68).  Unbehandelte Ratten und 
Ratten, die mit der Paclitaxel-Lösung behandelt worden waren, wurden als Kontrolle 
eingesetzt. 
Wegen der niedrigen Paclitaxel-Beladung der Nanopartikel konnte die empfohlene 
Dosierung von Paclitaxel (17,80 mg/kg (Fetell 1997, FDA)) nicht eingehalten werden.   
Deshalb wurden diese Paclitaxel-Zubereitungen in der gleichen Dosierung wie Doxorubicin 
appliziert (3 × 1,5 mg/kg an den Tagen 2, 5 und 8 nach Tumorimplantation).  Keine der 
Paclitaxel-Zubereitungen konnte die Überlebenszeit im Vergleich mit der Kontrolle 
verbessern, was an der niedrigen Dosierung und der kurzen Behandlungsdauer liegen könnte.  
 
Apolipoprotein A-I- und B-100-modifizierte Albumin-Nanopartikel zur Überwindung 
der Blut-Hirn-Schranke 
Apolipoprotein A-I und B-100 wurden kovalent durch den NHS-PEG-Mal 3400-Linker an 
HSA Nanopartikel (HSA-NP) gebunden.  Loperamid wurde als Model-Arzneistoff an die 
Nanopartikel adsorbiert und Mäusen injiziert und der analgetische Effekt mittels des Tail-
Flick-Tests bestimmt.  Nach 15 Minuten wiesen beide Nanopartikel-Zubereitungen, an die 
Apolipoprotein A-I oder B-100 gebunden worden war, starke analgetische Wirkungen auf, 
die bis zu einer Stunde dauerten.  Die MPE-Werte („maximal possible effect“-Wert) der 
Zubereitungen betrugen ca. 65% beziehungsweise 50% und waren statistisch unterschiedlich 
verglichen mit den beiden Kontrollen (unmodifizierte, Loperamid-beladene Nanopartikel 
und Loperamidlösung).  Letztere hatten keine Wirkung.  Das Ergebnis zeigte auch, dass 
mehr als ein Mechanismus der Interaktion der Nanopartikel mit den Endothelzellen des 
Gehirns existiert, welcher im Folgenden dann einen Transport der Arzneistoffe ins ZNS 
ermöglicht.  Apolipoprotein B-100 kann über Lipoprotein-Rezeptoren durch die BHS   Zusammenfassung 
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transportiert werden, Apolipoprotein A-I ermöglicht dies über SR-BI (Scavenger-Rezeptor), 
der auch in der BHS lokalisiert ist. 
 
Thalidomid-beladene Human-Serumalbumin-Nanopartikel (Thal-HSA-NP) 
Thalidomid ist ein antiangiogenetischer Arzneistoff mit schlechter Wasserlöslichkeit, der 
meistens oral verabreicht wird.  Dennoch wäre die parenterale Anwendung in besonderen 
klinischen Situationen zu bevorzugen, wie z.B. bei schwacher Darmabsorption oder bei 
durch Chemotherapie verursachter Übelkeit. 
Das Ziel dieses Teils der Arbeit war es, eine injizierbare Zubereitung auf Human-
Serumalbumin-Nanopartikel-Basis zu entwickeln.  Wie bereits früher berichtet wurde, ist die 
Thalidomidlöslichkeit in Wasser und in 5% Glukoselösung nur 52 µg/ml beziehungsweise 
70 µg/ml (Eriksson 2000).  Es konnte nun in der vorliegenden Arbeit gezeigt werden, dass 
die Thalidomidmenge in einer Zubereitung durch Bindung an die Nanopartikel verachtfacht 
werden konnte und die Thalidomidkonzentration in der Nanopartikelsuspension bis zu 400 
µg/ml betrug.  In dieser Studie wurde zum Vergleich zusätzlich der Einfluss von Hilfsstoffen 
auf die Thalidomidlöslichkeit untersucht.  Die Lösungen beinhalteten: 5% Glukose, 10% 
Polysorbat 80, 10% Poloxamer 188 oder Cremophor
® EL-Ethanol (51:49).  Thalidomid 
wurde als Racemat eingesetzt.  In keiner dieser Lösungen war jedoch die 
Thalidomidlöslichkeit höher als in der Nanopartikelzubereitung.  
Die Antitumoraktivität von unmodifizierten Thalidomid-beladenen HSA-NP (Thal-HSA-NP) 
und von mit Polysorbat 80-überzogenen Thal-HSA-NP (Thal-HSA-NP + PS 80) wurden 
sodann in 101/8 Gehirntumor-tragenden Ratten ermittelt.  Die Wirkungen dieser 
Zubereitungen wurden mit einer oralen Zubereitung verglichen.  Unbehandelte Tiere dienten 
als Kontrollgruppe.  Die Nanopartikel wurden intravenös appliziert.  Im Vergleich zu den 
Kontrollgruppen hat jedoch keine dieser Zubereitungen eine Wirkung auf die Verlängerung 
der Rattenüberlebenszeit gezeigt.  Dieses Ergebnis lag vermutlich an der niedrigen 
Dosierung und dem unadäquaten Dosierungsplan. 
 
Verkapselung von Diindolylmethan in Polymilchsäure-Nanopartikel 
3,3’-Diindolylmethane (DIM) gehört zu den Indolalkoloiden von Kreuzblütlern und besitzt 
eine Wirksamkeit gegen Krebs, besonders bei Estrogen-abhängigen Tumoren (Chen 1998).    Zusammenfassung 
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Der Nachteil von DIM ist seine schlechte Wasserlöslichkeit.  Zudem ist DIM 
lichtempfindlich und produziert farbige Abbauprodukte.  Allerdings behalten diese Produkte 
trotz ihres farbigen Aussehens ihre Wirkung.  Das Ziel in diesem Arbeitsteil war es zu 
untersuchen, ob sich die Wasserlöslichkeit von DIM und die Lichtstabilität durch die 
(Poly[Lactid-co-Glycolid]-Nanopartikel (PLGA-NP)) verbessert.  Die Verkapselung von 
DIM in PLGA-NP ergab eine wesentlich verbesserte Zubereitung:  DIM-Gehalt wurde 600-
fach erhöht und DIM konnte gegen die Farbveränderungen geschützt werden.    Theory 
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2 Theory: Drug delivery to the brain by nanoparticles 
The brain is one of the least accessible organs for the delivery of drugs due to the presence of 
the blood-brain barrier (BBB) formed by the cerebral capillary endothelial cells.  The BBB 
provides the neuroprotective function against harmful substances in the blood stream, while 
supplying the brain with the required nutrients for a proper function (Begely 2000).  
The existence of such a barrier was first noticed by Paul Ehrlich in the late 19th century.  In 
1900, Lewandowsky suggested a presence of the mechanical membrane which separates the 
blood from the brain and, therefore, limits the central nervous system (CNS) action of some 
intravenously administered drugs (Zlokovic 2008).  This theory was further expanded by 
Goldmann (1909, 1913) who administered a dye, trypan blue, to stain the brain and spinal 
cord tissue.  It was suggested that such a barrier did not exist between the cerebrospinal fluid 
(CSF) and the brain.  Electron microscopy (EM) studies with ferritin and horseradish 
peroxidase have shown that the BBB is localised at the level of tight junctions (TJ) between 
adjacent brain endothelial cells (BEC) (Reese and Karnovsky, 1967; Brightman and Reese, 
1969).  Later, the definition of the BBB has changed from being an impermeable barrier to a 
highly specialised and diverse transport system for chemically well-defined substrates 
(Zlokovic 2008).  
 
2.1 Structure of the blood-brain barrier 
The BBB limits transport into the brain through both, physical (tight junctions) and 
metabolic (enzymatic) barriers (Zlokovic 2008, Begley 2003a). 
 
2.1.1 Physical barrier: Tight junctions 
At the physical level, the BBB is composed of a tightly sealed monolayer of the BEC closely 
joined to each other by tight junctions, thus forming a continuous cellular membrane which 
restricts the transport of molecules from the blood to the brain interstitial fluid (BISF) and 
vice versa (Zlokovic 2008).  
   Theory 
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The tight junction consists of the three integral membrane proteins, claudin, occludin, and 
junctional adhesion molecule (JAM) which together with several peripheral proteins 
constitute the junctional complex (Figure 1).  
A number of peripheral proteins, regarded as scaffolding or linkers for the integral molecules 
of the tight junction in endothelia and epithelia, form a cytoplasmic plaque adjacent to the 
junctional cell membrane.  The plaque proteins are a part of the tight junction complex and 
include the guanylate kinases such as ZO-1 (220 kDa), ZO-2 (160 kDa) and ZO-3 (130 kDa). 
Another plaque protein is cingulin (140 kDa), which is myosin-like and binds to the ZO 
complex and to F-actin of the cytoskeleton (Begley 2003b). 
 
 
Figure 1. Simplified illustration of the molecular composition of the tight junctions (TJ) and adherent junction 
(AJ); The TJ proteins are occludin, claudins, zonula occludens (ZO)-1, ZO-2, ZO-3, cingulin, 7H6.  The AJ are 
composed of cadherins, catenins, and p120 (Kniesel 2000). 
 
2.1.2 Neurovascular units/cells associated to the BBB 
Pericytes are distributed discontinuously along the length of the capillaries and partially 
surround the endothelium.  The cerebral endothelial cells and the pericytes are surrounded by 
the same extracellular matrix (basement membrane).  Foot processes from astrocytes form a 
network fully covering the capillaries.  Axons from neurons also abut closely against the 
endothelial cells and contain vasoactive neurotransmitters and peptides.  Microglias 
(perivascular macrophages) are the resident immunocompetent cells of the brain and they are 
derived from systemic circulating monocytes and macrophages (Begley 2004) (Figure 2). 
   Theory 
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Figure 2. Schematic diagram of the neurovascular unit/cell association forming the BBB; Tight junctions and 
pericytes are surrounded by extracellular matrix.  Foot processes from astrocytes and axons are closely against 
the endothelial cells.  Microglias are the resident immunocompetent cells of the brain (Begley 2004). 
 
The cell membrane of the endothelial cell has a uniform thickness, with very few pinocytotic 
vesicles (hollowed out portion of the cell membrane filled with fluid, forming a vacuole 
which allows for nutrient transport), and it also lacks fenestrations (i.e. openings).   
Therefore, the transit across the BBB involves translocation through the capillary 
endothelium, the internal cytoplasmic domain, and then through the abluminal membrane 
and pericyte and / or basal lamina (Cucullo 2005). 
The cerebral capillary endothelial cell possesses a higher number and volume of 
mitochondria than the general body capillary cells suggesting that the enhanced cerebral 
capillary work capacity may be related to the energy-dependent transcapillary transport 
(Oldendorf 1977). 
 
2.1.3 Metabolic barriers: Enzymes 
The enzymatic barriers at the cerebral endothelia are capable of metabolising many drugs 
and solutes as they pass through the BBB. 
The barriers contain active phase 1 (cytochromes P450, flavin-dependent oxygenases, 
monoamine oxidases, reductases, hydrolases) and phase 2 enzymes (conjugating enzymes, 
sulphotransferases, GSH-transferases, UDP-glucuronosyltransferases) (Begely 2003b).    Theory 
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There are a number of enzymes specific for the brain capillaries.  Enzymes such as γ-
glutamyl transpeptidase (γ-GTP), alkaline phosphatase, and aromatic acid decarboxylase are 
present in the cerebral microvessels in elevated concentrations; yet in the non-neuronal 
capillaries the concentrations of these enzymes are either low or absent.  The presence of γ-
GTP and alkaline phosphatase enzymes at the luminal side of endothelium and functioning 
of the Na
+-K
+-ATPase and the sodium dependent (A-system) neutral amino acid transporter 
at the abluminal portion of the endothelium give the membrane surface of the endothelium a 
polarity feature. 
Structural, pharmacological, and biochemical evidence for luminal and abluminal 
polarization of receptors, enzymes, and channels at the cerebral endothelia (Vorbrodt 1993) 
establish the BBB to be a working non-stagnant membrane unequivocally evolved to 
maintain brain homeostasis.  
 
2.2 Transport across the blood-brain barrier 
2.2.1 Cell migration 
Under normal physiological condition, lymphocyte traffic into the CNS is very low and 
tightly controlled by the BBB.  In contrast, under inflammatory conditions of the CNS, such 
as multiple sclerosis, circulating lymphocytes and monocytes/macrophages readily cross the 
BBB and gain access to the CNS leading to edema, inflammation and demyelination. 
Passage across endothelium must be preceded by temporary adhesion of the lymphocytes to 
the endothelium by way of cell adhesion molecules expressed on both, immunocytes and 
endothelium (Figure 3a).  Immunocytes migrate across CNS endothelium both, 
paracellularly and transcellularly (Begley 2003b). 
 
2.2.2 Passive diffusion 
The passive diffusion proceeds from low to high concentrations.  Simple diffusion is a 
spontaneous process depending on random movement of the solutes (Figure 3b).  Some of 
the lipophilic substances (alcohol, narcotics, and anticonvulsants) can diffuse passively 
through the endothelial cell membrane and enter the CNS (Begley 2003b).    Theory 
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2.2.3 Carrier-mediated efflux 
Active efflux pumps such as the ATP-binding cassette (ABC) transporters, P-glycoprotein 
(Pgp), multidrug resistance associated protein (MRP), multi-specific organic anion 
transporter (MOAT), and breast cancer resistance protein (BCRP) represent the principle 
efflux mechanisms which transport a wide range of compounds out of the CNS.  The ABC 
transporters are able to hydrolyse ATP which provides the energy for moving the substrates 
against a concentration gradient and opposing their natural tendency to partition into the lipid 
of the cell membrane.  Pgp is the most important ABC transporter expressed at the apical 
surface of the choroid plexus.  Pgp is involved in extruding many of the drug molecules from 
the brain.  These drugs are mainly large planar molecules such as steroids and glucuronides 
(Cordon-Cardo 1989) (Figure 3c).  
 
2.2.4 Carrier-mediated influx 
Carrier-mediated transport at the BBB contributes to the transport of many necessary polar 
metabolites and nutiernts which they can carry into the CNS by transporters. Some polar 
substances such as monocarboxylates, hexoses, amino acids, nucleoside, glutathione, and 
small peptides are transported in this way. Carrier-mediated influx can be passive or 
secondarily active.  Some of these transporters are expressed in both, the luminal and 
abluminal membranes of the cerebral endothelial cells (Figure 3d). 
 
2.2.5 Vesicular transport 
Viruses and some solutes such as peptides and proteins are transported across the cells by 
vesicular transcytosis.  Transcytosis begins as a microinvagination of the cell membrane to 
form a caveola (pit) which later would pinch off and migrate to the opposite side of the cell 
membrane.  The free vesicle then would fuse and release its contents into the periendothelial 
basal lamina (Begely 2003b). 
   Theory 
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2.2.5.1 Absorptive-mediated transcytosis (AMT) 
Absorptive-mediated transcytosis is a nonselective, slow process by which endothelial cells 
endocytose macromolecules nonspecifically bound to the luminal surface, with subsequent 
discharge to the perivascular space.  Substances using this pathway include positively 
charged proteins that interact with negative electric charges of the endothelial membrane and 
accumulate on the membrane surface of the endothelial cells (Abbott 1996) (Figure 3f). 
 
2.2.5.2 Receptor-mediated transcytosis (RMT) 
The receptor at the apical plasma membrane of the endothelial cell binds to a circulating 
ligand (Figure 3e).  Once the receptor binds to the ligand, the process of endocytosis is 
initiated as the receptor–ligand complexes cluster and then the membrane invaginates.  This 
leads to the formation of intracellular transport vesicles.  Brain influx of nutrients such as 
iron, insulin, and leptin occurs by a transcellular receptor-mediated transport mechanism 
known as transcytosis (Brown 1991). 
 
2.2.6 The role of tight junctions 
The tight junctions between the BBB endothelial cells have a higher endothelial electrical 
resistance, in the range of 1500 - 2000 Ω × cm
2 (pial vessels), as compared to 3 - 33 Ω × cm
2 
in the other tissues.  The net result of this elevated resistance is a low paracellular pathway. 
The tight junction effectively blocks an aqueous route of free diffusion for polar solutes from 
the blood and prevents these solutes from free access to the brain interstitial (extracellular) 
fluid. 
As assessed in vitro by the passive flux or extracellular probes such as albumin or inulin, the 
phosporylation of the proteins constituting the tight junctions enhances their permeability. 
Moreover, extracellular signals can influence the permeability of the tight junctions by the 
cytoskeleton (Begley 2003b) (Figure 3g). 
 
Potential routes for transport across the BBB are schematically presented in Figure 3.   Theory 
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Figure 3. Potential routes for transport across the BBB.  (a) Leukocytes may cross the BBB adjacent to, or by 
modifying, the tight junctions.  (b) Solutes, especially those with lipophilic properties may passively diffuse 
through the cell membrane and cross the endothelium.  (c) Active efflux carriers may intercept some of these 
passively penetrating solutes and pump them out of the endothelial cell.  (d) Carrier-mediated influx, which 
may be passive or secondarily active, can transport many essential polar molecules such as glucose, amino 
acids, and nucleosides into the CNS.  (e) RMT can transport macromolecules such as peptides and proteins 
across the cerebral endothelium.  (f) AMT appears to be induced nonspecifically by charged macromolecules 
can also result in transport across the BBB.  (g) Tight junction modulation may occur, which relaxes the 
junctions and wholly or partially opens the paracellular aqueous diffusional pathway (taken from Begley 
2003a).  
 
2.3 Drug delivery to the CNS 
Many potentially active drugs are not able to enter the CNS in sufficient quantity to be 
effective.  In general, diffusion across the BBB is only feasible for lipophilic molecules 
(<500 Da) with fewer than five hydrogen bonds via lipid-mediated diffusion.  However, 
accumulation of these molecules in the brain is often restricted due to the ABC efflux 
transporters, such as Pgp or MRP (section 2.2.3).  
A route for drugs delivery into the CNS via the olfactory epithelium is another possibility for 
some type of drugs.  However, a significant fraction of this fluid appears to re-circulate back 
into the subarachnoid CSF and may carry the drug applied to the olfactory mucosa back into 
the subarachnoid space of the CNS (Begley 2003b).   Theory 
 
   
23   
  
The strategies employed to facilitate the drug transport to the CNS are described below. 
 
2.3.1 Craniotomy-based drug delivery 
Several strategies employ craniotomy-based drug delivery, including either intraventricular 
drug diffusion or local intracerebral implants (Begely 2004).  
Although these procedures can significantly increase drug levels in the brain, all of them are 
highly invasive.  In addition, the craniotomy-based drug delivery relies on diffusion from the 
local depot sites; since diffusion decreases with the square of the diffusion distance, the 
effective treatment volume is often limited (Pardridge 1999).  Indeed, the diffusional 
distance that can be reached in the brain using such systems does not exceed 5 mm whereas 
tumour areas beyond this distance remain unattainable (Roullin 2002). 
 
2.3.2 Disruption of the BBB 
The rate of extravasation of the systemically administered drugs into the brain parenchyma 
can be enhanced by an osmotic opening of the BBB (Misra 2003).  
The osmotic opening was developed initially for the patients with rapidly growing high 
grade gliomas.  Intracarotid injection of an inert hypertonic solution such as mannitol or 
arabinose or vasoactive agents such as bradykinin (Bonstelle 1983, Nomura 1994) has been 
employed to initiate endothelial cells shrinkage and opening of the BBB tight junctions for a 
period of a few hours (Misra 2003).  
 
The above approaches are most suited to short-term treatments, where a single or infrequent 
exposure to a drug is required.  The determination of the therapeutic drug levels after 
disrupting of the BBB showed that the drug accumulated in the tumour core, but it was 
absent at its growing margins.  Accordingly, the therapeutic drug levels could be found in 
necrotic tumour areas, while in peritumoural regions the drug levels were markedly lower or 
non-detectable (Donelli 1992). 
   Theory 
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2.3.3 Chemical modification of the drug 
The CNS penetration is feasible for substances characterised by low molecular weight, lack 
of ionisation at physiological pH, and lipophilicity.  Synthesising a hydrophobic analogue of 
small hydrophilic drugs is a strategy.  This strategy has been frequently employed, but the 
results have often been disappointing due to an unexpected toxic effect of the new 
hydrophobic analogue (Misra 2003).  Additionally, the new lipophilic compounds are often 
potential substrates for the ABC efflux transporters. 
Another approach for the delivery to the CNS is the use of a prodrug, which involves the 
administration of the drug in a form that is inactive, or weakly active, but it is readily able to 
penetrate the BBB.  In many cases, however, a suitable prodrug cannot be synthesised or the 
resulting molecule is too large. 
The conjugation of the drug with the BBB specific transport vector is another strategy.  This 
method takes advantage of the normal endogenous transport pathways within the brain 
capillary endothelium; the disadvantage is a low carrying capacity of the vector molecules 
that is generally limited by 1:1 stoichiometry of a carrier to a drug (Pardridge 1999). 
 
2.3.4 Inhibition of efflux mechanisms 
Several inhibitors, both competitive and noncompetitive, have been developed to modulate 
the activity of the major ABC transporters Pgp, MRP, and BCRP such as verapamil (Bart 
2000) or Pluronic
® L-61 (Venne 1996).  One recent example for inhibiting the activity of 
Pgp efflux pump is the co-administration of valspodar with paclitaxel which produced an 
increasing paclitaxel level in the brain. The results showed an improvement of the 
therapeutic effect which assessed as the tumour growth inhibition in mice (Fellner 2002). 
Although the use of the inhibitors of the ABC transporters can markedley enhance the BBB 
uptake of the drugs, the down-modulation of the efflux transport activity may, however, 
allow other toxic substrates to enter the brain more freely. Thus, the long-term treatment may 
not be possible due to enhanced adverse effects (Begley 2004). 
   Theory 
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2.4 Nanocarriers for brain delivery 
Employment of the nanocarriers is a new strategy to enhance the drug delivery across the 
BBB.  
Nanoparticles (NP) for purposes of drug delivery, are defined as submicron (<1 µm) 
colloidal particles.  This definition includes solid nanoparticles (nanospheres) in which the 
active ingredient (drug or bioactive agent) is adsorbed, dissolved, or dispersed throughout the 
matrix and nanocapsules in which the active ingredient is confined to an aqueous or oily core 
surrounded by a polymeric wall.  Alternatively, the drug can be covalently attached to the 
surface or into the matrix (Kreuter eds. 1994).  
The nanoparticles are generally made from biocompatible and biodegradable materials, such 
as polymers, either natural (e.g. gelatin, albumin) or synthetic (e.g. polylactides, poly(alkyl 
cyanoacrylates)) or solid lipids.  In the body, the drug loaded in nanoparticles will be 
released from the polymer matrix.  The release mechanism is usually diffusion assisted by 
matrix swelling, erosion, or degradation.  
In the early 1980s, Prof Speiser at the ETH (Swiss Federal Institute of Technology) in Zurich 
suggested that nanoparticles could be used for the drug delivery across the BBB.  He was 
also the first to systematically develop nanoparticles for drug delivery purposes (Kreuter 
2004).  
 
2.4.1 Biodistribution of the nanoparticles to the normal brain 
The pharmacokinetic rule states that the mass of drug delivered to the brain is equally 
proportional to the BBB permeability coefficient and the area under the curve (AUC; plasma 
drug concentration-time curve) (Pardridge 1999). 
The general approach to increase drug circulation time is the application of the long-
circulating nanoparticles that avoid their rapid clearance by the tissues of the mononuclear 
phagocyte system (MPS).  The particle uptake by macrophages could be decreased by 
interference with their opsonisation, which prevents complement activation and recognition 
of the particles (steric stabilisation of the particles or the so-called “stealth” effect).   
Generally, steric stabilisation of nanocarriers in the blood stream can be achieved by physical 
adsorption of non-ionic surfactants or amphiphilic block copolymers, such as poloxamers or   Theory 
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poloxamines (block copolymers of poly(oxyethylene) and poly(oxypropylene)) or by their 
incorporation during the production of NP.  Alternatively, particles can be formed from an 
amphiphilic copolymer, in which the hydrophobic block is able to form a solid phase, 
whereas the hydrophilic part provides the protection of the surface.  All of these 
technological approaches have proved to be successful for the extension of the circulation 
time of NP and, in accordance with the pharmacokinetic rule.  These approaches also 
afforded an enhancement of the brain delivery of NP and bound drugs (Moghimi 2001 and 
2003).  
Hydrophilic poly(ethylene glycol) (PEG) conformation at the surface of nanoparticles is 
another important factor for repelling of the opsonin and reducing the nanoparticle uptake by 
neutrophilic granulocytes in vivo.  The PEG blocks have a brush-like (elongated coil, high 
density) or a mushroom-like (random coil, low density) conformation (Figure 4).  The brush-
like and intermediate configurations of the PEG-blocks at the nanoparticle surface reduced 
phagocytosis and complement activation, whereas the mushroom-like configuration of these 
blocks activated the complement and favoured phagocytosis.  Gref et al. (Gref 2000) showed 
the maximum anti-opsonin effect with PEG of 5000 Da and above.  
 
 
Figure 4. Schematic diagrams of PEG configurations on the upper hemisphere of a polymeric nanoparticle.  (a) 
the low density “mushroom” configuration where most of the chains are located closer to the particles surface, 
(b) the high density of the PEG chains leads to the “brush” configuration where most of the chains are extended 
away from the surface (Owens 2006). 
 
This approach proved to be efficient for brain delivery.  As an example, doxorubicin (Dox) 
was delivered to the brain with the stealth (PEGylated) solid lipid nanoparticles (Zara 2002,   Theory 
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Fundaro 2000).  The pharmacokinetic study of Dox bound to solid lipid nanoparticles (SLN) 
administered intravenously in rabbits demonstrated that the circulation time of the 
nanoparticle-bound drug was considerably increased as well as the drug concentration in the 
brain.  The concentration of solid lipid nanoparticle was decreased in other organs (liver, 
heart, lungs, spleen, and kidney) compared to the drug in the solution.  It is noteworthy that a 
decrease of Dox accumulation in the heart will reduce the cardiotoxicity of this drug.  The 
integral pharmacokinetic parameter, the AUC of SLN-bound doxorubicin increased with the 
increasing content of a stealth agent (stearic acid - PEG 2000) present on the particles (Zara 
2002).  Compared to the non-stealth SLN, the SLN containing 0.45% of the stealth agent 
produced a 9-fold increase of Dox concentration in the brain. 
 
2.4.2 Distribution of the nanoparticles under the pathological condition of the 
brain 
The BBB function can be considerably compromised by tumour growth.  As shown by 
tomography and magnetic resonance imaging, microvascular permeability correlates with the 
tumour histological grade.  While the vasculature of low grade gliomas (brain tumours which 
arise from glial cells) is close to normal, high-grade gliomas are characterised by both, 
neovascularisation and vascular hyperpermeability, which is similar to other solid tumours, 
although less pronounced (Hobbs 1998, Roberts 2001, Pluen 2001, Vajkoczy 2004). 
In contrast to normal cerebral capillaries, vessels in gliomas are tortuous and sinusoidal; they 
are characterised by open interendothelial and transendothelial gaps, fenestrations, and 
increased microvascular diameter (3 - 40 µm versus ~3 - 5 µm for cortical capillaries) and 
vessel wall thickness (0.5 µm versus 0.26 µm) (Schlageter 1999).  These abnormalities 
contribute to an increase in non-selective transendothelial transport and microvascular 
permeability and, consequently, impairment of the BBB functions at the tumour site.  The 
intravenously injected nanoparticles and macromolecules (with a molecular weight of above 
45 kDa) are able to extravasate across the leaky endothelium and then they accumulate in the 
tumour. This phenomenon is known as ‘the enhanced permeability and retention effect’ (the 
EPR effect) (Figure 5). 
   Theory 
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Figure 5. Enhanced permeability and retention (EPR) effect (Yokoyama 2005). 
 
The lack of lymphatic drainage in tumours also contributes to the accumulation of the 
nanoparticles in certain solid tumours.   
 
However, in order to take good advantage of these features, the particles have to stay long 
enough in the circulation to reach the tumour, which can be achieved by PEGylation or by 
coating with certain surfactants (Kreuter 2004). 
A comparative biodistribution study was done for PEGylated poly(hexadecyl cyanoacrylate) 
nanoparticles (PEG-PHDCA-NP) and non-stealth PHDCA NP in rats bearing intracranial 9L 
glioblastoma (Brigger 2002).  As expected, accumulation in tumour was about 3 times higher 
for the long-circulating PEG-PHDCA-NP than for PHDCA-NP; the latter had a very short 
circulation time due to a rapid and massive uptake by the MPS tissues.  Nevertheless, both 
carriers were able to extravasate across the BBB at the tumour site and to accumulate 
preferentially in the tumour rather than in the peritumoural brain or the healthy contralateral 
hemisphere.  In addition, a 4- to 8-fold higher accumulation of the PEGylated NP was 
observed also in parts of the brain protected by the normal BBB, as compared to PHDCA-
NP. 
 
2.4.3 Brain delivery with PBCA nanoparticles coated with polysorbate 80 
One of the pioneer studies demonstrated the role of polysorbate 80 (Tween
® 80; PS 80) 
coating of the nanoparticles for brain delivery, was performed in vitro, for bovine brain 
microvessel endothelial cells (Borchard 1994).  The 
14C-labelled poly(methyl methacrylate) 
nanoparticle uptake into these cells was most effectively enhanced when they were coated 
with PS 80.  These results were later substantiated by Ramge et al. (Ramge 2000).  This   Theory 
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group investigated the uptake of rhodamine 6G-labelled poly(butyl cyanoacrylate) 
nanoparticles (PBCA-NP) into human as well as bovine primary brain capillary endothelial 
cells.  The uptake was evidenced by fluorescence measurements as well as by laser confocal 
scanning microscopy.  The PS 80-coated particles were taken up much more rapidly and in 
significant amounts, i. e. 20-fold, higher amounts than uncoated particles.  These studies 
indicated that the uptake apparently occurs by endocytosis.  Similar results were obtained 
with RBE4 cells (Alyautdin 2001). 
The efficacy of PS 80-coating for brain targeting in vivo was most clearly demonstrated by 
Gulyaev et al. (Gulyaev 1999).  PS 80-coated PBCA nanoparticles delivered doxorubicin in 
very considerable amounts to the rat brain (up to 6 µg/g), whereas a free drug could not 
penetrate across the BBB in detectable concentrations.  It is noteworthy that PS 80 coating 
only moderately increased the plasma AUC of the nanoparticle-bound Dox (by ~70%) which 
suggests that the mechanism of brain delivery could be specific (discussed below, section 
2.5.2).  
 
2.5 Pharmacological activity of the nanoparticle-bound drugs 
2.5.1 Neuroactive agents 
The PBCA-NP coated with PS 80 enabled transport of a number of drugs across the BBB, 
following intravenous injection.  These drugs include hexapeptide endorphin dalargin 
(Kreuter 1995, Alyautdin 1995), dipeptide kyotorphin (Schroeder 1998), loperamide 
(Alyautdin 1997), tubocurarine (Alyautdin 1998), and N-methyl-D-aspartate (NMDA) 
receptor antagonists MRZ 2/576 and MRZ 2/596 (Friese 2000a, b).   
The brain delivery of these substances using nanoparticles was supported by using 
pharmacological tests.  The nociceptive threshold of the nanoparticle formulations of 
dalargin, kytorphin, and loperamide was determined by the tail-flick test (Alyautdin 1995, 
Kreuter 1995) or by the hot-plate test (Schroeder 1996, Ramge 1999).  In contrast to the 
drugs bound to PS 80-coated NP, the drug solutions or uncoated nanoparticulate 
formulations did not exhibit any significant effects (Figure 6).  The antinociceptive effect of 
dalargin bound to PS 80-coated NP was accompanied by a pronounced Straub effect (tail   Theory 
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erection) and was totally blocked by a prior injection of naloxone (μ-opiate receptor 
antagonist) demonstrating the involvement of the opioid receptors.  These CNS effects 
provided additional evidence that dalargin was transported across the BBB in a dose-
dependent manner.  The antinociceptive effects of dalargin were obtained also when the NP 
were coated with polysorbates 20, 40, 60, or 80, whereas other surfactants, such as 
poloxamers 184, 188, 338, 407, poloxamine 908, Brij
®35, Cremophor
®EZ, or 
Cremophor
®RH 40 were ineffective (Schroeder 1998, Kreuter 1997).  
 
 
Figure 6. Antinociceptive effect after intravenous injection of different dalargin (Dal) formulation into ICR 
mice.  Percentage of maximal possible effect (MPE%) determined by tail flick test 45 min after i.v. injection of 
dalargin in solutions and bound to non-coated and polysorbate 80-coated PBCA-NP (n = 5); NP = 
nanoparticles; PS 80 = polysorbate 80. Values are mean ± SD.  Adapted from Kreuter et al. (Kreuter 1995). 
 
The same series of experiments were repeated with loperamide-bound PBCA-NP coated 
with PS 80.  Loperamide (μ-opiate receptor agonist) is a Pgp substrate; therefore it lacks the 
central pharmacological effect.  Again, a strong dose-dependent analgesic effect and a 
typical Straub effect were observed with loperamide after binding to nanoparticles and 
overcoating with PS 80.  There were no effects without this coating.   
Transport of tubocurarine across the BBB was demonstrated using an in situ perfused rat 
brain technique together with a simultaneous recording of the electroencephalogram 
(Alyautdin 1998).  Tubocurarine (a quaternary ammonium salt) does not penetrate into the 
brain across the normal BBB.  However, a direct intraventricular injection of tubocurarine 
provokes the development of epileptiform spikes that can be recorded by the encephalogram.    Theory 
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Neither tubocurarine solution nor tubocurarine-loaded NP without PS 80-coating or a 
mixture of PS 80 and tubocurarine was able to influence the encephalogram.  However, the 
addition of tubocurarine-loaded NP coated with PS 80 caused frequent severe spikes.  
 
A novel non-competitive NMDA receptor antagonist MRZ 2/576 is a potent but rather short-
acting anticonvulsant.  The short effect of this drug (5 - 15 min) is most probably due to its 
rapid elimination from the CNS by efflux transporters that can be blocked by probenecid.  
Administration of the drug-bound PBCA-NP coated with PS 80 prolonged the duration of 
the anticonvulsive activity in mice up to 210 min and after probenecid pre-treatment up to 
270 min compared to 150 min with probenecid and MRZ 2/576 alone (Friese 2000b).  The 
results of this study demonstrate that PS 80-coated PBCA-NP not only enhances the brain 
delivery of drugs that are not able to freely penetrate the BBB, but they can also prolong the 
CNS availability of the drugs that have a short duration of action. 
 
2.5.2 Doxorubicin 
Doxorubicin (Dox) is an anthracycline antibiotic with a broad spectrum of the anticancer 
activity.  Dox is a DNA intercalator and inhibits also the progression of the enzyme 
topoisomerase II.  However, due to delivery problems, Dox is so far not applied for the 
systemic treatment of gliomas: the drug is a substrate of the ABC transporter and does not 
penetrate into the brain in therapeutic concentrations (von Holst 1990).  However, Dox 
exhibits a cytotoxic effect against glioma cells in vitro and prolongs the survival time in 
patients with glioma upon intra-tumoural administration (Stan 1999, Walter 1995).  
 
The cytotoxicity of Dox-loaded PBCA-NP coated with different surfactants was investigated 
in the rat glioma cell lines GS-9L, F-98, and RG-2 employing the tetrazolium (MTT) and the 
lactate dehydrogenase (LDH) assays (Sanchez de Juan 2006).  The MTT assay based on the 
mitochondrial activity and LDH assay based on the LDH, released from the cytosol of 
damaged cellular membrane, are both demonstrating the cells viability after the exposure to 
the drug.  The results confirmed the high efficacy of Dox against glioblastoma cells in tissue 
cultures as suggested earlier by Stan et al. (Stan 1999).   Theory 
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The therapeutic potential of brain targeting using surfactant-coated Dox-loaded PBCA-NP 
was clearly demonstrated by the experiments concerning the chemotherapy of intracranial 
glioblastoma (Gulyaev 1999, Steiniger 2004, Ambruosi 2006a, Petri 2007). 
In the study of Steiniger et al. (Steiniger 2004) the glioblastoma-bearing rats (total n = 151) 
were subjected to 3 × 1.5 mg/kg or 3 × 2.5 mg/kg of Dox in different formulations injected 
intravenously on days 2, 5, and 8 after tumour implantation.  The most prominent result was 
achieved in the group treated with 3 × 1.5 mg/kg of Dox-bound to PS 80-coated NP: a 
significant increase in survival time was obtained and more than 20% animals showed a 
long-term remission (Figure 7).  
 
 
Figure 7. Percentage of survival (Kaplan-Meier plot) of rats with intracranially transplanted glioblastoma 101/8 
after intravenous injection of doxorubicin formulations: (left) doxorubicin dosage 1.5 mg/kg; (right) 
doxorubicin dosage 2.5 mg/kg, both administered on days 2, 5 and 8 using one of the following formulations; 
Dox, doxorubicin in saline; Dox+PS, doxorubicin in saline plus polysorbate 80; Dox-NP, doxorubicin bound to 
poly(butyl cyanoacrylate) nanoparticles; Dox-NP+PS, doxorubicin bound to poly(butyl cyanoacrylate) 
nanoparticles coated with polysorbate 80 (Steiniger 2004). 
 
These animals were sacrificed after 6 months, and no histological evidence of tumour was 
observed.  Preliminary histology confirmed lower tumour sizes and lower values for 
proliferation and apoptosis in this group.  The mean survival time was even more prolonged 
in the group treated with 3 × 2.5 mg/kg of Dox, indicating a dose dependence of the 
antitumour effect.  However, long-surviving animals in this group died before day 180 most 
probably due to the high toxicity of this regimen.  Interestingly, the survival time was also 
increased in the groups treated with Dox solution in 1% PS 80 and Dox bound to non-coated 
PBCA-NP.  This phenomenon could most probably be explained by the EPR effect   Theory 
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associated with a higher permeability of the BBB at the tumour site that allowed entry of 
other formulations into the brain (Vajkoczy 2004).   
The higher efficacy of the PS 80 coated nanoparticles may be explained by the ability of 
these carriers to deliver the drug across the BBB at an early stage of tumour development 
due to a receptor-mediated mechanism.  In this way doxorubicin is able to reach those parts 
of the brain which are still protected by an intact BBB. 
It is noteworthy that clinical signs of neurotoxicity were absent throughout the study.   
Moreover, the histological study of the animals treated with the dose of 3 × 2.5 mg/kg and 
sacrificed on day 12 did not reveal any signs of neurotoxicity.  
 
Ambruosi et al. (Ambruosi 2006) have extensively studied the role of passive doxorubicin 
transport across the leaky BBB to the brain tumour using PBCA-NP coated with two 
surfactants, poloxamer 188 and poloxamine 908.  The long-term remission of 20% (4/20) of 
both formulations was achieved and attributed to EPR effect.  Although poloxamer 188 and 
poloxamine 908 could not provide any drug transport across the intact BBB of healthy 
animals  (Kreuter 1997, Calvo 2001), these sufractants could facilitate the particle 
extravasation across the BBB at the tumour site. 
 
2.5.3 Mechanisms of drug delivery to the brain by nanoparticles  
A number of possibilities could explain the mechanisms of drug delivery across the BBB by 
means of NP: 
1.  Opening of the BBB due to surfactant coating or particle interaction with the brain 
endothelium:  A mechanism of general toxicity characterised by an increase in the 
permeability of endothelial cell membranes and/or an opening of the tight junctions between 
the endothelial cells.  
2.  Adhesion of NP to the capillary wall: Increased retention of NP in the brain blood 
capillaries could create a higher concentration gradient that would enhance the transport to 
the brain.   Theory 
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3. Endocytosis of the NP by brain endothelial cells: Uptake followed by the drug entering to 
the residual brain and diffusion after its release by desorption or biodegradation from the 
nanoparticle system (Begley 2000). 
4. Transcytosis of the NP: Translocation of the NP through the endothelial cell layer with 
bound drugs. 
5. Influence on the cell membrane permeability: The nanoparticle could induce changes in 
the endothelial cell membrane viscosity/fluidity thus enhancing drug penetration into these 
cells.   
6. Inactivation of the Pgp efflux pump: Certain surfactants, including PS 80, were shown to 
inhibit this efflux system and to reverse MDR (Woodcock 1990 and 1992, Zordan-Nudo 
1993, Nerurkar 1996). 
 
The mechanism of the delivery of the drugs across the BBB by NP is not still fully 
elucidated.  However, it is reasonable to assume that more than one mechanism could enable 
the significant drug transport by NP into the brain.  
 
The theory of the non-specific permeabilisation and then opening of the BBB, mechanism 1, 
is unlikely to contribute to the nanoparticle-mediated drug delivery to the brain.  The 
necessity of drug binding to the PBCA-NP and lack of efficacy of a drug in a surfactant 
solution is suggesting more specific mechanism for drug transport across the BBB 
(Alyautdin 1995, Gulyaev 1999, Kreuter 1995, Steiniger 2004, Kreuter 2003). 
Moreover, the integrity of the BBB in rats was evaluated by the measurement of the inulin 
spaces (Alyautdin 2001): After administration of PS 80-coated PBCA-NP, the space volumes 
increased only slightly without significantly disrupting the BBB. In another study, with an in 
vitro BBB model consisted of a co-culture of bovine brain capillary endothelial cells and rat 
astrocytes, the permeability was evaluated by measuring the flux of the exrtracellular 
markers [
14C]-sucrose and [
3H]-inulin across a cell monolayer.  After co-incubation of these 
cells with PS 80-coated or uncoated PBCA-NP, no significant changes in permeability were 
observed (Kreuter 2003). By contrast, in a similar study with the same BBB model, the result 
showed over 10-fold increase in the sucrose and inulin fluxes.  However, in this case, serum   Theory 
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was not added to the cell medium, which could impair the integrity of the cell layer (Olivier 
1999).  
Steiniger et al. (Steiniger 2000) demonstrated that slight changes in the in vitro models of the 
BBB can lead to considerable discrepancies in the results. In this study, a BBB model was 
made from a cultivated bovine brain capillary endothelial cells which was originating from 
the grey matter and no astrocytes were co-cultured. After incubation with 10 µg/ml of the NP 
preparation, the [
14C]-sucrose flux increased 2-fold with uncoated and 6.5-fold with PS 80-
coated PBCA-NP.   
 
In several studies, the opinion that toxicity is not the mechanism for the nanoparticle-
mediated drug transport across the BBB with other types of NP was substantiated (Calvo 
2001, Koziara 2003 and Lockman 2003).   
The evaluation of the modification of the BBB permeability due to PHDCA-NP or 
surfactants using [
14C]-sucrose was performed Calvo et al.  (Calvo 2001).  None of the 
nanoparticulate preparations modified the low passage of sucrose, which indicates that the 
penetration of the NP was not associated with the increase of the BBB permeability.   
However, 1% solution of PS 80 noticeably increased the concentration of sucrose in all the 
brain structures.  
 
Two types of SLN with a size of about 100 nm, consisting of emulsifying Wax / Brij
® 78 or 
Brij
® 72 / PS 80, were made by Koziara et al. (Koziara 2003) and Lockman et al. (Lockman 
2003).  These NP were labeled with entrapped [
3H]-cetyl alcohol and the permeability of the 
BBB was investigated by an in situ brain perfusion measuring the cerebral perfusion flow of 
the [
14C]-sucrose.  For both SLN types significant brain uptake was measured.  The transfer 
rate of the SLN stabilised by PS 80 (Brij
® 72/PS 80) NP from perfusion fluid into the brain 
was significantly higher than that of the NP stabilised by Brij
® 78 (E. wax/Brij
® 78).  At the 
same time, these NP did not induce statistically significant changes in the BBB integrity, 
permeability, or choline transport.  In addition, it was shown that the particles had a minimal 
effect on the BBB integrity.  The Western blot analysis confirmed that the incubation of 
these NP with bovine brain microvessel endothelial cells did not alter the expression of the 
BBB junctional proteins, such as occludin and claudin-1.  The above data suggest that the   Theory 
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brain uptake of these NP was not associated with paracellular transport or opening of the 
tight junctions.  
 
Although an increased concentration of the nanoparticles on the walls of the blood capillaries 
of the brain would enhance the transport across the endothelial cell layer and delivery to the 
brain, mechanism 2, the drug would still be subjected to very effective efflux pumps located 
in the luminal membrane of the endothelial cells such as Pgp. The efficient efflux of known 
substrates for Pgp loperamide, doxorubicin, and tubocurarine showed that this mechanism is 
largely insignificant (Begley 1996).  
The fundamental study of Tröster et al. (Tröster 1990) with 
14C-labelled poly(methyl 
methacrylate) nanoparticles (PMMA-NP) in rats investigated the influence of different 
surfactants on the biodistribution and the brain uptake.  The preparations were administered 
intravenously after incubation of the NP in 1% surfactant solutions.  Poloxamine 908 was the 
most effective among other surfactants for increasing the plasma concentration of the NP 
(100-fold increase 30 min after injection), whereas PS 80 produced only a 5-fold increase, 
yet showed a similar brain uptake.  The author suggested that the PMMA-NP were not 
engulfed by the endothelial cells lining the vasculature but rather adhered to these cells.  
This mechanism was also suggested by Zara et al. (Zara 2002), among other possibilities, for 
doxorubicin-loaded stealth solid lipid nanoparticles (SLN).  Doxorubicin was bound to these 
particles using hexadecylphosphate as counterion.  The enhanced uptake of doxorubicin in 
the brain was associated with the increase in the concentration of stealth agent in the SLN.  
Although the higher stealth agent concentration led to a parallel increase in the surface 
hydrophilicity of the carriers, it did not hinder the NP interaction with the cell membrane and 
the passage through the BBB.  This observation implies the involvement of an additional 
mechanism in the doxorubicin transport to the brain with the stealth SLN. 
 
Endocytosis of the NP by brain microvessel endothelial cells and release of the drug in these 
cells, mechanism 3, is the most likely mechanism which has been demonstrated for the drugs 
loaded in the PBCA-NP in vitro and in vivo (Kreuter 2001 and 2002a).  
In the study of Ambruosi et al. (Ambruosi 2005) the brain uptake of empty 
14C-PBCA 
nanoparticles overcoated with PS 80 and doxorubicin-loaded 
14C-PBCA nanoparticles   Theory 
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overcoated with PS 80 was investigated.  An about one hour delay in the increase in the brain 
concentrations with two polysorbate-coated nanoparticle preparations was observed.  This 
delay is attributed to delivery mediated by PS 80-coating (Alyautdin 1995 and 2001, Kreuter 
1995, Alyautdin 1997, Gulayev 1999) and might reflect the time-consuming process of 
endocytosis. 
In addition, the uptake of fluorescent PBCA-NP labelled with rhodamine 6G was observed in 
cultured human, bovine, and murine brain microvessel endothelial cells (Ramge 2000).  
Uptake of the surfactant-coated NP was far more pronounced compared to the uncoated 
particles, even though in the bovine cells a slight increase in uptake of the uncoated particles 
was observed with the increasing time of incubation.  Using image analysis software, a 20-
fold increase in uptake of coated with respect to uncoated nanoparticles was observed in 2 h.  
The human cells also exhibited the enhanced uptake of the coated NP.  
The uptake of fluorescent PBCA-NP by rat brain endothelial cells of the RBE4 cell line was 
also demonstrated by Alyautdin et al. (Alyautdin 2001).  The PBCA nanoparticles were 
labeled with fluorescein isothiocyanate (FITC) dextran 70,000.  After addition of PS 80-
coated NP, the cells showed a punctate appearance of fluorescence concentrated within the 
cells.  In contrast, after treatment with the uncoated nanoparticles no fluorescence was 
observable within the cells, even after the addition of a 10-fold higher concentration of 
nanoparticles, while a strong fluorescence was apparent in the surrounding medium.  In none 
of the above experiments addition of PS 80-coated or uncoated NP appeared to damage the 
RBE4 cells.  
There are indications that PS 80-coated PBCA-NP bind to a lipoprotein receptor, like low 
density lipoprotein receptor (LDL-R) or low-density lipoprotein receptor-related protein 
(LRP).  The polysorbate coating led to the adsorption of apolipoprotein E (Apo E) and 
apolipoprotein B (Apo B) from the blood after the i.v. injection.  The NP thus could mimic 
lipoprotein particles, which would then interact with the lipoprotein receptors located on the 
brain capillary endothelial cells.  A subsequent endocytosis of the NP together with the 
bound drugs would then occur (Kreuter 2004).  
Additionally, it was shown that coating of PBCA-NP with Apo E and B in the absence of 
surfactant was also sufficient for drug transport to the brain (Kreuter 2002).  PBCA-NP 
loaded with dalargin or loperamide were coated with the Apo AII, B, CII, E, or J without   Theory 
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coating or after precoating with PS 80.  After i.v. injection to mice the antinociceptive 
threshold was measured by the tail flick test.  An antinociceptive effect was achieved only 
after the treatment with dalargin- or loperamide-loaded PBCA-NP coated with PS 80 and/or 
with Apo B or E.  The effect was higher when the NP were first coated with PS 80 and then 
overcoated with apolipoprotein E.  Furthermore, the antinociceptive threshold of PS 80-
coated dalargin-loaded PBCA-NP was determined in Apo E-deficient and normal mice.  In 
the apolipoprotein E-deficient mice, the antinociceptive effect was considerably reduced in 
comparison to the normal mice.  Similar antinociceptive effects were also achieved after 
coating of dalargin-loaded particles with apolipoprotein B.  
 
Consistent results were reported in the study of Michaelis et al. (Michaelis 2006).  The 
human serum albumin nanoparticles (HSA-NP) were modified by covalent linkage to Apo E, 
and loperamide was absorbed on the surface of these NP.  The ability of these particles to 
transport loperamide across the BBB was tested via the tail-flick test.  Loperamide solution 
and unmodified HSA-NP loaded with loperamide were used as controls.  The Apo E-coupled 
HSA-NP revealed strong antinociceptive effects whereas the control formulations including 
non-modified HSA-NP were unable to transport loperamide across the BBB.  This result has 
corroborated the earlier findings which showed that association of Apo E to the nanoparticles 
can mediate the drug transport to the brain.  Bound drugs then may further be transported 
into the brain by diffusion after release within the endothelial cells or, alternatively, by 
transcytosis, as observed for LDL by Dehouck et al. (Dehouck 1997). 
Furthermore, Petri et al. (Petri 2007) observed the involvement of apolipoprotein A-I (Apo 
A-I) in the brain delivery of Dox loaded in the surfactant-coated PBCA-NP in glioblastoma-
bearing rats.  In this study, Dox loaded-PBCA-NP were produced using two different 
stabilisers, dextran and poloxamer 188 (Pluronic
® F68; F68).  Then the NP were overcoated 
with either F68 or PS 80.  The treatment regimen used in this study was 3 × 1.5 mg/kg on 
days 2, 5, and 8 after the tumour implantation. This regimen had previously proved to be 
efficient against glioblastoma (Steiniger 2004).  All formulations produced extended survival 
times when compared to untreated animals.  It was also shown that the presence of Dox and 
the NP as formulation parameters increased the therapeutic efficacy, whereas the effect of   Theory 
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the stabilisers/surfactants used (i.e. polysorbate 80, poloxamer 188, and dextran) could not be 
differentiated from each other.  
Both formulations of Dox containing poloxamer 188 as a coating material or as a stabiliser 
produced a long-term remission in 20% of the animals (4/20 and 2/10, respectively).  The 
effect of these formulations was comparable to that of doxorubicin bound to PBCA-NP 
stabilised with dextran and coated with PS 80, which produced 22% (5/23) of long-term 
survivors.  The study further investigated the plasma protein adsorption patterns of Dox-
loaded PBCA-NP stabilised with dextran and coated with poloxamer 188 or PS 80. Both 
formulations adsorbed high amounts of Apo A-I and J. Furthermore, the adsorbed amounts 
of albumin, IgG γ, Apo C-III, and thiostatin were comparable.  Differences could be 
observed, for example, in the adsorption of antitrypsin for the nanoparticles coated with 
poloxamer 188 and transferrin for the nanoparticles coated with PS 80 (Figure 8).  
 
 
Figure 8. Similarity of plasma proteins pattern adsorbed by Dox-loaded PBCA nanoparticles coated with 
polysorbate 80 (Dox-NP/Dex+PS 80) or poloxamer 188 (Dox-NP/Dex+F68) in rat plasma (taken from Petri 
2007). 
 
The protein patterns of the uncoated nanoparticles differed considerably from the adsorption 
pattern of the surfactant-coated nanoparticles.  The amount of albumin adsorbed on the 
surface of uncoated particles exceeded 50% of the total amounts of adsorbed proteins. 
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The role of PS 80-coating of the nanoparticles that facilitated their interaction with the brain 
microvessel endothelial cells has been also demonstrated for other types of NP.  Lipid drug 
conjugate (LDC) nanoparticles were composed of stearic acid and diminazene.  PS 80 was 
used as an emulsifier (Gessner 2001).  Confocal laser scanning microscopy of the murine 
brain tissue showed Nile Red-labelled LDC particles adhering to the endothelium of the 
brain vessels and dye diffusing into the brain tissue.  After incubation of the nanoparticles in 
murine plasma, the plasma protein adsorption pattern was investigated by two-dimensional 
electrophoresis.  The result revealed a strong adsorption of apolipoproteins A-I and A-IV 
onto LDC the nanoparticles surfaces.  However, apolipoprotein E could not be identified.  
The authors suggested that the ability of the PS 80-coated nanoparticles to deliver drugs to 
the brain is not only mediated by adsorption of apolipoprotein B and E but it probably 
involves a “team-work” of other apolipoproteins that prevent the hepatic uptake of the 
nanoparticles, thus facilitating brain delivery.  
Petri  et al.  (Petri 2007) suggested another hypothesis. It was hypothesized that ApoA-I 
adsorbed on the surface of Dox-loaded NP could bind to the scavenger receptor class B type 
I (SR-BI).  This receptor is expressed on the membranes of the endothelial cells of brain 
capillaries (Panzenboeck 2002, Balazs 2004, Krieger 1999).  The uptake of Dox into the 
cells could be assisted by circumvention of the transmembrane efflux pump Pgp, which is 
expressed by the blood-brain vessel endothelial cells and represents an important constituent 
of the BBB.  This circumvention could be enabled by simultaneous release of Dox and the 
degradation product of PBCA (= polycyanoacrylic acid) at the cell membrane.  An ion-pair 
previously formed by polycyanoacrylic acid and Dox could enable the crossing of the cell 
membrane without being recognised by Pgp (Verdiere 1997).  Retention of the particles by 
the SR-BI receptor on the cell walls combined with a slow degradation would augment this 
process.  
 
The adsorptive endocytosis is a likely mechanism of the enhanced transport of antisense 
oligonucleotides (ODN) across the BBB with the positively charged Nanogel™ particles 
(Vinogradov 2002 and 2004).  The main obstacle to effective therapy with ODN compounds 
is their anionic characteristic and relatively large molecular structure, which hampers their 
access to the target sites localised in the cell cytoplasm and/or nucleus.  On the other hand,   Theory 
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the positively charged NP are believed to interact electrostatically with the negatively 
charged cell membrane, which is followed by the internalisation of these particles within 
these cells via the adsorptive endocytosis.  Indeed, positively charged Nanogel formulation 
allowed more effective ODN transfer across the monolayers of brain microvessel endothelial 
cells, as compared to the electroneutral formulation.  This result is in concert with the in vivo 
data demonstrating the substantial brain/plasma ratio of the ODN achieved after injection of 
ODN-loaded Nanogel particles.  The cationic nature of this carrier system may also influence 
intracellular trafficking of ODN.  Thus, delivery with Nanogel particles afforded effective 
release of ODN and its accumulation within the nucleus, whereas free ODN molecules are 
mainly localised within endosomal and lysosomal compartments and their access to the 
nucleus is usually achieved only after the addition of chloroquine.  It is possible that 
following the internalisation, the cationic nanoparticles interact with the negatively charged 
endosomal membrane, which may cause destabilisation of the membrane and facilitate the 
release of ODN and its access to the nucleus.  
 
Presently, little is known about transcytosis of the nanoparticles with bound drugs, 
mechanism 4. It is possible that after their endocytotic uptake the particles can be 
transcytosed through the brain blood vessel endothelial cells.  
In vitro transctosis of LDL across the blood-brain barrier was observed in the Cecchelli-
Model by Dehouck et al.  (Dehouck 1997). Furthermore, cholesterol depletion was 
upregulated the expression of the LDL receptor in this model.   
Transcytosis of cationic polysaccharide nanoparticles coated with a lipid bilayer across the in 
vitro BBB model was observed by Fenart et al. (Fenart 1999).  The BBB model consisted of 
a co-culture of bovine brain capillary endothelial cells and rat astrocytes.  Neutral, anionic, 
and cationic 60-nm NP were prepared from cross-linked maltodextrin derivatised or not 
(neutral) with anionic (phosphates) or cationic (quaternary ammonium) ligands.  The 
particles were labelled with fluorescein and coated (or not) with a lipid bilayer.  Cationic 
lipid-coated NP were found to be the best for permeating across the BBB, whereas coating of 
the neutral particles did not significantly alter their permeation characteristics.  No 
modification of the paracellular permeability was observed during the incubation of cells 
with the NP, so this increase was not due to a breakdown of the barrier.  The distribution of   Theory 
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these particles throughout the cytoplasm was characteristic for transcytosis.  In contrast, the 
perinuclear localisation of non-coated polysaccharide nanoparticles showed an intracellular 
accumulation of these NP in a degradation compartment. 
 
The observations of Kreuter et al.  (Kreuter 2003) did not support the theory of the 
fluidisation of the endothelium by surfactants, mechanism 5. Experiments with some 
surfactants using the tail-flick test and dalargin showed that polysorbate 20, 40, 60 were able 
to transport dalargin into the brain and to produce an antinociceptive effect, although this 
effect was somewhat lower than with polysorbate 80.  However other polysorbates such as 
PS 83 and PS 85 did not induce a significant CNS effect.  This indicates that the transport of 
dalargin and the other drugs across the BBB cannot be due to a simple surfactant effect on 
the endothelial cells or on the tight junctions, since some of the surfactants were inactive.  It 
might be argued that polysorbates would interact much more strongly with the NP than other 
surfactants (Kreuter 1997). 
 
It was also reported that the treatment which caused membrane fluidisation can lead to 
inhibition of Pgp.  Pluronics with intermediate lipophilic properties, such as Pluronic
® P85, 
showed the strongest fluidisation effect on the cell membranes along with the most efficient 
reduction of intracellular ATP synthesis.  The changes in the cell membrane 
viscosity/fluidity inhibited the efflux system, such as Pgp, and facilitated the brain uptake of 
Pgp-dependent drugs (Batrakova 2001 and 2003).  
 
The enhanced drug delivery to the brain with PS 80-coated PBCA nanoparticles may be 
associated with the inhibition of the transmembrane efflux pumps, such as MRP and Pgp, 
mechanism 6.  Indeed, all drugs delivered to the brain with PS 80-coated NP, such as 
loperamide, dalargin, doxorubicin, and MRZ 2/576, are the Pgp and/or MRP substrates. 
The ability of PACA-NP to overcome MDR mediated by Pgp was described extensively 
(Vauthier 2003a, Hu 1996, Verdiere 1997).  Poly(isobutyl cyanoacrylate) NP could reverse 
the Pgp-dependent MDR to Dox and produced considerable cytotoxic effects in P388/ADR 
cells resistant to Dox (Hu 1996, Verdiere 1997, Vauthier 2003b).   Theory 
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Accordingly GS-9L cells exhibiting the highest Pgp expression were the most resistant 
toward both, free and nanoparticle-bound Dox.  Among the surfactants used, only PS 80-
coating significantly enhanced the cytotoxicity of the nanoparticle-bound doxorubicin in all 
cell lines, including the Pgp-expressing GS-9L cells, whereas the other surfactants, 
poloxamer 188, and poloxamine 908 (Tetronic
® 908), had negligible influence (Sanchez de 
Juan 2006).   
 
Possible mechanisms of Dox transport across the BBB with PACA-NP are summarised in 
Figure 9.  
 
 
Figure 9. Hypothetical mechanism of drug delivery to the brain by means of polysorbate 80-coated poly(alkyl 
cyanoacrylate) nanoparticles.  (1) adsorption of apolipoprotein(s) onto the nanoparticles; (2) transcytosis of the 
nanoparticles; (3) endocytosis followed by intracellular degradation of the nanoparticles, resulting in release of 
the drug and diffusion towards the interior of the brain; (4) inhibition of P-glycoprotein; (5) modulation of tight 
junction opening (taken and modified from Vauthier 2003b). 
 
2.6 Toxicological aspects 
As mentioned above, NP are able to reduce drug toxicity largely due to their altered body 
distribution and/or the absence of the peak concentration of the drug.  In addition, the use of 
nanoparticles has been shown to improve lifespan and inhibit tumour growth via an 
increased distribution in tumour.  
The acute toxicity after intravenous injection of doxorubicin bound to PBCA nanoparticles 
was investigated in healthy and glioma 101/8-bearing rats (Gelperina 2002).  No significant   Theory 
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difference in the parameters of acute toxicity were found between the four Dox formulations: 
Dox solution in saline, Dox solution in saline containing 1% PS 80, Dox bound to uncoated 
NP, and Dox bound to PBCA-NP coated with PS 80.  Moreover, the results of this study 
indicated that the toxicity of doxorubicin bound to NP is similar to or even lower than that of 
the free doxorubicin. 
It is known that Dox displays a pronounced cardiotoxicity that is associated with the peak 
cardiac concentration.  The results of a recent study by Pereverzeva et al. (Pereverzeva 2007) 
demonstrated that the hematological, cardiac, and testicular toxicity of doxorubicin could be 
reduced by binding the drug to PBCA-NP and even more considerably by binding the drug 
to HSA-NP.  The intravenously injected dose of Dox was 1.5 mg/kg.  It was administered 
three times with 72-h intervals (days 2, 5, and 8 after tumour transplantation).  Coating of 
PBCA-NP with PS 80 contributed to the reduction of the toxicity.  The lower toxicity of the 
nanoparticle formulations most probably can be explained by the altered biodistribution of 
the drug mediated by the NP.  
In another comparative toxicological study, Dox was injected at a higher dose of 6 mg/kg 
either as a single injection or in form of four weekly injections (Pereverzeva 2008).  The 
animals received for 4 and 40 days a single injection or for 25 and 61 days multiple 
injections.  The dynamics of body weight, haematological parameters, blood biochemical 
parameters, and urinalysis were determined.  The pathomorphological evaluation included 
macroscopic evaluation and weight measurement of the internal organs.  The heart, lung, 
spleen, testes, and liver were also subjected to a histological evaluation.  The overall result of 
this study suggested that the surfactant-coated nanoparticles formulation of Dox possesses a 
very favorable toxicological profile.  Specifically, this study revealed again a major 
advantage of these NP - a considerably reduced cardio- and testicular toxicity, as compared 
to a free drug, thus corroborating previous observations (Couvreur 1982 and 1986, 
Pereverzeva 2007).  
 
Similar toxicological observations were made in the above mentioned chemotherapy study of 
Steiniger et al. (Steiniger 2004).  A limited dose-dependent systemic toxicity was found in 
the group treated with Dox in saline.  The autopsy of the whole body in healthy animals in 
this study revealed an empty gastrointestinal tract only in animals treated with Dox solution.    Theory 
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Healthy animals treated with Dox solution also showed slight signs of lung edema, which 
was confirmed by histology.  These changes were not observed in animals treated with Dox 
bound to the NP. 
Importantly, an indication of short-term neurotoxicity (increased apoptosis in areas distant 
from the tumour, increased the expression of glial fibrillary acidic protein (GFAP) or ezrin 
on distant astrocytes or degenerative morphological changes of neurons) were entirely absent 
in the animals sacrified on the day 12 post-implantation.  The neurotoxicity indication were 
also absent in long-term survivors with no sign of chronic glial activation in areas distant 
from the tumour site.  Moreover, long-term survivors did not exhibit any obvious 
neurological symptoms (Steiniger 2004). 
 
In conclusion, the injectable NP carriers have the ability to revolutionize the treatment of the 
CNS diseases. In particular, they have a potential for the systemic chemotherapy of 
glioblastomas.    Materials and Methods 
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3 Materials and Methods 
3.1 Poly(butyl cyanoacrylate) nanoparticles 
Three drugs, doxorubicin hydrochloride, loperamide hydrochloride, and paclitaxel, were 
loaded to PBCA nanoparticles.  The nanoparticles were prepared by anionic polymerisation 
of n-butyl-2-cyanoacrylate (BCA) in the presence of the drug. 
 
Chemicals Manufacturer/supplier 
0.01 N Hydrochloric acid   Merck, Darmstadt 
1 N Sodium hydroxide   Merck, Darmstadt 
1,2-Dioleoyl-sn-Glycer-3 
Phosphoethanolamine-N-
[Methoxy(Polyethylene glycol)-5000] 
sodium salt (PEG-PE) 
Avanti Polar Lipids, Alabaster 
Dextran 70,000  Sigma, Steinheim 
D-mannitol Merck,  Darmstadt 
Doxorubicin hydrochloride  Sicor, Milan 
Loperamide hydrochloride  Sigma, Steinheim 
Milli-Q
® water  Millipore, Eschborn 
n-Butyl-(2)-cyanoacrylate (Sicomet
® 6000)  Sichel-Werke, Hannover 
Paclitaxel  Yick-Vic Pharm-Chem. LTD, Hong-Kong 
Poloxamer 188 (Pluronic
® F68)  Sigma, Steinheim 
Solvents: dichloromethane, ethanol, 
ethylacetate, isopropanol  
Sigma, Steinheim 
Polysorbate 80 (Tween
® 80)  Fluka, Seelze 
  
Instruments Manufacturer/supplier 
Analytical balance Sartorius CP 224S  Sartorius, Göttingen 
Eppendorf Centrifuge 5415D  Eppendorf AG, Hamburg 
Knick pH-Meter 766  Knick, Berlin 
   Materials and Methods 
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Lyovac GT 2 Freeze-dryer  Leybold AG, Köln 
Magnetic Stirrer RCT basic  IKA Labortechnik, Staufen 
Magnetic Variomag
® Multipoint HP15  Dr.Hoiss & Partner, München 
Saftey Cabinet Herasafe HS 12  Heraeus, Hanau 
Sintered glass filter (G2)  Schott, Mainz 
Ultrasonicator Sonorex RK 31  Bandeline, Berlin 
  
Working parameters   
Freeze-drying  24 h at 2×10
-3 mbar 
Stirring rate  550 rpm 
Temperature  25 °C 
 
3.1.1 Doxorubicin-loaded PBCA nanoparticles 
Doxorubicin-loaded PBCA nanoparticles (Dox-PBCA-NP) were prepared by anionic 
polymerisation, as described by Steiniger et al. (Steiniger 2004).  1% (w/v) of BCA was 
added to a 1% (w/v) dextran 70,000 solution in 0.01 N HCl (pH 2) under constant stirring.  
After 40 minutes, doxorubicin hydrochloride was added into the polymerisation medium to 
obtain a final doxorubicin concentration of 0.25%.  The polymerisation process was carried 
out for 2.5 h and then was completed by neutralisation with 0.1 N NaOH to pH value of 6.5 
± 0.5.  The nanosuspension was filtered through a sintered glass filter G2 (pore size of 40 - 
100 µm) to remove agglomerates that could occur during particle formation.  Then the 
nanoparticles were freeze-dried in the presence of mannitol (3% w/v) that was used as 
cryoprotector.  The samples were stored in a cool (4 °C) and dry place and protected from 
light.   
After reconstitution with water, the freeze-dried nanoparticles yielded a homogeneous 
colloidal suspension stable for at least 24 h.  
In some cases, for better reconstitution, vortexing (mechanical shaking) or ultrasonication 
were applied for 1 - 2 min. 
Empty PBCA-NPs were prepared as described above in the absence of the drug. 
   Materials and Methods 
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3.1.2 Preparation of drug-loaded PBCA nanoparticles in the presence of organic 
solvents 
The drug-loaded PBCA nanoparticles were prepared by anionic polymerisation of n-butyl-2-
cyanoacrylate in the presence of a drug.  1% n-butyl-2-cyanoacrylate was added to a solution 
of dextran 70,000 (1% w/v) and poloxamer 188 (0.2% w/v) in 0.01 N HCl (pH 2.0) under 
stirring.  In the case of paclitaxel, 1% PEG-PE also was used as an alternative stabiliser 
instead of dextran and poloxamer 188.  After 30 minutes, the drug was added as a 1% 
solution in an organic solvent as follows: loperamide was dissolved in dichloromethane 
(CH2Cl2), methanol (MeOH) or ethanol (EtOH); paclitaxel was dissolved in 
dichloromethane, methanol, iso-propanol (i-PrOH), or ethylacetate (EtOAc).  The final drug 
concentration in the reaction media was 0.1% (w/v).  The drug-to-polymer ratio was 1:10.  
The ratio organic phase – aqueous phase was always 1:10 (v/v).  After 2.5 h the 
polymerisation was completed by neutralisation with 0.1 N NaOH.  Stirring was continued 
for another 1.5 h at room temperature to achieve evaporation of the organic solvent; then the 
suspension was filtered through a G2 sintered glass filter to remove the agglomerates, and 
the final volume was adjusted to the initial quantity by water.  The suspension was freeze-
dried after addition of 3% w/v mannitol as a cryoprotector.  
 
Empty PBCA-NPs were prepared, as described above, in the absence of the drug.  Organic 
solvents were added into the polymerisation medium 30, 40, or 60 min after the monomer.  
 
3.1.3 Characterisation of nanoparticles 
The PBCA nanoparticles were tested in vitro for their size, size distribution, morphology, 
surface charge, drug loading, and drug content.  Additionally, the particles prepared in the 
presence of organic solvents were tested for residual amount of these solvents. 
 
 
   Materials and Methods 
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3.1.3.1 Determination of the particle size and the zeta potential 
Chemicals Manufacturer/supplier 
Milli-Q
® water  Millipore, Eschborn 
 
Instruments Manufacturer/supplier 
Dipcell Malvern,Worcestershire 
Malvern Zetasizer 3000 HSA   Malvern,Worcestershire 
PCS-Cuvets (10 x 10 x 48 mm)   Sarstedt,  Nürnbrecht 
 
Working parameters   
Refractive index  1.333 
Scattering angle  90 °C 
Temperature  25 °C 
Viscosity  0.01 poise 
 
Particle size and polydispersity of the nanoparticles were measured by photon correlation 
spectroscopy (PCS).  The samples were diluted 1:400 with purified water (Milli-Q
® water).  
Milli-Q
® water refers to ultra-pure laboratory grade water that has been filtered and purified 
by reverse osmosis. 
The zeta-potential (ξ-Potential) of the nanoparticles was measured by microelectrophoresis 
using the Dip Cell and the same equipment.  Since the charge measurement depends on the 
ionic strength and the pH of the medium, all samples were prepared in purified water. 
 
 
 
 
 
 
   Materials and Methods 
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3.1.3.2 Analytical ultracentrifugation (ANUC) 
Chemicals Manufacturer/supplier 
Milli-Q
® water  Millipore, Eschborn 
Sodium Chloride  Merck, Darmstadt 
 
Instruments Manufacturer/supplier 
An-50Ti Rotor  Beckman Coulter, Fullerton 
Beckman Optima XL-A Ultracentrifuge Beckman  Coulter,  Fullerton 
 
Working parameters   
Optical turbidity  Between 0.6 and 0.7 at 420 nm 
Optical path length of Cuvette   1 cm 
Optical path length of double-sector  12 mm 
Rotor speed  3000 or 4000 rpm 
Temperature  20 °C 
 
Additionally, the particle size of empty and loperamide-loaded nanoparticles was evaluated 
by analytical ultracentrifugation on the basis of sedimentation velocity analysis, as described 
in Vogel et al. (Vogel 2002), Langer et al. (Langer 2003), and Bootz et al. (Bootz 2004).  
After redispersion the freeze-dried samples in water, they were further diluted 20-fold with a 
0.9% NaCl solution in distilled water.  Optical turbidity was between 0.6 and 0.7 at 420 nm 
in a 1 cm cuvette.  The sedimentation velocity experiments were carried out using a 
Beckman Optima XL-A ultracentrifuge with an An-50Ti rotor, and double-sector charcoal-
filled Epon centerpieces of 12 mm optical path length.  Apparent absorbance (turbidity) 
versus radius data A(r,t) were collected at 420 nm, using a radial step size of 0.03 mm.  The 
sedimentation velocity data were modeled as a distribution of non-diffusing particles using 
the l-s g*(s) variant of the Sedfit program.  The apparent sedimentation coefficients s20 were 
transformed to standard conditions and given as s20,w modeled as l-s g*(s) distribution of 
non-interactive species used in the Sedfit program by Schuck et al. (Schuck 2000).  For 
transformation of the g*(s) data into diameter distribution g*(d) based on a solid sphere 
model, the partial specific volume of the particles as 0.871 was used (Bootz 2004).   Materials and Methods 
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3.1.3.3 Scanning Electron Microscopy (SEM) 
Chemicals Manufacturer/supplier 
Milli-Q
® water  Millipore, Eschborn 
Sodium Chloride  Merck, Darmstadt 
 
Instruments Manufacturer/supplier 
Aluminum sample plate  Work Studio, Frankfurt University 
EM Hitachi S-45000   Hitachi, Tokyo 
Paint Shop Pro 5  Jasc, Fremont 
 
Working parameters   
Detector  Upper detector 
Duration of gold spraying  40 s 
Electron emission   15-25 kv 
A freeze-dried nanoparticle sample was redispersed in water to its initial volume and further 
diluted with water (1:10).  The nanoparticles were applied to an aluminum sample plate and 
dried at room temperature for 2 h.  In order to create electrical conductibility, the 
nanoparticles were placed onto an agar sputter coater and sprayed with gold for 40 s under 
argon gas.  Then the sample was analysed with a field emission electron microscope at 15 - 
25 kV with an upper detector.  The pictures were taken using a digital system and the Paint 
Electronic software. 
 
3.1.3.4 Atomic Force Microscopy (AFM) 
Chemicals Manufacturer/supplier 
Milli-Q
® water  Millipore, Eschborn 
 
Instruments Manufacturer/supplier 
Nanoscope IIIa AFM  
with commercial Si3N4 tip 
Veeco, Santa Barbara 
Silicon plates  VWR, Darmstadt   Materials and Methods 
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Working parameters   
Temperature  25ºC 
 
The samples were prepared by simply drying a small amount of the nanoparticle dispersion 
on the silicon plates.  The measurement was done by an atomic force microscope in tapping 
mode.  After the measurement, the images were flattened and no other filtering was done. 
 
3.1.3.5 Evaluation of the loading capacity of the nanoparticles 
Chemicals Manufacturer/supplier 
Acetonitrile Merck,  Darmstadt 
Milli-Q
® water  Millipore, Eschborn 
 
Instruments Manufacturer/supplier 
HPLC UV/VIS system 
Interface: D-7000 
Pump: D-7120 
Autosampler: D-7200 
Detector: D-7420, UV/VIS 
Merck Hitachi, Darmstadt 
Centrifuge filter devices  
(Ultrafree MC, 100,000 NMWL) 
Millipore, Eschborn 
 
Working parameters   
Duration and speed of centrifugation  15 min at 16000 x g 
 
The drug content was measured after dissolution of the freeze-dried formulation in 
acetonitrile.  The insoluble material was separated by centrifugation.  The samples were then 
diluted with acetonitrile, and the drug concentrations were analysed by high performance 
lipuid chromatograph (HPLC), as described below.  
The amounts of free drug that are associated with the nanoparticles were calculated after 
separation by ultrafiltration: 400 μl of the nanoparticle suspension were centrifuged in   Materials and Methods 
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centrifuge filter devices.  100 μl of the filtrate were diluted with 900 μl water, and the 
concentration of the free drug was assessed by HPLC.  
The percentage of the nanoparticle-bound drug was calculated by subtracting the free drug in 
the supernatant from the total amount in the vials. 
The loading capacity of the nanoparticles (µg/mg) was calculated as the ratio of the drug 
content to the polymer amount, as assessed by the determination of the yield of PBCA 
(section 3.1.3.6). 
For poorly water soluble drugs that had a negligible detectable free-drug in supernatant, the 
term encapsulation efficiency was used.  The encapsulation efficiency (%) was calculated as 
the ratio of the drug content to the initial drug amount added. 
 
3.1.3.5.1 Doxorubicin assay  
Chemicals Manufacturer/supplier 
Acetonitrile Merck,  Darmstadt 
Milli-Q
® water  Millipore, Eschborn 
Trifluoroacetic acid (TFA)  Fluka, Seelze 
 
Instruments Manufacturer/supplier 
HPLC column: 
Lichrospher
®-100 HPLC RP-18 
Merck, Darmstadt 
 
 
HPLC parameters   
Detection wavelength   λ = 250 nm 
Flow rate  0.8 ml/min 
  
Mobile phase   
water:acetonitrile:TFA 70:30:0.1 
Volume of injection  20 μl 
The assay of doxorubicin was performed by HPLC as described by Ambruosi et al. 
(Ambruosi 2006a).  Accurately weighed amounts of doxorubicin were dissolved in 5 ml of   Materials and Methods 
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acetonitrile-water.  This solution was further diluted to obtain solutions with known 
concentrations in the range of 25 - 250 μg/ml.  The chromatograms of these solutions were 
registered, and the peak areas were measured.  The retention time was about 12 min.  
 
3.1.3.5.2 Loperamide assay  
Chemicals Manufacturer/supplier 
Acetonitrile Merck,  Darmstadt 
Ethanol Merck,  Darmstadt 
Milli-Q
® water  Millipore, Eschborn 
Sodium phosphate (NaH2PO4 × 2 H2O) 
buffer: (3.12 g/l) 
Merck, Darmstadt 
 
Instruments Manufacturer/supplier 
HPLC column: 
Luna
® 250 × 4.6 mm 5 μm particle C18 
Phenomenex, Torrance 
 
 
HPLC parameters   
Detection wavelength  λ = 195nm 
Flow rate 
 
1 ml/min 
Mobile phase  
Acetonitrile:Sodium phosphate buffer  
 
40:60 
Volume of injection  20 μl 
 
The assay of loperamide was carried out as described by Chen et al.  (Chen 2000).  
Loperamide stock solution (10 mg/ml) was prepared in 70% ethanol.  This solution was 
further diluted to obtain solutions with known concentrations in the range of 10 - 100 μg/ml.  
The chromatograms of these solutions were registered and the peak areas were measured.  
The retention time of loperamide was 22 min.  
   Materials and Methods 
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3.1.3.5.3 Paclitaxel assay  
Chemicals Manufacturer/supplier 
Acetonitrile Merck,  Darmstadt 
Milli-Q
® water  Millipore, Eschborn 
 
Instruments Manufacturer/supplier 
HPLC column: 
Lichrospher
®-100 HPLC RP-18 
Merck, Darmstadt 
 
 
HPLC parameters   
Detection wavelength  λ = 227nm 
Flow rate  1 ml/min 
 
Mobile phase  
Acetonitrile:Water 
 
 
6:40 
Volume of injection  20 μl 
The assay of paclitaxel was performed as described in (Krishnadas 2003).  A stock solution 
of paclitaxel in acetonitrile (1 mg/ml) was prepared.  This solution was further diluted to 
obtain solutions with known concentrations in the range of 10 - 100 μg/ml.  The 
chromatograms of these solutions were registered, and the peak areas were measured.  The 
retention time of paclitaxel was 5 min.   
 
3.1.3.6 Determination of polymer yield 
Chemicals Manufacturer/supplier 
1 N NaOH   Merck, Darmstadt 
Dichlormethane Merck,  Darmstadt 
Milli-Q
® water  Millipore, Eschborn 
n-Butanol Merck,  Darmstadt 
n-Pentanol Fluka,  Seelze 
Sodium sulfate, water-free  Merck, Darmstadt   Materials and Methods 
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Instruments Manufacturer/supplier 
Gas Chromatograph: 5890 Series II  Hewlett-Packard, Bad Homburg 
Integrator: HP3396 A 
Fused Silica Capillary Column: 
(25 m × 0.25 mm ID) 
Macherey-Nagel, Düren 
 
GC parameters   
Injector   split / splitless HP 19251 – 60540, 250 °C 
Detector  FID, 250 °C 
Oven temperature  Gradient: 45 °C (3 min) → 10 °C (1 min) 
→ 130 °C (4 min) 
Stationary phase  
Polyethylene glycol-2-nitroterephthalic acid 
 
0.1 µm film thickness 
Gas  Auxillary gas Helium, Hydrogen and Air 
Column flow  1.0 ml/min 
Split flow  10.0 ml/min 
Septum flow  1.1 ml/min 
Column + Aux  35 ml/min 
Column + Aux + Air   430 ml/min 
Column + Hydrogen + Aux  65 ml/min 
Column head pressure  94 kPa 
 
The yield of PBCA was evaluated by the amount of butanol formed after hydrolysis of 
PBCA by sodium hydroxide, as described by Langer et al. (Langer 1994).   
0.5 ml of the nanoparticle suspension were mixed with 0.5ml of 2 N NaOH and shaken 
overnight at room temperature to hydrolyze the ester groups of the polymer.  50 µl of this 
solution were mixed with 50 µl of internal standard (pentanol 0.5% solution) and diluted 
with 900 µl of water.  500 µl of this dilution were extracted with 1000 µl of 
dichloromethane, which then was dried with water-free sodium sulfate.  1 µl of the sample 
was injected into the gas chromatograph (GC) and analysed for the amount of butanol. 
   Materials and Methods 
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3.1.3.7 Determination of residual organic solvents 
Chemicals Manufacturer/supplier 
Benzene Sigma,  Moscow 
Dimethylsulfoxide (DMSO)  Sigma, Moscow 
Solvents: ethanol, iso-propanol, 
dichloromethane, ethylacetate 
Sigma, Moscow 
 
Instruments Manufacturer/supplier 
Gas chromatograph: Crystall 2000  Chromatech, San Diego 
Quartz capillary column: Zebron ZB-1 
(methylpolysiloxane, 30 m × 0.53 mm × 0.3 µm) 
Phenomenex, Torrance 
 
GC parameters   
Carrier gas  Nitrogen 
Carrier gas velocity  30 cm/s 
Column temperature  90 °C 
Gas flow regulation  1:7 
Injection volume  1 µl 
Temperature of detector and injector  200 °C  
 
Empty PBCA nanoparticles prepared in the presence of organic solvents were tested for 
residual amount of these solvents.  The sample of PBCA nanoparticles prepared according to 
the standard technique in the absence of the organic solvents was used as control.  The 
residual amount of the organic solvents in the nanoparticles was measured by GC.  The 
samples of freeze-dried nanoparticles (0.20 - 0.30 g) were dissolved in 3 ml of DMSO.  This 
solution was mixed with 1 ml of internal standard (0.01% benzene).  1 μl of this mixture was 
injected into the GC system, and the concentration of the organic solvent was measured.  As 
shown by the background measurements, the detection limits for the solvents were as 
follows: ≥ 30 ppm for ethanol and dichloromethane, ≥ 20 ppm for iso-propanol, and ≥ 5 - 10 
ppm for ethylacetate. 
    Materials and Methods 
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Preparation of the solutions: 
Internal standard: 0.2 ml of benzene was transferred into a 25 ml vessel and diluted with 
DMSO to 25ml.  1 ml of this solution was transferred into a 10 ml vessel and diluted with 
DMSO to 10 ml. 
Standard solution: 0.10 g of ethanol, iso-propanol, dichloromethane, and ethylacetate were 
transferred to 25 ml vessels and diluted to 25 ml with DMSO.  1 ml of each solution and 2.5 
ml the internal standard solution were transferred to 10 ml vessels and diluted to 10 ml with 
DMSO. 
Sample solution: approximately 0.20 - 0.30 g of the sample were transferred in to a vial, 3ml 
of DMSO and 1 ml of the internal standard solution was added.  The clear solution was 
injected into a chromatograph. 
The content of organic solvents was calculated as: 
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Where: 
o
i
r
i S and S ⋅ ⋅ - peak area of an i-residual solvent in the chromatogram of the sample and 
standard solution, respectively. 
o
ст
r
ст S and S ⋅ ⋅ - peak area of benzene (internal standard) in the chromatogram of the sample 
and standard solution, respectively. 
o
i m - weight of an i-residual solvent in the chromatogram of the standard solution 
x m - weight of a sample 
 
3.1.4 Coating of the nanoparticles with surfactants 
The surface-modified nanoparticles were used in the in vivo experiments.  For the surface 
modification, the freeze-dried nanoparticles were reconstituted with 1% (w/v) polysorbate 80 
or poloxamer 188 (Table 1) and incubated for 30 minutes.   
   Materials and Methods 
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Table 1. Characteristics of surfactants used for coating of the nanoparticles. 
Surfactant MW  (Da) 
CMC, 
µM 
CMC% 
(w/v) 
HLB Reference 
Polysorbate 80  1310 12  0.0016  15  Merck  index 
Poloxamer 188  8400 – 8800  1140  1  29  Sigma Aldrich 
CMC = critical micellar concentration, HLB = hydrophilic lipophilic balance 
 
3.1.5 In vivo experiments  
3.1.5.1 Tail-flick test 
 
The analgesic effect of the different nanoparticles preparation was measured using the tail-
flick test.  The tail-flick test measures the nociceptive threshold of the animals (mice) as they 
respond to the application of a hot light ray from a quartz projection bulb to a small area of 
their tails, so that the time for tail withdrawal is recorded.  To prevent injuries the test was 
automatically truncated after 10 s (cut-off time).  The response time for each animal was 
measured before (= pre-drug latency) and 15, 30, 45, 60, 90, 120, and 180 min after dosing 
(= post-drug latency).  The maximal possible effect (MPE%) was calculated using the 
following equation: 
 
 
The loperamide formulations were administered in the dose of 7 mg/kg into the tail vein.   
 
 
Animals Supplier 
Female ICR (CD1) mice 23 - 28 g  Halan Winkelmann, Borchen 
  
Instruments Manufacturer/supplier 
Tail-Flick Analgesia meter  Ugo Basile   Materials and Methods 
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3.1.5.1.1 Loperamide-loaded PBCA nanoparticles for tail-flick test 
The animals were divided randomly into 3 groups (n = 10) and the following formulations 
were used:  
•  Solution of loperamide in 2.6% aqueous ethanol  
•  Loperamide bound to non-coated PBCA nanoparticles stabilised with dextran (1%) 
and poloxamer 188 (0.2%)  
•  Loperamide bound to PBCA nanoparticles stabilised with dextran (1%) and 
poloxamer 188 (0.2%) coated with PS 80.   
The concentration of loperamide in the injection solutions was 0.7 mg/ml. 
 
3.1.5.2 Chemotherapy of 101/8 rat glioblastoma using doxorubicin 
formulations 
The animal experiments were performed in accordance to the German Guidelines for Animal 
Experiments and authorized by the German Tierschutzgesetz and the Allgemeine 
Verwaltungsvorschrift zur Durchführung des Tierschutzgesetzes and were authorized by the 
Regierungspräsident Darmstadt (V54 - 19 c 20/15 - F116/15).  
 
3.1.5.2.1 Intracranial implantation of rat glioblastoma 
Animals Supplier 
Male Wistar rats (200 - 250 g)  Harlan Winkelmann GmbH, Borchen 
  
Instruments Manufacturer/supplier 
Glue (Turbo 2000 Kleber Universal)  Boldt & Co, Wermelskirchen 
Stereotactic device  Leitz, Wetzlar 
Tuberculine syringe   B. Braun, Melsungen 
 
The rat 101/8 glioblastoma was initially generated by injection of α-dimethylbenzanthracene 
into the brain of Wistar rats (Yablonovskaya 1970).  The transplantation of 101/8 
glioblastoma in the present study was performed using fresh tumour tissue.  Tumour tissue   Materials and Methods 
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from frozen stocks was transplanted into adult male Wistar rats which were caged in groups 
of 5 and acclimatized for 1 week and fed ad libitum with standard laboratory food and water.  
For tumour implantation, animals were deeply anesthetized by intraperitoneal injections of 
ketamin (80 mg/kg).  Through a midline sagittal incision, a burr hole of 1.5 mm in diameter 
was made with a dental drill at a point 2 mm posterior to the right coronal suture and 2 mm 
lateral to the sagittal midline.  Tumour cells were introduced into a tuberculin syringe linked 
to a 21 gauge needle.  The tip was placed 4 mm below the bone surface and the tumour tissue 
was injected into the bottom of the right lateral ventricle.  The scalp incision was closed with 
surgical glue.  On day 14 after transplantation, the animals were sacrificed by carbon dioxide 
asphyxiation, and then decapitated.  The tumour was excised, chopped with a scalpel, and 
triturated.  Fresh tumour tissue (~ 10
6 tumour cells) was inoculated into the brain of the 
animals in the experimental groups, as described above.  
 
3.1.5.2.2 Doxorubicin formulations and treatment regimen 
The animals with implanted tumours were randomly divided into 3 groups; 
•  Untreated animals (control, n = 20) 
•  Animals treated with doxorubicin in solution (Dox-sol, n = 18) 
•  Animals treated with doxorubicin bound to PBCA nanoparticles coated with PS 80 
(Dox-NP + PS 80, n = 18).   
The treatment regimen was 3 × 1.5 mg/kg on days 2, 5, and 8 after tumour implantation.  
The formulations were injected i.v. into the tail vein.  The animals were sacrificed by carbon 
dioxide asphyxiation on days 10, 14, or 18 post-tumour implantation (n = 6/time point). 
Untreated animals (Control, n = 20) were sacrificed on days 6, 8, 10, 12, or 14 post-tumour 
implantation (n = 4/time point). 
 
3.1.5.2.3 Histological analysis 
Chemicals Manufacturer/supplier 
Zinc formalin solution  Thermo Shandon, Pittsburgh 
   Materials and Methods 
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For histological analysis, brains were removed and fixed in zinc formalin solution at least 48 
h and embedded in paraffin followed by routine hematoxylin and eosin (H&E) staining on 5 
μm thick sections using routine protocols (Schoch 2006). One slide was prepared and 
analyzed for each animal. 
 
3.1.5.2.4 Immunohistochemical analysis 
Chemicals Manufacturer/supplier 
Biotinylated Isolectin B4  B-1205, 1:20, Vector Labs, Burlingame 
Bovine serum albumin (BSA)  Sigma-Aldrich, Deisenhofen 
Diaminobenzidine (DAB)  Sigma-Aldrich, Deisenhofen 
Histofine universal immuno-peroxidase 
polymer 
Nichirei Biosciences Inc., Tokyo 
Mouse monoclonal antibody against GFAP DakoCytomation,  Glostrup 
Rabbit monoclonal antibody against ki67  Neomarkers, Lab Visions Products, 
Fremont 
Triton X-100  Zytomed, Berlin 
 
Five μm thick deparaffinated sections were used for staining procedures.  All slides were 
counterstained with alum-hematoxylin.  Blocking of endogenous peroxidase activity was 
performed with 0.3% H2O2 for 15 min.  For antigen retrieval, the slides were boiled for 1 h 
in 10 mM citrate buffer (pH 6.0) for staining with antibodies against glial fibrillary acidic 
protein (GFAP) and Ki67.  Then mouse monoclonal antibody against GFAP (M0761, 1:100) 
or rabbit monoclonal antibody against ki67 (RM-9106-S, 1:50) in blocking buffer (5% goat 
serum / 45% Tris buffered saline pH 7.6 (TBS) / 0.1% Triton X-100 in antibody diluent 
solution were applied over night.  Histofine universal immuno-peroxidase polymer or anti-
mouse or anti-rabbit were applied after washing with TBS.  For staining with Isolectin B4, 
the slides were treated in a microwave oven (640 W) for 20 min in 1 mM EDTA (pH 8.0).  
Then, biotinylated Isolectin B4 (B-1205, 1:20) was applied for 30 min at room temterature in 
100  μg/ml bovine serum albumin (BSA) in blocking buffer without goat serum.   
StreptABComplex HRP duet solution (K0492, DakoCytomation) was applied after washing   Materials and Methods 
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with PBS.  The peroxidase reaction was detected using diaminobenzidine (DAB) as 
chromogen.  As negative control, alternating sections were incubated without primary 
antibody or Isolectin B4. 
 
3.1.5.2.5 Measurement of tumour size 
Instruments Manufacturer/supplier 
Axioskop microscope  CarlZeiss Microimaging, Göttingen 
Neurolucida software-controlled computer 
system 
MicroBrightField Europe, Magdeburg 
 
An Axioskop microscope and a Neurolucida software-controlled computer system were used 
for quantitative analysis of the area occupied by the tumour on H&E stained tissue sections 
to determine tumour size in each animal. 
 
3.1.5.2.6 Analysis of proliferation 
To analyse proliferation, immunohistochemical staining with antibodies against Ki67 were 
performed on tissue sections in each animal.  The percentage of positively stained nuclei of 
all counterstained nuclei was determined in three visual fields (total area examined was 0.36 
mm
2). 
 
3.1.5.2.7 Analysis of vessel density 
Instruments Manufacturer/supplier 
Axioskop microscope  CarlZeiss Microimaging, Göttingen 
Axiovision software  MicroBrightField Europe, Magdeburg 
 
To analyse vessel density, tissue sections were stained with Isolectin B4 and analysed with 
Axiovision software.  The software quantified the percentage of the area occupied by 
Isolectin B4
+ vessels in visual fields with a size of 0.412 mm
2.   Materials and Methods 
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3.1.5.2.8 Analysis of necrosis 
For the analysis of necrosis, the following scoring system was applied to hematoxylin and 
eosin stained sections (only the tumour was assessed): 0 – no necrosis, 1 – solitary necroses, 
2 – less than 50% of tumour area occupied by necroses, 3 – more than 50% of the tumour 
area occupied by necroses. 
 
3.1.5.2.9 Analysis of GFAP expression of glioma cells 
For the analysis of GFAP expression, a score was assigned to tissue sections 
immunohistochemically stained with an antibody against GFAP only considering the area 
occupied by the tumour: 0 – no positive cells, 1 – less than 10% positive cells, 2 – more than 
10% positive cells but less than 50% of cells, 3 – more than 50% of tumour cells positive for 
GFAP. 
 
3.1.5.2.10 Analysis of microvascular proliferation 
For the analysis of microvascular proliferation, the following scoring system was applied to 
hematoxylin and eosin stained sections (only the tumour was assessed): 0 – no microvascular 
proliferation, 1 – solitary nodules of microvascular proliferation, 2 – more than five nodules 
of microvascular proliferation. 
 
3.1.5.2.11 Analysis of VEGF expression of glioma cells 
For the analysis of VEGF expression, the following score was assigned to tissue sections 
immunohistochemically stained with an antibody against VEGF only considering the area 
occupied by the tumour: 0 – no positive cells, 1 – weak staining intensity, 2 – moderate 
staining intensity, 3 – strong staining intensity. 
 
3.1.5.2.12 Statistical analysis 
All experiments were performed in a blinded manner. In case of comparision of two 
independent groups at a certain time point, the pairwise Student’s t-test was used for the   Materials and Methods 
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statistical evaluation. In case of simultaneous comparison of all three groups at a certain time 
point, non-parametric, Kruskal-Wallis with post-hoc tests were used. 
 
3.1.5.3 Chemotherapy of 101/8 rat glioblastoma using paclitaxel 
formulations 
Animals Supplier 
Male Wistar rats (200 - 250 g)  Harlan Winkelmann GmbH, Borchen 
 
Paclitaxel formulations were used for chemotherapy of 101/8 glioblastoma in rats.  Paclitaxel 
formulations were injected i.v. into the tail caudal vein with the rate of 1 ml/min.  The 
animals were implanted intracranially with the orthotopic tumour model 101/8 glioblastoma 
(sections 3.1.5.2.1 - 3). 
The treatment regimen was 3 × 1.5 mg/kg as drug (total dose 4.5 mg/kg) on days 2, 5, and 8 
post-tumour implantation. 
The animals were divided randomly into 4 groups (n = 10) and the following formulations 
were used:  
•  Paclitaxel-loaded  PBCA nanoparticles (PXL-NP) 
•  Paclitaxel-loaded PBCA nanoparticles + polysorbate 80 (PXL-NP + PS 80) 
•  Paclitaxel-loaded PBCA nanoparticles + poloxamer 188 (PXL-NP + F68 ) 
•  Paclitaxel in organic solution (PXL) 
The organic solvent contained 51% chremophor and 49% ethanol. 1 mg paclitaxel was 
dissolved in this solvent which prior to the administration was diluted with 5% glucose 
solution to obtained the desired dosage. The untreated animals were used as control. 
The antitumour efficacy of these formulations was estimated by Kaplan-Meier plots which 
estimate the survival function from life-time data. The results also are presented as numeric 
values in the form of median and mean survival times.  Median survival times are defined as 
the time from treatment at which half of the populations with tumour were found to be still 
alive.  The mean survival time is estimated as the area under the survival curve, which it is 
the average time that animals remained alive.   Materials and Methods 
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3.2 Human serum albumin nanoparticles 
Chemicals Manufacturer/supplier 
2, 4, 6-trinitrobenzenesulfonic acid (TNBS)  Sigma, Steinheim 
2-iminothiolane⋅HCl (Traut´s reagent)  Sigma, Steinheim 
Apolipoprotein A-I (Apo A-I)  Calbiochem, Darmstadt 
Apolipoprotein B-100  Calbiochem, Darmstadt 
Ethanol Merck,  Darmstadt 
Glutaraldehyde 25%  Sigma, Steinheim 
Human serum albumin (Fraction V) 
(purity 96 - 99%), 65,000 Da 
Sigma, Steinheim 
Milli-Q
® water  Millipore, Eschborn 
NHS-PEG-Mal 3400  Nektar, Huntsville 
 
Instruments Manufacturer/supplier 
Aluminum boats  Lüdi, Flawil 
Centrifuge filter devices  
(Ultrafree MC 30,000 NMWL) 
Millipore, Eschborn 
D-Salt™ Dextran desalting columns  Pierce, Rockford 
Eppendorf Centrifuge 5417  Eppendorf AG, Engelsdorf 
Eppendorf thermomixer 5436  Eppendorf AG, Engelsdorf 
Filtration unit  Schleicher und Schüll, Dassel 
Magnetic Variomag
® Multipoint HP15  Dr. Hoiss & Partner, München 
Micro BCA protein assay kit  Pierce, Rockford 
Peristaltic pump  Ismatec IPN, Glattbrugg 
Spectrophotmeter Hitachi U3000  Berkshire, UK 
Supermicro Balance  Sartorius, Goettingen 
 
Working parameters   
Duration and speed of centrifugation  8 min at 16000 x g 
Rate of pumping  1 ml/min   Materials and Methods 
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Rate of stirring  500 rpm 
Temperature 25  °C 
 
3.2.1 Nanoparticle preparation 
Empty HSA nanoparticles were prepared by an established desolvation technique (Weber 
2000a, Langer 2003).  Briefly, 200 mg of HSA were dissolved in 2.0 ml of a 10 mM NaCl 
solution.  The solution of HSA was filtered through 0.22 μm pore size Teflon syringe filters 
to remove dimmers and trimers.  After the adjustment of the pH to 8.5, the desolvation of the 
HSA was performed by drop-wise addition of 8.0 ml ethanol under constant stirring.  100% 
cross-linked nanoparticles were obtained by adding 0.588 μl of 8% glutaraldehyde per mg of 
HSA.  After 24 h of constant stirring, the resulting nanoparticles were purified by 3 cycles of 
centrifugation.  After yield determination (section 3.2.1.1) of the nanoparticles, the samples 
were redispersed to the desired concentration (10 mg/ml) in water.  Each redispersion step 
was performed in an ultrasonic bath. 
 
3.2.1.1 Yield determination of the HSA nanoparticles 
In order to adjust the concentration of the nanoparticle, the content was determined by 
gravimetry (Dreis 2007).  A 50.0 μl aliquot of the nanoparticle suspension was transferred to 
aluminum boats and dried for 2 h at 80 °C; the mass of the particle residue was determined 
using a Supermicro Balance. 
 
3.2.1.2 Preparation of sulfhydryl-reactive HSA nanoparticles 
The nanoparticles were centrifuged and redispersed in phosphate buffered saline (PBS), pH 
of 8.0.  A 10-fold molar excess of the NHS-PEG-Mal 3400 linker was added to the medium 
and for enhancing the reaction, the suspension was shaken for 1 h at room temperature.  
Afterward, the activated nanoparticles were purified by centrifugation and redispersion as 
described in section 3.2.1. 
   Materials and Methods 
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3.2.1.3 Purification of apolipoproteins A-I and B-100 
The purification of the apolipoproteins was performed as described by Michaelis et al. 
(Michaelis 2006).  A D-salt
TM Dextran Desalting column, equilibrated with PBS and 
saturated with a 1% albumin solution, was used according to the instruction sheet.  The 
apolipoprotein solutions were added to the column, and fractions were collected stepwise by 
photometrical detection of the proteins at 280 nm in order to separate the apolipoproteins 
from disturbing salts. 
 
3.2.1.4 Thiolation of apolipoproteins  
In order to attach the apolipoproteins to the activated HSA nanoparticles, sulfhydryl groups 
had to be introduced into the apolipoproteins.  The apolipoproteins were dissolved in a PBS 
solution, pH 8.0, and a 50-fold molar excess of 2-iminothiolane (Traut’s reagent) was added.  
The mixture was incubated for 12 h at 22 ºC.  The purification of the proteins was performed 
by size exclusion chromatography as described above (section 3.2.1.3).  
 
3.2.1.5 Modification of the nanoparticles by thiolated apolipoproteins  
For the conjugation, 2 ml of thiolated lipoprotein solutions were added to 2 ml of activated 
nanoparticles and the mixture was stirred for 12 h at room temperature.  The apolipoprotein-
conjugated nanoparticles were purified by three steps of centrifugation and redispersed in 
water.  Supernatants were collected to determine the amount of unbound apolipoproteins by 
standard micro BCA protein assay.   
 
3.2.1.5.1 Micro BCA protein assay 
500 µl of micro BCA working reagent was added to 500 µl of the supernatant; then the 
mixture was incubated for 1h at 37 °C.  The samples were analysed spectrophotometically at 
562 nm.  The protein content of the samples was calculated relative to reference samples, 
which contained different concentrations of protein (HSA standards).  
   Materials and Methods 
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3.2.1.6 Loperamide loading in the apolipoprotein-modified nanoparticles 
10 mg of the apolipoprotein-modified nanoparticles were incubated with 400 µl of 
loperamide solution (10 mg/ml in 42% (v/v) aqueous ethanol) under shaking for 2 h at room 
temperature.  Then the mixture was centrifuged, and the concentration of unbound 
loperamide was determined in supernatant by HPLC.  The nanoparticles were washed with 
water by centrifugation (16000 g, 8 min) and then redispersed in water for injection.  The 
final concentration of the nanoparticles in the resulting suspension was 10 mg/ml. 
Unbound loperamide in the supernatant was detected by HPLC according see section 
3.1.3.5.2.   
 
The size, polydispersity and the surface charge of the nanoparticles were measured as 
described in section 3.1.3.1. 
 
3.2.2 Apolipoprotein-modified HSA nanoparticles for tail-flick test 
Animals Supplier 
Female ICR (CD1) mice 23 - 28 g  Halan Winkelmann, Borchen 
 
The tail-flick test was performed as described above (see 3.1.5.1).   
 
The animals were divided randomly into 4 groups (n = 10) and the following loperamide 
formulations were used.  
•  Loperamide-loaded in HSA nanoparticles with covalently attached apolipoprotein A-I 
•  Loperamide-loaded in HSA nanoparticles with covalently attached apolipoprotein B-100 
•  Loperamide-loaded in unmodified HSA nanoparticles 
•  Loperamide in solution 
 
The dose of loperamide was 7.0 mg/kg.  To prevent any injuries, the test was automatically 
aborted after 10 seconds.  The response time for each animal was tested before and 15, 30, 
45, 60, 90, 120, and 180 minutes after dosing. 
   Materials and Methods 
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3.2.3 Loading of thalidomide in HSA nanoparticles  
Chemicals Manufacturer/supplier 
Dimethylsulfoxide (DMSO)  Sigma, Steinheim 
Ethanol Merck,  Darmstadt 
Thalidomide Gruenenthal,  Stolberg 
Triethylamine Sigma,  Steinheim 
 
Instruments Manufacturer/supplier 
Eppendorf Centrifuge 5417  Eppendorf AG, Engelsdorf 
Eppendorf thermomixer 5436  Eppendorf AG, Engelsdorf 
Magnetic Variomag
® Multipoint HP15  Dr. Hoiss & Partner, München 
 
Working parameters   
Duration and speed of centrifugation  8 min at 20000 x g 
Rate of stirring  500 rpm 
Solvent: ethanol-DMSO  8:2  
Temperature 25  °C 
 
The HSA nanoparticles were prepared by the earlier established desolvation technique as 
described in section 3.2.1. 
 
The preparation of thalidomide-loaded HSA nanoparticles (Thal-HSA-NP) was performed 
by adding 0.1% triethylamine after redispersing of 10 mg HSA nanoparticles in 1 ml of 
thalidomide solution in a mixture ethanol-DMSO (8:2).  The final concentration of 
thalidomide in the solvent was one mg/ml.  The samples were shaken with thermomixer for 
24 h.  The residues of organic solvents were removed after being washed three times with 
purified water. Then nanoparticles were characterised for their size, polydispersity, and 
surface charge as described in section 3.1.3.1. 
For the estimation of drug loading the supernatants were collected after each cycle of 
washing and analysed by UV/VIS HPLC as described below (section 3.2.3.1).   Materials and Methods 
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3.2.3.1 Determination of thalidomide loading  
After each nanoparticle centrifugation, 100 μl of the supernatant were diluted with 900 μl of 
a mixture ethanol-DMSO (8:2).  For preparing standard dilutions, thalidomide was dissolved 
in the same solvent.  These standard dilutions were in 80 - 120% range of the theoretical 
thalidomide concentration in the nanoparticle formulations.  This solution was further diluted 
to obtain solutions with known concentrations in the range of 10 - 250 μg/ml.  The spectra of 
the samples were recorded and calculated with values from standard solutions.  
The drug loading (% of total amount) was calculated by subtracting the free drug amount in 
the supernatant from the total amount in the vials.  The drug concentration was determined 
with HPLC as described on section 3.2.3.1.1. 
The size, polydispersity and the surface charge of the nanoparticles were measured as 
described in section 3.1.3.1. 
 
3.2.3.1.1 Thalidomide assay by HPLC 
Chemicals Manufacturer/supplier 
Milli-Q
® water  Millipore, Eschborn 
Acetonitrile Merck,  Darmstadt 
 
Instruments Manufacturer/supplier 
HPLC column: 
Lichrospher
®-100 HPLC RP-18 
 
Merck, Darmstadt 
 
HPLC parameters   
Detection wavelength   λ = 220 nm 
Flow rate  1.2 ml/min 
Mobile phase 
Water:Acetonitrile 
 
75:25 
Volume of injection  20 μl 
   Materials and Methods 
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The assay was performed as described by Gossen et al. (Goosen 2002) and using the Hitachi 
D7000 HPLC system (section 3.1.3.5.1).  Under these conditions, the retention time for 
thalidomide was about 8 min.  
 
3.2.3.2 Thalidomide solubility in different solvents and surfactants 
Chemicals Manufacturer/supplier 
Glucose Sigman,  Steinheim 
Milli-Q
® water  Millipore, Eschborn 
poloxamer 188 (Pluronic
® F68)  Sigma, Steinheim 
Solvents: dimethylsulfoxide, ethanol Sigma,  Steinheim 
Thalidomide Gruenenthal,  Stolberg 
Polysorbate 80  Fluka, Seelze 
 
Instruments Manufacturer/supplier 
Filtration unit  Schleicher und Schüll, Dassel 
 
Working parameters   
Duration of storage  24 h 
Rate of stirring  500 rpm 
Solvent: ethanol-DMSO  8:2 
Temperature 25  °C 
 
The solubility of thalidomide was tested in the mixture of the water-miscible organic solvent 
(ethanol-Cremophor
® EL, 49:51).  The solubility was also tested in water, 5% glucose as 
well as 10% aqueous solutions of surfactants, such as poloxamer 188 and PS 80.  A known 
amount of drug (1000 μg/ml) was weighed, dissolved in the above solvents, and stored for 
24 h at room temperature.  Then these suspensions were filtered through Teflon syringe 
filters (pore size 0.22 μm) to remove crystals.  100 μl of each suspension was diluted with 
900  μl of ethanol-DMSO (8:2), and the concentration of thalidomide was measured by   Materials and Methods 
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HPLC.  The concentrations of thalidomide in these media were compared with those of 
thalidomide-loaded HSA nanoparticles. 
3.2.3.3 Chemotherapy of 101/8 rat glioblastoma using thalidomide 
formulations 
Animals Supplier 
Male Wistar rats (200 - 250 g)  Harlan Winkelmann GmbH, Borchen 
 
Thalidomide formulations were used for chemotherapy of 101/8 glioblastoma in rats.   
Thalidomide formulations were injected i.v. into the tail caudal vein with the rate of 1 
ml/min.  The animals were implanted intracranially with the orthotopic model tumour 
glioblastoma 101/8 (sections 3.1.5.2.1-3).  The treatment regimen was 3 × 1 mg/kg as drug 
(total dose 3 mg/kg) on days 2, 5, and 8 post-tumour implantation. 
 
The animals were divided randomly into 4 groups (n = 10) and the following formulations 
were used:  
•  Thalidomide-loaded to HSA nanoparticles (Thal-HSA-NP) 
•  Thalidomide-loaded to HSA nanoparticles coated with 1% polysorbate 80 (Thal-
HSA-NP + PS 80) 
•  Thalidomide dissolved in corn oil and applied orally with gavage (Thal)  
•  Untreated animals (control) 
 
 
 
 
 
 
 
 
 
   Materials and Methods 
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3.3 Diindolylmethane-loaded poly(lactide-co-glycolide) nanoparticles 
 
Chemicals Manufacturer/supplier 
3,3’-Diindolylmethane (DIM)  Bioresponse LLC, Boulder 
Human serum albumin (HSA)  Sigma, Steinheim 
Mannitol Sigma,  Steinheim 
Milli-Q
® water (purified water)  Millipore, Eschborn 
Poloxamer 188 (Pluronic
® F68)  Sigma, Steinheim 
Polyvinylalcohol (PVA)  Sigma, Steinheim 
Resomer
® RG 502 H  
(50 lactide:50 glycolide), i.v. 0.2 dL/g 
Boeringher Ingelheim, Germany 
Solvents: acetonitrile, acetone  Merck, Darmstadt 
 
Instruments Manufacturer/supplier 
Lyovac GT 2 Freeze-dryer  Leybold AG, Köln 
Magnetic Variomag
® Multipoint HP15  Dr. Hoiss & Partner, München 
Peristaltic pump  Ismatec IPN, Glattbrugg 
Sintered glass filter (G2)  Schott, Mainz 
 
 
3.3.1 Preparation of DIM-loaded PLGA nanoparticles by nanoprecipitation 
The poly(lactide-co-glycolide) nanoparticles (PLGA-NP) were prepared by 
nanoprecipitation  (Bozikir 2005).  Polyvinylalcohol (PVA), HSA or poloxamer 188 
(Pluronic
® F68; F68) were used as stabilisers.  Briefly, 100 mg of the polymer (Resomer
® 
Working parameters   
Duration of evaporation procedure  4 h 
Freeze-drying  24 h at 2 × 10
-3 mbar 
Rate of pumping  1 ml/min 
Rate of stirring  600 rpm 
Temperature 25  °C   Materials and Methods 
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RG 502, i.v. 0.2 dL/g) and 10 mg of 3,3’-diindolylmethane (DIM) were dissolved in 3 ml of 
acetone.  This solution was added under magnetic stirring into a 1% solution of either 
stabiliser (10 ml) at a rate of 1.0 ml/min using a tubing pump.  Stirring was continued in 
open vials for 4 h to achieve evaporation of the organic solvent and formation of the 
nanoparticles; then the suspension was filtered through a G2 glass filter to remove the 
agglomerates, and the final volume was adjusted to the initial quantity by water.  The 
suspension was freeze-dried after the addition of 3% w/v mannitol used as a cryoprotector. 
Empty PLGA nanoparticles were prepared, as described above, in the absence of the drug.  
 
3.3.1.1 Characterisation of the DIM-loaded PLGA nanoparticles 
The size, polydispersity and the surface charge of the nanoparticles were measured as 
described in section 3.1.3.1.  The drug content was measured after dissolution of the freeze-
dried formulation in acetonitrile.  The insoluble material was separated by centrifugation. 
The samples were then diluted with acetonitrile, and the drug concentrations were analysed 
by HPLC, as described in the section 3.3.3.1.  All of the experiments were performed in 
triplicate and the result given as the average with standard deviation (mean ± SD). 
 
3.3.2 Determination of DIM maximum solubility in aqueous media 
Chemicals Manufacturer/supplier 
0.01 N Hydrochloric acid   Merck, Darmstadt 
Milli-Q
® water  Millipore, Eschborn 
Potassium dihydrogen phosphate (KH2PO4) Sigma,  Steinheim 
 
 
Determination of maximum solubility of DIM in aqueous media was performed by shake-
flask method as described by Lindenberg et al. (Lindenberg 2004).  The drug was weighed in 
Instruments Manufacturer/supplier 
Polymax 1040 orbital shaker  Heidolph, Schwalbach 
Syringeless filters; Uniprep
®  Whatman Int. Ltd.,  Springfield Mill   Materials and Methods 
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excess of its expected solubility in Uniprep
® vials equipped with a 0.45-μm membrane filter.  
Then 2 ml of either Milli-Q
® water, 0.01 N HCL (pH 2.0), or phosphate buffer (pH 7.4) 
(USP) were added into the vial.  The vials were incubated at 37 ± 0.5 °C while shaking on a 
“Polymax 1040” orbital shaker.  The samples of the solutions were taken after 4 or 24 h by 
pressing the Uniprep
® plunger down, diluted as appropriate, and the concentration of DIM 
was analysed by HPLC, as described below (section 3.3.3.1).  The measurements were done 
in triplicate (mean ± SD). 
 
3.3.3 Determination of DIM stability in organic media 
Solutions of DIM in acetone and acetonitrile were prepared to test DIM stability in organic 
media which were used for the preparation of the nanoparticle formulations; the 
concentration was either 15 µg/ml or 25 mg/ml.  The samples were stored in clear and brown 
flasks at room temperature and analysed by HPLC for degradation products.  The assay was 
performed after 4 and 24 h and then after one week. 
 
3.3.3.1 DIM assay by HPLC 
Chemicals Manufacturer/supplier 
Acetonitrile Merck,  Darmstadt 
Milli-Q
® water  Millipore, Eschborn 
Trifluroacetic acid (TFA)  Sigma, Steinheim 
 
Instruments Manufacturer/supplier 
HPLC column: 
Lichrospher
®-100 HPLC RP-18 
 
Merck, Darmstadt 
 
HPLC parameters   
Detection wavelength   λ = 280 nm 
Flow rate  1.0 ml/min 
    Materials and Methods 
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Mobile phases 
A: 0.2% TFA water 
B: 0.2% TFA in acetonitrile 
A (30%) 7 min → B (30%) 13 min 
 
Volume of injection  20 μl 
 
Accurately weighed amounts of DIM were dissolved in 5 ml of the acetonitrile and further 
diluted with the same solvent to obtain solutions with known concentrations in the range of 
10 - 250 μg/ml.  The chromatograms of these solutions and the peak areas were registered.  
The retention time was about 7 minutes.   Results 
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4 Results 
4.1 Poly(butyl cyanoacrylate) nanoparticles 
Doxorubicin-loaded poly(butyl cyanoacrylate) nanoparticles coated with polysorbate 80 
(Dox-NP + PS 80) have previously exhibited a high antitumour effect against the rat 
glioblastoma 101/8 (Steiniger 2004).  The objective of the present study was to substantiate 
these findings by extensive histological investigation. 
 
Similarly to the previous protocols used by Steiniger et al. (Steiniger 2004) or Petri et al. 
(Petri 2007), the PBCA nanoparticles were prepared by anionic polymerisation carried out 
by the addition of the monomer (n-butyl-2-cyanoacrylate; n-BCA) into the polymerisation 
medium, which consisted of an aqueous acidic solution of 0.01 N HCl and dextran 70,000 
used as a stabiliser.  The polymerisation was initiated by the OH
- ions resulting from the 
dissociation of water (Figure 10).  The polymerisation was completed after 2.5 h (Bootz 
2004) and the medium was neutralised with 0.01 N sodium hydroxide.   
 
 
Figure 10. Polymerisation mechanism of poly(alkyl cyanoacrylate) (R = alkyl function). Taken from Bootz et 
al. (Bootz 2005). 
 
The doxorubicin (Dox) solution was added into the polymerisation medium 40 minutes after 
the monomer to prevent the drug interference in the polymerization.  The final drug 
concentration was 0.25%.  
 
   Results 
 
   
79   
  
4.1.1 Characterisation of doxorubicin poly(butyl cyanoacrylate) nanoparticles 
The physicochemical characterization of the nanoparticles included measurement of the size 
and polydispersity, surface charge, investigation of the particle morphology by SEM, and 
evaluation of the drug loading and drug content. 
 
4.1.1.1 Size, polydispersity, and surface charge of the nanoparticles  
The size of the nanoparticles was determined by photon-correlation spectroscopy (PCS).  
The result showed that the doxorubicin-loaded polysorbate 80-coated nanoparticles had an 
average diameter of 260 ± 5 nm.  The empty nanoparticles prepared in the absence of drug 
had a slightly smaller size of 230 ± 5 nm.  For both empty and drug-loaded nanoparticles, the 
polydispersity index was 0.02.  Coating with surfactant had no influence on the size 
distribution. 
 
The empty and drug-loaded nanoparticles showed negative zeta potentials in distilled water.  
The empty nanoparticles had an average surface charge of -12 ± 5 mV.  Coating of dextran-
stabilised nanoparticles with polysorbate 80 (PS 80) had slightly reduced the surface charge 
values.  The average surface charge of the Dox-NP + PS 80 was -19 ± 2 mV.  
 
4.1.1.2 Morphology of the nanoparticles 
The morphology of the nanoparticles was investigated by scanning electron microscopy 
(SEM) without further purification.  Typical micrographs of the empty and drug-loaded 
nanoparticles are shown in Figure 11.  The most prominent property of the particles was their 
almost perfect spherical shape.  The bi-modal size distribution, which is characteristic for 
dextran stabilised PBCA-NP, were also observable in these figures.  The result of SEM 
measurements was in accordance with the PCS results: it showed a mean average size for 
empty nanoparticles of about 200 - 230 nm.  The loaded nanoparticles had an average size of 
about 250 - 260 nm. 
   Results 
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Figure 11. Morphology of the PBCA nanoparticles determined by SEM.  (A) empty (B) doxorubicin-loaded 
poly(butylcyanoacrylate) nanoparticles, after freeze-drying.  Bimodal distribution is visible in both samples, 
Bar: 1µm. 
 
4.1.1.3 Drug loading 
The percentage of doxorubicin bound to poly(butyl cyanoacrylate) nanoparticles   was 
assessed in the supernatant of the nanoparticles suspension after centrifugation and   
calculated by subtracting the free drug from the total amount in the vials.  It was shown that 
70% of the drug in the nanoparticle suspension was associated with the nanoparticles.  This 
result was reported in the previous studies (Steiniger 2004, Petri 2007).   
The loading capacity of the nanoparticles calculation (mg DOX/mg PBCA) was possible 
after assessment of the polymerisation yield and the solubilisation of the nanoparticles in 
acetonitrile.  The polymerisation yield for Dox-NP + PS 80 was 70 ± 10% which was higher, 
as compared to empty nanoparticles (65 ± 1.5%).  The loading capacity of the nanoparticles 
was 0.154 mg doxorubicin per 1 mg polymer.   
 
4.1.2 Histopathologic and immunocytochemical evaluation of the treatment with 
different formulations of doxorubicin 
The 101/8 glioblastoma is an orthotopic rat model of glioblastoma showing a high cellularity 
with brisk mitotic activity, necroses, focal microvascular proliferation, and an invasive 
growth pattern with destruction of parenchymal structures in the host brain satisfying the 
criteria for the diagnosis of glioblastoma multiforme (Figures 12 and 13).     Results 
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Figure 12.  Decreased tumour size following treatment with doxorubicin.  Rat 101/8 glioblastoma was 
implanted into the hemisphere of Wistar rats.  Untreated animals (Control), animals treated by intravenous 
injections of doxorubicin in solution (Dox-sol), or doxorubicin bound to polysorbate 80-coated PBCA 
nanoparticles (Dox-NP + Ps 80), both 3 × 1.5 mg/kg on days 2, 5, and 8 were sacrificed at indicated time 
points.  Hematoxylin-eosin staining of representative brains on day 10, 14, and 18 after tumour implantation is 
displayed.  Note the decreased tumour size in the Dox-sol and especially the Dox-NP + PS 80 group. 
 
The tumour shows generally a reproducible growth pattern leading to death of untreated 
animals 15 to 17 days after intracerebral implantation.  The untreated control animals were 
sacrificed on days 6, 8, 10, 12, and 14 after implantation (Table 2). The brains were analysed 
histologically to determine the tumour size, proliferation of the tumour cells, vessel density, 
and area of necrosis.   
 
Table 2. Incidence of 101/8 glioblastoma formation in control animals and animals treated with doxorubicin 
formulations. 
Group 
Doxorubicin 
dose 
(mg/kg) 
Number of rats with tumours / total number of rats 
Day 6  Day 8  Day 10  Day 12  Day 14  Day 18 
Control  -  3/4  4/4  4/4 4/4 4/4  - 
Dox-sol  3 x 1.5  -  -  5/6  -  5/6  6/6 
Dox-NP + PS 80  3 x 1.5  -  -  4/6  -  3/6  4/6   Results 
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Figure 13. Morphological alterations in following treatment with doxorubicin.  Hematoxylin-eosin staining and 
immunohistochemical staining with antibodies against the glial fibrillary acidic protein (GFAP), Ki67, and with 
Isolectin B4 (Isolectin) in brain sections of untreated control animals (Control), animals treated with 
intravenous injections of doxorubicin in solution (Dox-sol), or with doxorubicin bound to polysorbate 80-
coated PBCA nanoparticles (Dox-NP + PS 80) is displayed.  Scale bar = 50 μm. 
 
Six days after intracerebral implantation, 3 out of 4 of these animals developed a tumour. 
After 8, 10, 12, and 14 days all of the controls animals had tumours.  The 101/8 glioblastoma 
showed an increase in size from 2 ± 2 mm
2 (maximal cross-sectional area) 6 days after the 
implantation to 25 ± 8 mm
2 14 days after the implantation (Figures 12 - 14a).   
 
The proliferation of tumour cells remained high at all time points ranging from 78 ± 7% to 
86  ± 7% Ki67
+ cells (Figure 14b).  The vessel density was negligible 6 days after the 
implantation but increased significantly reaching a peak of 11 ± 2% of the total cross-
sectional tumour area 10 days after the implantation (Figure 14c).  Furthermore, necroses 
were absent in the tumours in control animals 6 and 8 days after the implantation while a 
high degree of necrosis was observed 10, 12, and 14 days after the implantation (Table 3).     Results 
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Figure 14. Treatment with nanoparticle-coated doxorubicin has antiangiogenic effects.  Untreated animals 
(Control), animals treated with intravenous injections of doxorubicin in solution (Dox-sol) or doxorubicin 
bound to polysorbate 80-coated PBCA nanoparticles (Dox-NP + PS 80) both, 3 × 1.5 mg/kg on days 2, 5, and 8 
were sacrificed at different time points after implantation.  Statistical analysis of tumour size (a) estimated by 
the maximal area occupied by the tumour in serial sections, proliferation (b) determined by analysing the 
percentage of tumour cells stained with antibodies against Ki67, and vessel density (c) determined by 
measuring the percentage of the tumour area occupied by cells stained with Isolectin B4 are displayed.  On day 
14 after tumour implantation, the tumour area occupied by Isolectin B4
+ cells was negligible in the Dox-NP + 
PS 80 group.  On day 18, the columns for the Dox-NP + PS 80 group display the mean values and standard 
deviations of this group without the outlier.  The values for the outlier are marked by the (†) symbol.    Results 
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Table 3.  Histological and immunohistochemical evaluation of intracranially implanted 101/8 glioblastoma after treatment with formulations of doxorubicin. 
Type of 
evaluation 
Day 6  Day 8  Day 10  Day 12  Day 14  Day 18 
Control 
Dox-
sol 
Dox-
NP + 
PS 80 
Control 
Dox-
sol 
Dox-
NP + 
PS 80 
Control 
Dox-
sol 
Dox-
NP + 
PS 80 
Control 
Dox-
sol 
Dox-
NP + 
PS 80 
Control 
Dox-
sol 
Dox-
NP + 
PS 80 
Control 
Dox-
sol 
Dox-
NP + 
PS 80 
Necrosis 
(Score) 
0 - - 0 - - 3 1 0 3 - - 3 2 0 -  3 1 
GFAP 
(Score) 
1 - - 2 - - 1 1 1 1 - - 2 1 0 -  2 1 
Microvasscular  
Proliferation  
(Score) 
0 - - 1 - - 1 0 0 1 - - 2 1 0 -  1 0 
VEGF 
(Score) 
1 - - 2 - - 2 2 0 2 - - 1 2 0 - 2 1 
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Microvascular proliferation was detected from day 8 after implantation.  No significant 
differences were detected in the GFAP expression with a patchy low to moderate expression 
at all time points.  Thus, the 101/8 rat glioblastoma model closely resembled human 
glioblastomas and showed a reproducible growth pattern allowing its application in the 
evaluation of potential new therapies for glioblastoma. 
The effect of systemic chemotherapy on the temporal development of the 101/8 glioblastoma 
was evaluated using two different formulations of doxorubicin; doxorubicin bound to PBCA 
nanoparticles coated with PS 80 (Dox-NP + PS 80), and doxorubicin in solution (Dox-sol), 
which compared to the untreated controls.  The Dox-NP + PS 80 treatment significantly 
decreased tumour formation.  In the control groups, from day 8 to day 14, all animals 
developed tumours. The tumour incidence at all three comparable time points (day 10, 14 
and 18) for the Dox-sol group was 16 out of 18 and for the Dox-NP + PS 80 groups was  
only 11 out of 18 (Table 2).  Tumour size, proliferation of tumour cells, vessel density, and 
necrosis were compared between the Dox-NP + PS 80, Dox-sol, and control group on day 10 
and 14 after the implantation (Figure 14, Table 3).  Additionally, the Dox-NP + PS 80 and 
Dox-sol groups were compared on day 18 after the implantation.  Previous experiments 
demonstrated that only a minor fraction of the animals in the control group survived longer 
than 16 days (d) after implantation (Steiniger 2004); therefore, day 14 was chosen as the last 
time point for the tumour assessment in the control group. 
 
4.1.2.1 Tumour size  
On day 10, there was a significantly decreased tumour size in the Dox-sol (p = 0.025) and 
the Dox-NP + PS 80 (p = 0.0003) groups when compared to the control group (Table 4, 
Figure 14a).  The mean areas occupied by the tumours on H&E stained brain sections for the 
groups of untreated animals, Dox-sol and Dox-NP + PS 80 were 9.4 ± 5.2 mm
2 , 2.4 ± 1.2 
mm
2 and 0.3 ± 0.4 mm
2, respectively.  
On day 14, the mean tumour size in the control group reached 24.9 ± 7.6 mm
2.  Dox-NP + 
PS 80 considerably inhibited the tumour growth: the tumour size in this group was only 0.4 ± 
0.2 mm
2 (Figure 14a).  The tumour growth in Dox-sol was also inhibited and reached 11.1 ± 
11.3 mm
2.  Statistically significant differences were found between the control and Dox-NP   Results 
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+ PS 80 group both on day 10 (p = 0.0003) and day 14 (p = 0.0028) after the implantation. 
There were also statistical significance differences found between the Dox-sol and Dox-NP + 
PS 80 groups on day10 (p = 0.025) and on day 14 after the implantation (p = 0.04) (Table 4). 
The considerable increase in efficacy of the tumour growth inhibition enabled by Dox-NP + 
PS 80 was also visible on day 18 after implantation.  The mean tumour size - including one 
outlier - in this group was 11.7 ± 22.4, whereas in the Dox-sol group, the size reached 23.0 ± 
13.5 mm
2.  It is important to note that only one animal (the outlier) in the Dox-NP + PS 80 
group developed a considerable tumour of 45 mm
2, whereas the tumours of other animals 
were below 1 mm
2 (Figure 14a).  Without the outlier, the mean tumour area in this group is 
0.48  ± 0.29 mm
2, which is significantly lower, as compared to the Dox-sol group (p ≤ 
0.0005) (Table 4).  Thus, treatment of 101/8 rat glioblastoma with Dox-NP + PS 80 
significantly decreased the incidence of tumours and tumour size when compared to the 
Dox-sol and the untreated control groups. 
 
4.1.2.2 Proliferation 
Proliferation was determined by immunohistochemical staining with antibodies against Ki67.  
Proliferation showed stable levels in all groups (Figure 14b) with an average of 80 ± 8% 
Ki67
+ cells in the control group versus 71 ± 11% and 58 ± 8% in the Dox-sol and Dox-NP + 
PS 80 group, respectively.  On day 10, the Dox-sol and the Dox-NP + PS 80 groups showed 
a significantly decreased proliferation after the implantation, when compared to the control; 
p = 0.02 and 0.005 respectively. No statistical significancy was observed on day 14 between 
the groups (Table 4 and Figure 14b).  However, a significant decrease of the tumour cells 
proliferation was observed on day 18 when compared with the Dox-sol group (p < 0.0005). 
Thus, treatment with Dox-NP + PS 80 decreased proliferation of the tumour cells when 
compared to treatment with Dox-sol and untreated control animals. 
 
4.1.2.3 Vessel density 
The vessel density in the tumour tissue was determined by measuring the percentage of the 
tumour area occupied by blood vessels and microvascular proliferation in serial sections   Results 
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(Figure 14c).  On day 10, the tumours in animals treated with Dox-NP + PS 80 showed a 
decreased vessel density when compared to animals treated with Dox-sol or untreated control 
animals (2 ± 2%, 7 ± 4%, 11 ± 2%, respectively). A statistical significant difference was 
found only between the control and the Dox-NP + PS 80 groups (p = 0.017) (Table 4).  The 
advantage of Dox-NP + PS 80 became even more pronounced on day 14: the vessel density 
in this group was negligible, whereas in the group treated with Dox-sol the density was 
similar to the untreated control (8 ± 6% and 9 ± 4%, respectively).  On day 18 after the 
implantation, the vessel density was decreased in the Dox-NP + PS 80 group when compared 
to the Dox-sol group (3 ± 5% and 6 ± 1%, respectively).  Again the high standard deviation 
for the Dox-NP + PS 80 group is due to the single outlier.  Without the outlier the mean 
vessel density in the Dox-NP + PS 80 group is 0.85 ± 0.28% which in this case, the 
difference between the Dox-NP + PS 80 and Dox-sol groups was statistically significant (p ≤ 
0.0005) (Table 4).  Thus, vessel density in the tumour tissue was drastically decreased after 
treatment with Dox-NP + PS 80 when compared to treatment with Dox-sol and untreated 
control animals. 
 
4.1.2.4 Expression of glial fibrillary acidic protein (GFAP), expression of 
vascular endothelial growth factor (VEGF), incidence and dimension of 
necrosis, and microvascular proliferation 
The efficacy of the chemotherapy was further characterized by GFAP expression, VEGF 
expression, the incidence and dimension of necrosis, and microvascular proliferation (Table 
3).  While no considerable differences were observed in GFAP expression, the expression of 
VEGF was decreased in the Dox-NP + PS 80 group when compared to the Dox-sol and the 
control group at all time points (Figure 13).  The incidence of necrosis was decreased in the 
Dox-sol group when compared to untreated control animals. Necrosis was rarely observed in 
the Dox-NP + PS 80 group.  Microvascular proliferation increased with time in the control 
group.  The Dox-sol group showed decreased microvascular proliferation when compared to 
the control group, while in the Dox-NP + PS 80 group microvascular proliferation was 
completely absent.  Thus, treatment of rat 101/8 glioblastoma with Dox-sol led to a slight 
decrease of necrosis and microvascular proliferation, whereas Dox-NP + PS 80 drastically 
decreased necrosis and led to the complete disappearance of microvascular proliferation.   Results 
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Table 4. Statistical analysis of the anti-tumour effect of doxorubicin formulations in rats bearing intracranial 
101/8 glioblastoma tumour.  
Type of test 
Day of 
fixation 
Groups p-value 
Tumour size 
Day 10 
Control vs Dox-sol  0.025* 
Control vs Dox-NP + PS 80  0.0003* 
Dox-sol vs Dox-NP + PS 80  0.025* 
Day 14 
Control vs Dox-sol  0.15 
Control vs Dox-NP + PS 80  0.0028* 
Dox-sol vs Dox-NP + PS 80  0.04* 
Day 18**  Dox-sol vs Dox-NP + PS 80  <0.0005* 
Proliferation 
Day 10 
Control vs Dox-sol  0.02* 
Control vs Dox-NP + PS 80  0.005* 
Dox-sol vs Dox-NP + PS 80  1 
Day 14 
Control vs Dox-sol  1 
Control vs Dox-NP + PS 80  0.16 
Dox-sol vs Dox-NP + PS 80  0.58 
Day 18**  Dox-sol vs Dox-NP + PS 80  <0.0005* 
Vessel Density 
Day 10 
Control vs Dox-sol  0.17 
Control vs Dox-NP + PS 80  0.015* 
Dox-sol vs Dox-NP + PS 80  0.2 
Day 14 
Control vs Dox-sol  0.35 
Control vs Dox-NP + PS 80  <0.0005* 
Dox-sol vs Dox-NP + PS 80  <0.0005* 
Day 18**  Dox-sol vs Dox-NP + PS 80  <0.0005* 
* Statisticaly significant. The significance level was set at 0.05 (p ≤ 0.05). 
** The comparison between the two groups was performed with the pairwise Student’s t-test. The simultaneous 
comparison between three groups was evaluated with the Kruskal-Wallis model with post-hoc test. 
 
4.1.3 Characterisation of drug-loaded PBCA nanoparticles prepared in the 
presence of organic solvents 
The drug-loaded PBCA nanoparticles were produced by anionic polymerisation of n-butyl-2-
cyanoacrylate in the presence of a drug.  The polymerisation media consisted of a solution of 
stabilisers/surfactants in a mixture of 0.01 N HCl and an appropriate organic solvent (9:1).    Results 
 
   
89   
  
Two substances were chosen; paclitaxel, a widely used antitumour agent and a model drug, 
loperamide (opiate receptor agonist).  The paclitaxel solubility in water is about 1 μg/ml 
(Liggins 1997); the solubility of loperamide is about 2 μg/ml (Merck ed. 2001).  These drugs 
are sufficiently soluble in organic solvents (Merck 2001, Kim 2004).  The drug-to-polymer-
ratio was 1:10.  The particles were stabilised by commonly used excipients, dextran 70,000 
(1%) and poloxamer 188 (0.2%) or, in the case of paclitaxel, also by PEG-PE, a micelle-
forming PEGylated phospholipid.   
 
The data on the influence of organic solvents on the physicochemical parameters of the drug-
loaded and empty PBCA nanoparticles are presented in Tables 5 - 7 and Figures 15 - 17.   
 
4.1.3.1 Size, polydispersity and surface charge of the nanoparticles 
The average particle diameter and polydispersity of the nanoparticles are shown in Table 5.  
The polymerisation of n-butyl-2-cyanoacrylate in the presence of dextran and poloxamer 188 
enabled the preparation of 220 nm nanoparticles with a narrow polydispersity of 0.05, which 
correlates with the results of other studies (Bootz 2004, Ambrousi 2006).   
 
Table 5.  Physicochemical parameters of empty PBCA nanoparticles prepared in the presence of organic 
solvents (a mean value of 3 measurements ± SD). 
Organic solvent 
Particle size measured by PCS  Charge 
(mV) 
Yield of PBCA 
(%)  Mean diameter (nm)  Polydispersity 
None  220 ± 5  0.05 ± 0.02  -17  65 ± 1.61 
MeOH  200 ± 11  0.045 ± 0.015  -12  50.50 ± 2.0 
EtOH  230 ± 10  0.035 ± 0.02  -10  45.55 ± 6.25 
i-PrOH  240 ± 8  0.02 ± 0.01  -10  56.29 ± 2.0 
EtOAc  195 ± 7  0.05± 0.01  -11  56.70 ± 10.5 
CH2Cl2  185 ± 5  0.025 ± 0.01  -14  65.60 ± 2.6 
CH2Cl2/PEG-PE  320 ± 10  0.3 ± 0.05  -17  55.87 ± 5.11 
   Results 
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The presence of the organic solvents in the polymerisation medium did not considerably 
influence the physicochemical parameters of the empty nanoparticles.   
The surface charges of all samples were negative with values between -10 to -17 mV with 
similar sizes in the range of 185 - 240 nm and a narrow size distribution of 0.02 to 0.05.  The 
empty nanoparticles produced using 1% PEG-PE were characterised by a larger size of 320 
nm with a higher polydispersity of 0.3.  The results of the PCS measurements of the particle 
size were consistent with the data obtained by analytical ultracentrifugation (Figure 15).   
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Figure 15. Particle size distribution determined by analytical ultracentrifugation (ANUC) of empty (dotted 
line) and loperamide-loaded (solid line) PBCA nanoparticles prepared in the presence of dichloromethane after 
freeze-drying. 
 
The empty nanoparticles showed a relatively homogeneous size distribution with a peak at 
220 nm.  A broad shoulder in the range of ~ 250 nm and a small peak at about 500 nm were 
obviously caused by the presence of particles of these sizes.  These particle populations, 
however, were not large since they did not produce any significant isolated peaks.  
The size and size distribution of loperamide-loaded PBCA nanoparticles determined by PCS 
and analytical ultracentrifugation did not differ significantly from those of empty 
nanoparticles (Table 5 - 6, Figure 15).   
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Table 6. Parameters of loperamide-loaded PBCA nanoparticles prepared in the presence of organic solvents 
(mean values ± SD from three replicate samples). 
Organic 
phase 
Substance 
solubility 
(mg/ml)* 
Particle size measured by 
PCS  Surface 
charge 
(mV) 
Encapsulation 
efficiency 
(%) 
Loading capacity 
(µg bound drug/ 
mg PBCA) 
Drug conc. 
 in the 
nanoparticle 
suspension 
(mg/ml) 
Yield of 
PBCA 
(%) 
Mean 
diameter 
(nm) 
Polydispersity 
MeOH  28.6  225 ± 5  0.035 ± 0.02  -5  82.5 ± 5  157.44  0.825 ± 0.05  52.4 ± 10.9
EtOH  5.37  245 ± 5  0.030 ± 0.01  -10  85.5 ± 5  145.41  0.85.5 ± 0.05  58.8 ± 20.5
CH2Cl2  35.1  223 ± 5  0.020 ± 0.01  -4  80.2 ± 2  131.60  0.802 ± 0.02  60.9 ± 10.1
* Data from Merck index, edition 13 
 
The surface charges were less negative, as compared to the empty particles, but remained 
negative in the range of -5 mV to -10 mV.  The encapsulation efficiency of loperamide was 
as high as 80 - 85%; the capacity of the particles reached 130 - 160 µg bound drug/mg 
PBCA.  The yield of PBCA was 50 - 60%, which was similar to that of the empty 
nanoparticles.   
 
Table 7. Parameters of paclitaxel-loaded PBCA nanoparticles prepared in the presence of organic solvents 
(mean values ± SD from three replicate samples). 
Organic 
phase 
Substance 
Solubility
* 
Particle size measured by 
PCS  Surface 
charge 
(mV) 
Encapsulation 
efficiency 
(%) 
Loading 
capacity 
(µg bound 
drug/ 
mg PBCA) 
Drug conc. 
 in the 
nanoparticle 
suspension 
(mg/ml) 
Yield 
of 
PBCA 
(%) 
Mean 
diameter 
(nm) 
Polydispersity
MeOH  Soluble  353.2 ± 3.3  0.36 ± 0.02  -15  20 ± 5  32.0  0.20 ± 0.05  62.5 
i-PrOH  Soluble  421.3 ± 42.3  0.38 ± 0.05  -19  16.5 ± 2  31.31  0.165 ± 0.02  52.7 
EtOAc  n/a  365.8 ± 2.3  0.58 ± 0.01  -11  20.5 ± 2  30.73  0.205 ± 0.02  66.7 
CH2Cl2  Soluble  307.6 ±12  0.24 ± 0.03  -17  24.2 ± 5  40.33  0.242 ± 0.05  60 
CH2Cl2/ PE-
PEG 
n/a  355.3 ± 5  0.33 ± 0.05  -20  45 ± 5  55.90  0.45 ± 0.05  80.53 
* Data from Kim et al. (Kim 2004). 
 
The size of paclitaxel-loaded nanoparticles was larger than the empty nanoparticles, with the 
mean particle diameters ranging from 308 nm to 427 nm depending on the solvent that was 
used.  The polydispersity was also higher – up to 0.3 (Table 7).   
The charge of these particles did not considerably differ from that of the empty particles.     Results 
 
   
92   
  
4.1.3.2 Morphology of the nanoparticles 
The morphology of the PBCA nanoparticles was investigated by scanning electron 
microscopy (SEM) and atomic force microscopy (AFM).  The samples for microscopy were 
prepared after freeze-drying without further purification.  Typical micrographs of empty and 
loperamide-loaded particles are shown in Figures 16 and 17.  
 
 
Figure 16 Scanning electron micrographs (SEM) of the PBCA nanoparticles prepared in the presence of 
dichloromethane after freeze-drying and redispersion in water: (A) empty and (B) loperamide-loaded 
nanoparticles.  Bar: 800 nm. 
 
  It can be seen that both types of particles had a spherical shape.  Importantly, the 
micrographs of loperamide-loaded particles did not exhibit any crystals on the surface of the 
particles or in the medium, which indicates that all drugs in this formulation were indeed 
encapsulated and not precipitated in the form of crystals.  
 
 
Figure 17. AFM surface morphology of the PBCA nanoparticles in the presence of dichloromethane after 
freeze-drying and redispersion in water: (A) empty and (B) loperamide-loaded nanoparticles.  Bar: 200 nm.   Results 
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4.1.3.3 Particle yield 
The yield of PBCA particles were measured with gas chromatography.  The particle yield 
appeared to be lower in the presence of alcohols and ethylacetate, whereas dichloromethane 
did not affect this parameter.  The polymerisation time before adding the organic solvent (30, 
40, or 60 min) did not produce any considerable changes in the above parameters of the 
empty nanoparticles.  The presence of the drug appeared to have no major influence on the 
particle yield.  However, the polymerisation yield in the presence of PEG-PE reached about 
80%, which was the highest particle yield compared to other excipient (dextran 70,000 (1%) 
and poloxamer 188 (0.2%)) (Tables 5 - 7). 
 
4.1.3.4 Drug loading 
The encapsulation efficiency of paclitaxel in the particles stabilised by dextran and 
poloxamer 188 was low (16 - 24%); however, in the presence of PEG-PE the loading 
increased to 45% and the capacity reached 55 µg/ mg PBCA (Table 6).  PEG-PE also 
produced the highest PBCA yield of 80%; whereas for other samples, the yield remained in 
the range of 50 - 65%. 
The concentration of loperamide in the nanoparticle suspensions was ~ 0.8 mg/ml.  The 
measurements of the drug loading performed after freeze-drying demonstrated that the 
filtrates obtained by ultrafiltration of the nanoparticle suspension contained only trace 
amounts of free drugs, which suggested that practically all of the drugs in the formulations 
were incorporated in the nanoparticles.  Therefore, the nanoparticles enabled a 400-fold 
increase in drug content in an aqueous medium (800 μg/ml versus initial 2 μg/ml) (Table 6).  
Similar results were obtained for paclitaxel: its total concentration in the aqueous medium 
was increased 200-fold for the dextran/poloxamer-stabilised particles and 450-fold in the 
case of PEG-PE (Table 6). 
 
4.1.3.5 The content of residual organic solvents 
The residual content of the organic solvents in the samples of empty nanoparticle after 
freeze-drying was analysed by gas chromatography.  It was found that the nanoparticles   Results 
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produced in the presence of ethanol contained the highest residual amount of 1400 ppm 
organic solvents, whereas the particles produced in the presence of ethylacetate exhibited 
only trace amounts of 5 ppm.  The amounts of residual solvents in the samples prepared in 
the presence of iso-propanol and dichloromethane were 340 ppm and 50 ppm, respectively.   
 
4.1.3.6 Loperamide-loaded PBCA-based formulations for the tail-flick test 
The pharmacological efficacy of the nanoparticulate loperamide was tested using the tail-
flick test, as described by Alyautdin et al. (Alyautdin 1997).  The antinociceptive effects of 
the formulations measured as percentage of a maximal possible effect (MPE%) are presented 
in Figure 18.   
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Figure 18. Antinociceptive effect of loperamide formulations assessed by a tail-flick test after i.v. injection in 
mice (7.0 mg/kg): ● loperamide bound to non-coated, ○ polysorbate 80-coated PBCA nanoparticles and 
▲loperamide solution (n = 10). 
 
It can be seen that loperamide bound to PBCA nanoparticles coated with polysorbate 80 
produced an analgesic effect that reached its maximum of 80% MPE 15 min after injection 
and was measurable for 120 min.  As expected, loperamide in solution was ineffective, and   Results 
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after 60 minutes the evaluation of this formulation was terminated.  These data correlate with 
the results of Alyautdin et al. (Alyautdin 1997).  Similarly to the polysorbate 80-coated 
nanoparticles a considerable analgesia also was produced by the non-coated nanoparticles.  
The maximal effect of the non-coated nanoparticles formulation (100% MPE) was observed 
15 min after injection. However, in this case analgesia lasted only 60 min. 
 
4.1.3.7 Treatment of rats bearing intracranial transplanted glioblastoma 
101/8 using paclitaxel-loaded nanoparticle formulations 
The antitumour efficacy of paclitaxel in three nanoparticle formulations including paclitaxel 
bound to PBCA nanoparticles (PXL-NP), PXL-NP coated with polysorbate 80 (PXL-NP + 
PS 80), and PXL-NP coated with poloxamer 188 (PXL-NP + F68) was tested in 
glioblastoma-bearing rats. Untreated glioblastoma-bearing rats and the animals treated with 
the paclitaxel solution (PXL) were used as controls.  
The brain tumour model and the treatment regimen for the present study were chosen based 
on the results of the previous experiments, where this experimental protocol using 
doxorubicin formulations proved to be effective (Steiniger 2004, Ambrousi 2006, Petri 
2007).  Therefore, the objective of this experiment was to investigate if this technology could 
be extended to paclitaxel.   
Due to the low loading of paclitaxel to PBCA-NP, administration of a high dose was not 
possible. Therefore, the chemotherapy of paclitaxel was carried out using the total dose of 
4.5 mg/kg (3 × 1.5 mg/kg).  The result of the chemotherapy is presented as numeric values in 
the form of median and mean survival time (Table 8) and the Kaplan-Meier survival curves 
(Figure 19).  
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Table 8. Median and mean survival time of the 101/8 glioblastoma-bearing rats after treatment with different 
paclitaxel formulations; (PXL-NP), PXL-NP coated with polysorbate 80 (PXL-NP + PS 80) or coated with 
poloxamer 188 (PXL-NP + F68), and paclitaxel solution (PXL) which compared with untreated animals 
(Control). 
Groups 
Survival time, days 
Median Mean 
Untreated control  11 13 
PXL  14 15 
PXL-NP  12 13 
PXL-NP + PS 80  13 14 
PXL-NP + F68  15 14 
 
The median survival time represents the day at which half of the populations with tumour 
were still alive.  As seen from Table 8, the median of survival in the groups treated with PXL 
and PXL-NP + F68 were 14 and 15 days, respectively, which was slightly higher than in the 
other groups.  The mean survival times measured starting from the day of the tumour 
implantation were similar in all groups (14 days).  None of the groups treated with paclitaxel 
formulations showed improvement in the mean survival time, as compared to the untreated 
animals.   
As seen from the Kaplan-Meier survival curves, the longest survival time was achieved in 
the group treated with paclitaxel solution:  25% of the animals (2/8) survived till day 20 post-
tumour implantation.  However, this effect was not significant.  In addition, there were no 
cases of long-term remission. 
   Results 
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Figure 19. Survival (Kaplan-Meier plot) of rats bearing intracranially transplanted 101/8 glioblastoma after i.v. 
administration of paclitaxel-loaded in PBCA nanoparticles formulation; (PXL-NP), PXL-NP coated with 
polysorbate 80 (PXL-NP + PS 80) or coated with poloxamer 188 (PXL-NP + F68) which compared with 
paclitaxel solution (PXL), and untreated animals (Control). 
 
All animals were sacrificed after the appearance of the clinical signs of the disease (mostly 
day 15).  The macroscopical observation of the internal organs showed no signs of drug 
related toxicity.  
 
4.2 Characterisation of human serum albumin nanoparticles 
The human serum albumin nanoparticles (HSA-NP) were prepared by desolvation of HSA 
with ethanol followed by crosslinking with glutaraldehyde (Weber 2000a, Weber 2000b).  
The desolvation procedure was performed by the addition of the desolvating agent, ethanol 
to the protein.  The desolvation resulted in the precipitation of the HSA macromolecules.  
With the help of ethanol the swelling of macromolecules in solution reversed, and the 
diameter of the macromolecule coil become smaller.  After a certain degree of desolvation, 
the molecules began to aggregate.  When sufficient desolvation had occurred, phase 
separation took place (Kreuter, J. Ed. 1994). 
After the desolvation of HSA solution, the nanoparticles were stabilised with glutaraldehyde.  
The aldehyde amount was corresponding to 100% of the theoretic amount necessary for the   Results 
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quantitative cross-linking of the 59 ε-amino groups in the HSA molecules of the particle 
matrix (Langer 2003, Weber 2000a). 
The resulting nanoparticles were purified by repetitive washing and the pellets were re-
dispersed to the original volume in water.  
 
4.2.1 Size, polydispersity and surface charge of the nanoparticles 
By using a combination of the pump-controlled system and adjusting of the pH in the 
presence of sodium chloride, rather homogenous sizes and polydispersities of the 
nanoparticles were achieved.  The size of the empty nanoparticles at pH 8.0 was about 170 ± 
20 with the polydispersity of 0.25 ± 0.05.  The purification process removed all particles of 
diameter below 50 nm, which lead to much more narrow size distributions.  The size of 
nanoparticles after purification was 200 ± 25 nm with a narrow size distribution of 0.05 ± 
0.01.  
The surface charge of the empty nanoparticles was -50 ± 6.5 mV. 
 
4.2.2 Characterisation of the HSA nanoparticles modified by apolipoprotein A-I 
and B-100 
The mechanism of the delivery of the drugs across the BBB by nanoparticles still is not fully 
elucidated.  The involvement of different apolipoproteins which enable the interaction of the 
nanoparticles with the brain endothelial cells and subsequent drug transfer into the brain was 
demonstrated in different studies (Kreuter 2002, Gessner 2001, Petri 2007). 
In the present study, apolipoprotein A-I (Apo A-I) and B-100 (Apo B-100) were covalently 
coupled to human serum albumin (HSA-NP), and the central analgesic effect of loperamide 
which was adsorbed to the nanoparticles surface was tested with the tail-flick test.  
For the covalent attachment of the apolipoproteins to the nanoparticle, it was necessary to 
achieve reactive sulfahydryl functions on the surface of the nanoparticles.  The nanoparticles 
were activated using a heterobifuntional PEG-based crosslinker; NHS-PEG3400-MAL.   
At pH 8.0, the spacer reacted selectively with primary amine groups which were available on 
the nanoparticle surface.  To achieve complete reaction, the spacer was used in 50-fold molar   Results 
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excess.  After 2 h, the unreacted spacer was separated with centrifugation from NHS-PEG-
MAL activated nanoparticle (Figure 20).  The nanoparticles were redispersed in phosphate 
buffer (pH 8.5). 
 
 
Figure 20. Chemical representation of the nanoparticles with the bifunctional NHS-PEG-MAL (mw = 3400). 
 
In a second step, a free sulfyhydryl group was introduced on the surface of apolipoproteins 
by reaction of apolipoprotein amino groups with 2-iminothiolane (Figure 21).  2-
iminothiolane (Traut’s reagent) is a water soluble reagent and reacts at pH 7 to 10.  
 
 
Figure 21. Thiolated apolipoprotein. 
 
After thiolation of the apolipoproteins, the nanoparticles were attached via a thioether 
linkage between the sulfhydryl reactive NHS-PEG-maleimide group of the activated 
nanoparticles and the sulfhydryl groups on the apolipoprotein surface.  The apolipoproteins 
were employed in the highest concentrations (Table 9) that could be attached to the 
nanoparticles.  The Apo A-I concentration was 150 µg/ml nanoparticle suspension which 
was 3 times higher than that of Apo B-100 (50 µg/ml).     Results 
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Loperamide was loaded by the absorption method on the surface of the nanoparticles.  The 
final HSA nanoparticles concentration was 10 mg/ml corresponding to 0.7 mg loperamide.   
Figure 22 shows the schematic structure of the covalently apolipoprotein modified HSA 
nanoparticles. 
 
Figure 22. Schematic illustration of covalently apolipoprotein-modified HSA-NP. Thiolated apolipoprotein 
attached via thioether linkage to activated nanoparticles. Loperamide loaded to nanoparticle by adsorption 
method. 
 
4.2.2.1 Size, polydispersity and surface of the nanoparticles 
Table 9 shows three preparations based on the HSA nanoparticles which were used in the 
tail-flick test: loperamide-loaded unmodified nanoparticles (HSA-NP), loperamide-loaded 
HSA nanoparticles with covalently attached apolipoproteins A-I or B-100 (HSA-NP+ApoA-
I, HSA-NP+ApoB-100, respectively). 
The nanoparticle preparations were characterised by a similar size, polydispersity index, and 
zeta potential.  The size of the nanoparticles with covalently bound ApoB-100 was about 240 
nm which was slighty bigger than that of HSA-NP modified with Apo A-I (225 nm) and the 
unmodified loperamide-loaded nanoparticles (218 nm).  The attachment of apolipoproteins 
slightly increased the nanoparticles polydispersity from 0.05 (HSA-NP) to 0.3 (HSA-NP + 
Apo A-I) and 0.6 (HSA-NP + Apo B-100).  The surface charges remained negative for all 
particles.  However, the empty nanoparticles showed a slightly more negative charge (-42 
mV).  
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Table 9. Physicochemical characteristics of loperamide-loaded HSA nanoparticles (HSA-NP) with 
apolipoproteins A-I and B-100 (Apo A-I, Apo B-100) covalently attached using the NHS-PEG-Mal 3400 
linker. 
Preparations 
Mean 
particle size 
(nm) 
Polydispersity 
Charge 
(mV) 
Loperamide 
conc. 
(mg/ml) 
Apolipoprotein 
conc. (μg/ml) 
HSA-NP + Apo A-I  225 0.38  -  35  0.86 150 
HSA-NP + Apo B-100  240 0.66  -  37  0.86  50 
HSA-NP  218 0.05  -  42  0.86  - 
 
The highest concentrations of the apolipoproteins which could bind to the HSA nanoparticles 
were differed from each other (Table 9). The highest apolipoprotein A-I concentration was 
150 µg/ml of the nanoparticle suspention which was three times higher compared to the 
nanoparticle preparation with apolipoprotein B-100. However the loperamide loading was 
similar for all nanoparticle preparations.   
 
4.2.2.2 Tail-flick test with apolipoprotein-modified HSA nanoparticle 
formulations  
The antinociceptive response demonstrating the transport of loperamide across the BBB was 
measured by the tail-flick test after intravenous injection of the loperamide formulations in 
mice.  A significant antinociceptive response was achieved only in animals treated with 
loperamide bound to HSA nanoparticles modified by the apolipoproteins A-I and B-100 
compared, whereas the effect of empty nanoparticles and the loperamide solution was 
negligible (Figure 23).   Results 
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Figure 23. Maximal possible effect (MPE) (mean ± SD) of the antinociceptive response of male ICR (CD-1) 
mice after injection of one of the following loperamide formulations into the tail vein in the dose of 7.0 mg/kg 
(n = 10): ● loperamide loaded in HSA nanoparticles with covalently attached apolipoprotein A-I; ○ loperamide 
loaded in HSA nanoparticles with covalently attached apolipoprotein B-100; ▼loperamide loaded HSA-NP, 
and U loperamide solution.  
 
The antinociceptive effect of the particles modified by apolipoprotein A-I reached 65% after 
15 min.  The maximal possible effect (MPE) of the particles modified by apolipoprotein B-
100 at this time was below 50% but was still statistically different (2p < 0.02) from the 
loperamide solution and the unmodified nanoparticles.  The antinociceptive effect of these 
preparations lasted for over 60 minutes, although at this time, there was no significant 
difference between two types of the modified nanoparticles.  The loperamide-loaded 
unmodified nanoparticles and loperamide solution produced no considerable effect (MPE 
below 20%).   
These results clearly demonstrated that the binding of apolipoproteins to the surface of the 
nanoparticles facilitated the transport of this drug across the BBB. 
   Results 
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4.2.3 Thalidomide bound to human serum albumin nanoparticles 
The empty HSA nanoparticles were prepared using the desolvation technique as described in 
the section 3.1.  For thalidomide loading in the HSA-NP, 1 mg of the drug was dissolved in 1 
ml of ethanol-DMSO (8:2) mixture.  The drug solution then was added to 10 mg of HSA-NP.  
To destabilise the crystalline structure of thalidomide and to enhance the loading, 10 µl 
trietylamine was added to the suspension, and the mixture was shaken for 24 h.  
 
4.2.3.1 Size, polydispersity, and surface of the nanoparticles 
The size of empty nanoparticles produced at pH 8.5 was 173 ± 24 nm with a narrow 
polydispersity of 0.05 ± 0.01.  The purification process slightly increased the size to 185 ± 
10 nm.  After thalidomide loading to HSA-NP, the size of the nanoparticles was increased to 
210  ± 40 nm (Figure 24).  However, the polydispersity was not changed and remained 
similar to the empty nanoparticles after the purification (0.05 ±  0.01). 
 
 
Figure 24. Average size of empty HSA nanoparticles (before and after purification with water) and 
Thalidomide loaded HSA-NP. 
 
The charge of the nanoparticles was -50 ± 6.5 mV and did not change after the drug loading.  
   Results 
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4.2.3.2 Drug loading 
The loading (%) was calculated as the ratio of the drug bound to the particles to the initial 
drug concentration.  The result showed that the loading of thalidomide to HSA-NP 
considerably increased after the addition of triethylamine.  The solubility of thalidomide in 
20 mg/ml HSA-NP suspension reached up to 800 μg of thalidomide (40 µg Thal/mg HSA-
NP), whereas the solubility of the free drug (a mixture of enantiomers) in water and 5% 
glucose solution was only 52 and 70 μg/ml, respectively (Eriksson 2000). 
 
4.2.3.3 Solubility of thalidomide 
Thalidomide has a poor solubility in water.  For this reason, only peroral formulations of this 
drug are available, although parenteral administration would be desirable in some clinical 
situations (Eriksson 2000).  
The purpose of this set of experiments was to investigate the possibility to increase the 
solubility of thalidomide by using pharmaceutical excipients.  These solvents included 5% 
glucose solution, 10% polysorbate 80, 10% poloxamer 188, cremophor
® EL-ethanol (51:49).  
Thalidomide was used in a form of racemate (a mixture of two enantiomers).  The aqueous 
solubility of thalidomide in water and 5% glucose solution was also tested.  The result was 
compared with the thalidomide concentration in the HSA-NP formulation (400 µg Thal/ml 
NP suspension). 
These formulations were also tested for their stability (storage for 24 h at room temperature).  
The concentration of thalidomide after 24 h was measured by HPLC and compared with the 
freshly prepared formulations.  The preparations containing more than 5 % of precipitated 
thalidomide were discarded.  
The solubility of thalidomide in 10% solutions of poloxamer 188 or polysorbate 80 was 
154.75 and 213.13 μg/ml, respectively.  Similar solubility (215 μg/ml) was achieved using 
the mixture of 51% Cremophor
® EL and 49% ethanol.  These results are summarised in 
Figure 25.   Results 
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Figure 25. Solubility of thalidomide in different  organic solvents; water, 5% glucose solution, 10% 
polysorbate 80, 10% poloxamer 188, 51% cremophor and 49% ethanol and thalidomide-HSA-NP. 
 
The thalidomide solubility in water and in 5% glucose was 50 and 75 μg/ml, respectively, 
which correlated with the results of Eriksson et al. (Eriksson 2000). 
In neither of these formulations, solubility of thalidomide could exceed the content of 
thalidomide in the nanoparticle formulation (400 μg/ml).  Furthermore, the solubility of 
thalidomide in clinically applicable vehicles such as 0.5% solutions of polysorbate 80 or 
poloxamer 188 was only 75 μg/ml, i.e. the same as in the 5% glucose solution. 
 
4.2.3.4 Treatment of rats bearing intracranial transplanted glioblastoma 
101/8 using different thalidomide formulations 
The antitumour efficacy of the unmodified thalidomide-loaded HSA-NP (Thal-HSA-NP) and 
Thal-HSA-NP coated with 1% polysorbate 80 (Thal-HSA-NP + PS 80) were evaluated in the 
glioblastoma-bearing rats.  The effect of these formulations was compared to orally 
administered thalidomide.  Untreated animals were used as control.  The nanoparticle 
formulations were injected intravenously into the tail caudal vein.  The treatment regimen 
was 3 × 1 mg/kg (total dose 3 mg/kg) on days 2, 5, and 8 post-tumour implantation. 
Figure 26 shows the Kaplan-Meier survival plot of the rats treated with these formulations.  
All animals died between day 20 and 25 post-implantation.  
   Results 
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Figure 26. Survival (Kaplan-Meier plot) of rats bearing intracranially transplanted 101/8 glioblastoma after i.v. 
administration of thalidomide-loaded in HSA nanoparticles included, the unmodified surface thalidomide HSA-
NP (Thal-HSA-NP), coated with 1% polysorbate 80 (Thal-HSA-NP + PS 80). 
 
Table 10. Median  and mean survival time of the 101/8 glioblastoma-bearing rats after treatment with different 
thalidomide formulations. 
Groups 
Survival time, days 
Median Mean 
Untreated control  17 15 
Thalidomide (oral)  16 16 
Thal-HSA-NP  19 15 
Thal-HSA-NP + PS 80  18 14 
 
As seen in Table 10, the median and mean survival times among the groups were similar.  
The group treated with thalidomide given orally survived longer than other groups with 
mean survival of 16 days.  The unmodified thalidomide-loaded HSA-NP had the highest 
median time of the day 19 compared to other groups.  However, these differences were not 
significant.  
Thus, thalidomide formulations did not increase survival time of tumour-bearing rats.  All 
the animals were sacrificed after the appearance of the tumour-related illness.   Results 
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4.3 Characterisation of poly(lactide-co-glycolide) nanoparticles 
Poly(lactide-co-glycolide) nanoparticles (PLGA-NP) were produced by the precipitation 
solvent diffusion technique.  In this study, polymers were dissolved in an organic solvent 
miscible with water (acetone) and dispersed in an aqueous phase containing a colloid 
stabiliser. The stabilisers were polyvinyl alcohol (PVA), human serum albumin (HSA), and 
poloxamer 188 (F68).  The almost instantaneous diffusion of the organic solvent into the 
aqueous phase resulted in the precipitation of the copolymers as in the form of the 
nanoparticles.  Then the solvent was evaporated.   
The hydrophobic drug, 3,3’-diindolylmethane (DIM), was dissolved in acetone and added to 
the preparation as described above.  The drug-to-polymer ratio was 1:10.   
For a more homogenous nanoparticles preparation, a pump was used for the addition of the 
organic phase.  
4.3.1 Size, polydispersity, and surface charge of the nanoparticles 
The physicochemical parameters of the nanoparticles are shown in Table 11.  It can be seen 
that the size and surface charge of the nanoparticles depended on the type of a stabiliser and 
were not influenced by the presence of DIM.  Among the preparations, the HSA-stabilised 
nanoparticles had the biggest size of about 330 nm and the lowest negative surface charge  
(-40 mV).  These nanoparticles also had a slightly higher polydispersity of 0.18 - 0.15.  Other 
nanoparticles had similar sizes of 225 - 269 nm and polydispersity of 0.03 - 0.11. 
 
Table 11. Physicochemical parameters of empty and DIM-loaded PLGA nanoparticles 
Stabiliser  
(1% w/v) 
DIM conc. 
in  
NP suspension 
(mg/ml)* 
Mean diameter 
(nm) 
PD 
Surface charge 
(mV) 
PVA  - 269.2  0.03  -20.4 
  0.65 263.5  0.08  -24.2 
HSA  - 333.9  0.18  -38.2 
  0.71 334.7  0.15  -42.3 
F68  - 225.3  0.08  -34.5 
  0.67 234.2  0.11  -38.1 
* Initial DIM concentration in the reaction medium was 1 mg/ml.   Results 
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4.3.2 Morphology of the nanoparticles 
Investigation of the nanoparticle morphology was performed by scanning electron 
microscopy.  Figure 27 shows the nanoparticles after freeze-drying which were redispersed 
in water.  The samples were used without further purification. 
 
 
Figure 27. Scanning electron micrographs of PLGA nanoparticles after freeze-drying and redispersion in 
water: (A) empty and (B) DIM-loaded nanoparticles stabilised with PVA, (C) empty and (D) DIM-loaded 
nanoparticles stabilised with HSA.  Bar: 1000 nm. 
 
It can be seen that only particles stabilised with PVA had a round shape.  It is obvious from 
Figure 27 that the preparation method applying a pump system led to the homogenous mean 
particle size as well as to the narrow particle size distribution. The nanoparticles stabilised 
with HSA were not spherical and were not always stable after reconstitution in water. No 
signs of DIM crystallisation were detected in the samples (Figure 27). 
4.3.3 Drug loading 
All types of the nanoparticles enhanced the content of DIM in the aqueous media, which 
reached 0.65 - 0.71 mg/ml (Table 11). Therefore the DIM solubility was increased 650 - 700-
fold, as compared to its solubility in the aqueous solution.  The drug might be entrapped and 
adsorbed on the nanoparticle surface.  Interestingly, the nanoparticles stabilised by PVA and 
HSA also seemed to increase the photostability of DIM.   
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4.3.4 Determination of maximum solubility in aqueous media 
The solubility data obtained using the filter device and the shake-flask method, is displayed 
in Figure 28.  The maximum concentration of DIM in aqueous media used in this study was 
~ 1 µg/ml.  The solubility was not influenced by pH and was similar in water, 0.01 N HCl or 
PBS pH 7.4 (Figure 28).  The solubilities after 24 h were similar to the values obtained after 
4 h. 
 
 
Figure 28. Maximum concentration solubility of DIM in water, 0.01 N HCl or phosphate buffer pH 7.4 after 4 
and 24 h. 
 
4.3.5 DIM stability in organic media 
The HPLC detection limit of DIM in acetone and acetonitrile was 1.5 µg/ml.  After 4 h, the 
solutions in acetone and acetonitrile acquired a red colour indicating the appearance of a 
degradation product.  However, the retention time of DIM and its area under the curve values 
were not changed as compared to the chromatographs of the freshly prepared solutions.  No 
extra peak was observed at either of 15 µg/ml or 25 mg/ml concentrations during 4 and 24 h 
or after one week.  The brown flask could not protect the solution from the formation of a 
red-coloured product.    Discussion 
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5 Discussion 
5.1 Doxorubicin-loaded poly(butyl cyanoacrylate) nanoparticles  
The objective of this study was the in-depth evaluation  of antitumour effect of doxorubicin 
bound to PBCA nanoparticles coated with polysorbate 80 (Dox-NP + PS 80) against 101/8 
rat glioblastoma.  This tumour model is an orthotopic model initially generated by the 
injection of α-dimethylbenzanthracene into the cerebellum of Wistar rats followed by a 
serial transplantation of the tumour tissues into the hemisphere of Wistar rats 
(Yablonovskaya 1970).  Thus, the rat 101/8 glioblastoma differed from other established rat 
brain tumour models that were generated by an injection of derivatives of nitrosourea or 
Rous sarcoma virus or by xenografting human glioma cell lines (Barth 1998).  The 101/8 
glioblastoma is characterised by a reproducable host survival time of sufficient duration to 
permit therapy and determination of its efficacy.  Indeed, this model has been successfully 
applied in a variety of studies for the evaluation of experimental therapies (Steiniger 2004, 
Gelperina 2002, Ambruosi 2006).  
The morphological evaluation of the 101/8 glioblastoma performed in this study also 
evidenced that the proliferation of this tumour remained at high levels throughout the host 
survival time.  Moreover, the tumour showed a reproducible growth pattern and temporal 
development that is comparable to human glioblastomas.  The tumours increased in size, 
vessel density, necrosis, and showed abundant microvascular proliferation.  Furthermore, the 
101/8 glioblastoma showed an invasive growth pattern with tumour cells diffusely 
infiltrating surrounding host brain at the edge of the solid tumour mass without signs of 
encapsulation.  Thus the 101/8 rat glioblastoma fulfills most criteria for a valid glioma model 
(Barth 1998, Peterson 1994, Maggio 1996).  It can also be qualified as a reliable brain 
tumour model for therapeutic studies besides the established models such as the F98 (Barth 
1998) and 9L gliosarcoma (Weizsacker 1981), the C6 glioma (Benda 1971), and RG2 glioma 
(Ko 1980).  
According to Professor Glatzel (Institut fuer Neuropathologie, Universtaetsklinikum 
Hamburg, Eppendorf), the 101/8 rat glioblastoma is the experimental rat glioblastoma that 
most resembles human glioblastomas (personal communication). 
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The effects of the therapy of this orthotopic rat glioblastoma model using Dox-NP + PS 80 
and Dox-sol was evaluated by morphometric, histochemical and immunohistochemical 
methods.  It was shown that the tumour formation was significantly reduced in the Dox-NP + 
PS 80 versus the Dox-sol and control groups.  These data confirmed the results of the earlier 
study where more than 20% of the animals treated with Dox-NP + PS 80 showed the long-
term remission in the same glioblastoma model (Steiniger 2004).  This effect was 
presumably mediated by the antiangiogenic or cytotoxic effects of doxorubicin.  Stan et al. 
(Stan 1999) described a dose-dependent cytotoxic effect of doxorubicin on glioma cell lines 
in vitro. These authors showed that pre-treatment of tumour cells with doxorubicin precluded 
tumour formation after implantation of tumour cells on the chorioallantoic membrane of 
embryonated hen eggs. 
Moreover, treatment with doxorubicin-loaded nanoparticles showed reduced proliferation 
and tumour sizes when compared to treatment with doxorubicin in solution and untreated 
control animals.  The antiproliferative effect of doxorubicin was described in organotypic 
multicellular spheroids of glioma cells in vitro (Kaaijk 1996) and also after subcutaneous 
implantation of rat C6 glioma cells (Van Waarde 2007).  However, both are models that do 
not require passage through the BBB.  In our study, doxorubicin in solution produced 
decreased proliferation of the tumour cells and reduced tumor sizes when compared to 
untreated controls. However, the excellent result achieved by Dox-NP + PS 80 confirms 
again that the enhanced transport of doxorubicin through the BBB drastically improves the 
drug effect against intracranial glioblastoma.  
The vessel density, necrosis, and expression of VEGF were decreased and microvascular 
proliferation was absent in animals treated with doxorubicin-loaded nanoparticles when 
compared with untreated controls.  Treatment with a solution of doxorubicin showed a 
tendency towards the decreased vessel density that was not statistically significant.  At the 
same time, measurements of vessel density and microvascular proliferation in Dox-NP+PS 
80-treated rats demonstrated that the drastic decrease of the vessel density going hand in 
hand with the virtual absence of microvascular proliferation.  These data corroborated the 
results of the previous studies showing the antiangiogenic effects of doxorubicin (Bocci 
2002, Zhou 2002, Straubinger 2004). 
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5.2 Drug-loaded PBCA nanoparticles prepared in the presence of organic 
solvents 
The objective of this part of the study was to develop a method for the loading of water-
insoluble  drugs in the PBCA nanoparticles.  The drug-loaded poly(alkyl cyanoacrylate) 
nanoparticles are generally prepared by anionic polymerization of alkyl cyanoacrylates in an 
aqueous acidic media in the presence of a drug.  Commonly used stabilisers are dextran 
and/or poloxamer 188 (Vauthier 2003, Couvreur 1979).  This method allows efficient 
loading of hydrophilic or amphiphilic drugs such as ampicillin or doxorubicin (Youssef 
1988, Steiniger 2004).  However, it is not obviously suitable for the encapsulation of poorly 
soluble drugs.  Attempts to overcome this difficulty included the preparations of the particles 
in the ethanol-containing media (Alyautdin 1997, Beck 1994) or in the presence of 
cyclodextrins (Duchene 1999).  While the first method is applicable only to the drugs that are 
soluble in ethanol and is difficult to reproduce, cyclodextrins indeed allowed to considerably 
increasing the encapsulation efficiency of poorly soluble substances, such as progesterone 
and testosterone. 
In the present study, the method of the preparation was modified so that the drug-loaded 
PBCA nanoparticles were produced in aqueous media containing 10% (v/v) of the organic 
solvents.  The type of solvent was chosen depending on the drug solubility.   
This study shows that the presence of organic solvents did not significantly influence the 
morphology of the nanoparticles or their physicochemical parameters, such as the surface 
charge, size and polydispersity, as well as the yield of the polymer.  Importantly, the solvents 
could be efficiently removed from the nanoparticles by evaporation under normal pressure 
and subsequent lyophilisation.  The residual amounts of the solvents in the nanoparticles met 
the requirements of the European Pharmacopoeia (Eur Pharm. 5
th eds.). 
A high loading of loperamide of about 80% in the nanoparticles was achieved with all tested 
solvents.  The loading capacity of the particles reached 130 - 160 µg bound drug/mg PBCA.  
In the study of Alyautidin et al. (Alyautidin 1997), where the PBCA nanoparticles were 
manufactured in 50% aqueous ethanol, a considerably lower encapsulation efficiency of 
loperamide (47%) was obtained. 
The encapsulation efficiency of paclitaxel was much lower - about 25%.  Therefore, the 
loading capacity of the particles reached only 30 - 40 µg bound drug/mg PBCA.  These   Discussion 
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parameters were considerably improved when a PEGylated phospholipid was used as a 
stabiliser: the encapsulation efficiency increased to 45% and the loading capacity to 55 
µg/mg PBCA.  This result correlates with the results of Mitra and Lin et al. (Mitra and Lin 
2003) who also showed that the loading of paclitaxel in PBCA nanoparticles could be 
increased in the presence of lipids.  A higher encapsulation of paclitaxel was achieved in the 
presence of PEG-PE. It is probably explained by a more efficient solubilisation of paclitaxel 
within PEG-PE micelles and/or the affinity of these micelles to the growing nanoparticle 
matrices.   
As shown by the determination of the drug loading after freeze-drying, both, loperamide and 
paclitaxel, were almost fully encapsulated in the nanoparticles. The formulations contained 
only trace amounts of free drugs.  This conclusion is further supported by the absence of the 
crystals in the micrographs of loperamide-loaded nanoparticles.  Remarkably, by means of 
the nanoparticles, the content of these substances in the aqueous media for a given volume 
could be increased 200 - 450-fold. 
 
5.2.1 Analgesic effect of loperamide-loaded in PBCA nanoparticles (tail-flick 
test) 
The pharmacological efficacy of the nanoparticulate formulations of loperamide was tested 
using a tail-flick test.  Loperamide is a peripherally acting opioid receptor agonist used for 
the management of chronic diarrhea.  This drug is a substrate of P-glycoprotein (Pgp), its 
lack of central opioid effects is due to the efflux activity of the Pgp at the blood-brain barrier 
(Upton 2007).  As shown by previous studies, the PBCA nanoparticles coated with 
polysorbate 80 enabled the delivery of a number of drugs, including loperamide, across the 
blood-brain barrier.  In particular, in the study of Alyautdin et al. (Alyautidin 1997) 
loperamide bound to PBCA nanoparticles coated with polysorbate 80 produced a 
considerable analgesic effect thus providing evidence of the CNS activity, whereas the free 
drug was ineffective.  Similar results were obtained in the present study.  However, in 
contrast to the study of Alyautdin et al. (Alyautidin 1997), loperamide bound to the non-
coated nanoparticles also produced a significant analgesia, which was equally pronounced 
although less prolonged as compared to the polysorbate 80-coated particles (Figure 18).     Discussion 
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Obviously, this result suggests that poloxamer 188-coated nanoparticles also enabled the 
delivery of loperamide across the blood-brain barrier thus inducing the CNS effect.  This 
result correlates with the data obtained in a recent study of Petri et al. (Petri 2007), which 
provided evidence that the coating of PBCA nanoparticles with poloxamer 188 could 
facilitate drug delivery to the brain.  
 
5.2.2 Chemotherapy of 101/8 glioblastoma using paclitaxel-loaded PBCA 
nanoparticles 
The natural taxan diterpenoid paclitaxel is one of the most important anticancer agents.   
Although it is known that paclitaxel exhibits activity against malignant glioma and brain 
metastases (Fellner 2002), its application for the treatment of brain tumours is limited since 
this drug is a substrate of Pgp and, therefore, its penetration into the CNS is not efficient.  
The attempts to increase the drug concentrations in the parenchyma by co-administration of 
the efflux pump inhibitors have been abandoned due to substantial toxicity (Fellner 2002).  
As shown by the previous studies, the PBCA-NP coated with polysorbate 80 (PS 80) or 
poloxamer 188 (F68) could efficiently transport doxorubicin (also a Pgp substrate) across the 
BBB (Steiniger 2004, Ambruosi 2006, Petri 2007).  The uptake of doxorubicin into the brain 
blood vessels endothelial cells possibly also could be assisted by the circumvention of the 
Pgp caused by a simultaneous release of doxorubicin and the degradation product of PBCA 
(polycyanoacrylic acid) at the cell membrane.  An ion-pair formed by polycyanoacrylic acid 
and doxorubicin could enable passage of doxorubicin across the cell membrane without 
being recognized by P-glycoprotein (Verdiere 1997).  Moreover, in the case of brain tumour, 
the penetration of the nanoparticles into the tumour could be enhanced due to a higher 
permeability of the BBB at the tumour site (EPR effect).  
Therefore, in the present study, it was also assumed that loading of paclitaxel in the surface-
modified PBCA-NP would increase the drug therapeutic effect against glioblastoma.   
To evaluate paclitaxel delivery to the brain, three paclitaxel-loaded nanoparticle formulations 
including the unmodified nanoparticles and particles coated with surfactants (polysorbate 80 
or poloxamer 188) were tested against 101/8 human glioblastoma implanted in rats.  The   Discussion 
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effect of the nanoparticulate formulations was compared to that of a paclitaxel solution.  
Untreated rats were used as control.  
The recommended dose of paclitaxel against human glioblastoma is 140 mg/m
2 (Fetell 1997, 
FDA) which corresponds to the rat dose of about 17.80 mg/kg.  However, due to the low 
loading of paclitaxel to nanoparticles, this dose could not be administered.  Therefore, the 
same dose regimen as doxorubicin was used for the chemotherapy of 101/8 glioblastoma.  
Thus the treatment regimen was 3 × 1.5 mg/kg on days 2, 5, and 8 post-tumour implantation 
(total dose was 4.5 mg/kg).  None of the formulations containing paclitaxel could improve 
survival time compared to the control groups.  Since the cytotoxic effect of paclitaxel 
depends on two important factors – the dose and duration of exposure, this lack of efficacy in 
the present experiment is most probably explained by the low dose and short treatment 
course.  Indeed, in the study performed by Xu et al. (Xu 2005) the antitumour effect of the 
nanoparticle-bound paclitaxel in mice was achieved at a much more intensive treatment 
regimen of 5 x 20 mg/kg/day.  The effect of the paclitaxel conjugate with Angiopep-2 (an 
aprotinin-derived peptide) against intracerebral U87 MG glioblastoma was also achieved 
after injection of the dose of 5 × 25 mg/kg (Regina 2008).   
 
5.3 Human serum albumin nanoparticles 
5.3.1 Covalent linkage of Apolipoprotein A-I and B-100 to human serum 
albumin nanoparticles 
Previously it was believed that apolipoprotein E and to a minor extent apolipoprotein B play 
a crucial role in the delivery of the drugs to the brain by nanoparticles (Kreuter 2002).  Both 
apolipoproteins bind to lipoprotein receptors including low-density lipoprotein receptor or 
LDL-R (Knott 1986, De Loof 1986, Kreuter 2004) and lipoprotein receptor-related protein, 
LRP  (Dergunov 2004, Croy 2004).  Moreover, the LDL-R is up-regulated on the brain 
endothelium compared to peripheral vessels (Dehouck 1997, Lucarelli 2002, Vasile 1983, 
Meresse 1989), and lipoprotein particles appeared to be transported across the BBB by 
transcytosis (Dehouck 1997).  As a consequence, it was hypothesized that the nanoparticles 
with adsorbed or covalently attached apolipoprotein B or E mimic lipoprotein particles, and   Discussion 
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that this represented the exclusive or at least dominating mechanism of the nanoparticle-
mediated drug transport across the BBB. 
Indeed, the results of the present study corroborate the previous observation.  The 
apolipoproteins B or E attached to the particle surface serve as vectors trafficking 
nanoparticles to the brain, thus providing the analgesic effect of the otherwise CNS-inactive 
drug  (Kreuter 2002, Michaelis 2006).  Furthermore, as evidenced by a pharmacological 
response, the brain delivery of loperamide also could be mediated by apolipoprotein A-I. 
However, the mechanism of its interaction with the brain vessel endothelial cells is different 
and it occurs via a different receptor.  Apolipoprotein A-I is one of the major components of 
high density lipoproteins (HDL), whose function is to transfer cholesterol between cells and 
other lipoproteins.  This transfer is facilitated via highly specific interaction of HDL with the 
scavenger receptor class B type I (SR-BI) located at the BBB (Krieger 1999, Petri 2007, 
Balazs 2004).  It is, therefore, possible that drug delivery to the brain by HSA nanoparticles 
is enabled by the interaction of apolipoprotein A-I attached to these particles with the SR-BI 
expressed by the brain vessels endothelial cells.   
Interestingly, the results of the present study correlate with the study about the interaction of 
lipid drug conjugate (LDC) nanoparticles with the brain vessels endothelial cells which 
considerable amounts of apolipoprotein A-I were found to be adsorbed on their surface from 
the blood (Gessner 2001).   
 
5.3.2 Thalidomide bound to HSA nanoparticles 
In this part of the study, the therapeutic potential of thalidomide bound to the HSA 
nanoparticles for the therapy of rats with intracranially implanted glioblastomas was 
investigated.  The accumulation of albumin in solid tumours forms the rationale for 
developing the albumin-based drug delivery systems for tumour targeting.  Albumin 
accumulates in malignant tissue due to two major reasons:  Firstly, albumin is a major energy 
and nutrition source for the tumour growth (Stehle 1997). Secondly, penetration of albumin 
into the tumour could be enhanced due to the leaky capillaries feeding the tumour and 
defective lymphatic drainage system (EPR effect).  The tumour uptake of albumin can be   Discussion 
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easily visualised by injecting the Evans Blue dye that binds rapidly and tightly to circulating 
albumin and makes the tumour turn blue withing few hours post injection.  
Recently, a methotrexate-albumin conjugate, an albumin-bound prodrug of doxorubicin, i.e, 
the (6-maleimido)caproylhyrazone, and paclitaxel bound to albumin nanoparticles 
(Abraxane) have been evaluated clinically.  Specifically, Abraxane has been approved for 
treating meastatic breast cancer.  Additionally, the biodegradability, lack of toxicity, and 
immunogenicity of denaturated albumin makes it an ideal candidate for drug delivery (Kratz 
2008).  
Thalidomide is a known teratogenic agent which induces the inhibition of the blood vessel 
growth in the development of fetal limb buds.  The mechanism of action of thalidomide is 
complex and it probably includes different molecular targets.  The inhibition of angiogenesis 
by interrupting processes mediated by bFGF and/or vascular endothelial growth factor 
(VEGF) is one of the prominent thalidomide mechanisms of action (Eleutherakis-
Papaiakovou 2004).  The effect of thalidomide on the glioma and glioblastoma as highly 
vascularised tumours that overexpress angiogenic factors provides the rationale for the 
evaluation of antiangiogenic effect of thalidomide-loaded nanoparticles.  Since 
antiangiogenic action of doxorubicin loaded nanoparticles was indicated by the histological 
investigations (section 5.1) the loading of nanoparticles with thalidomide appeared as a 
rational strategy.  However, monotherapy of brain tumours using thalidomide seems to be 
not effective.  As shown by the results of three phase II trials including patients with 
recurrent glioma, astrocytoma or glioblastoma multiforme thalidomide was generally well 
tolerated but objective responses were rare (Papaiakovou 2004).  The daily dose was from 
100 to 1200 mg.   
Similarly, in our study, thalidomide bound to HSA nanoparticles had exerted no effect on the 
prolongation of the survival times in the rats bearing glioblastoma, as compared to the 
untreated animals.  There was also no improvement in the group treated with polysorbate 80-
coated nanoparticles.  The treatment regimen in our study was 3 × 1 mg/kg on days 2, 5, and 
8 post-tumour implantation (the total dose was 3 mg/kg).  The poor results in the thalidomide 
groups treated orally suggest that the dose level and the dosing regimen were not adequate. 
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5.4 DIM loaded in PLGA nanoparticles 
Poly (lactide-co-glycolide) nanoparticles (PLGA-NP) are a biodegradable polymeric system 
has a good CNS biocompatibility.  Kreuter et al. (Kreurter 2008) have recently shown that 
doxorubicin loaded in the PLGA nanoparticles coated with poloxamer 188 have promising 
effects for the treatment of brain tumours.  Treatment of 101/8 glioblastomas with this 
formulation yielded 40% of long term survivors.   
In the present study, a carcinogenesis inhibitor, diindolylmethane (DIM; Figure 29), was 
loaded to PLGA-NP.  DIM is a cruciferous indole which exhibits a potential cancer-
protective effect especially in estrogen-related conditions (Chen 1998).  The active agent, 
DIM, is derived from the digestion of indole-3-carbinol, found in Brassica vegetables such as 
broccoli and cauliflower. 
 
 
Figure 29. Structure of 3-(1H-Indol-3-ylmethyl)-1H-indole, 3,3’-Diindolylmethane (DIM). 
 
Because of its various potent anticancer properties, the National Cancer Institute of the 
United States has begun clinical trials of DIM as a therapeutic treatment for numerous forms 
of cancer.  It is currently being used as a part of treatment for tumours in the upper 
respiratory tracts caused by the Human Papilloma Virus.  The disadvantage of DIM is its 
very low solubility in water.  Moreover, this substance is sensitive to light and forms highly-
coloured degradation products which do not affect the efficacy of the final formulation but 
they are unfavourable for its appearance.  
The nanoparticles were prepared by the nanoprecipitation method.  The preparation of the 
nanoparticles by using a pump for the addition of the organic phase (1 ml/min) yielded 
relatively homogeneous preparations with reproducible characteristics, whereas manual 
addition of the organic phase resulted in the variability in size of the nanoparticles for the 
same preparation procedure.  Encapsulation of DIM in PLGA-NP appears to be a suitable 
formulation approach that enables a >600-fold increase of DIM content in aqueous media 
and can increase DIM photostability.   Conclusion 
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6 Conclusion 
6.1 Antiangiogenic effects of doxorubicin-loaded poly(butyl cyanoacrylate) 
nanoparticles 
Immunohistology showed that the rat 101/8 glioblastoma is a valid brain tumour model with 
morphologic characteristics of human glioblastoma.  The intravenous treatment with 
doxorubicin-loaded polysorbate 80-coated nanoparticles reduced tumour formation, tumour 
size, and proliferation of tumour cells.  Importantly, the intratumoural vessel density and 
necrosis were drastically reduced and microvascular proliferations were absent pointing to 
antiangiogenic effects of doxorubicin.  This study confirms the promise of nanoparticles in 
the delivery of compounds to the central nervous system.  Furthermore, it indicates that the 
growth-retarding effect of doxorubicin on gliomas may be attributed to antiangiogenic 
effects. 
 
6.2 Encapsulation of water-insoluble drugs in poly(butyl cyanoacrylate) 
nanoparticles 
The preparation of poly(butyl cyanoacrylate) nanoparticles by anionic polymerization in 
aqueous-organic media appeared to be a suitable method for encapsulation of water-
insoluble substances.  Among other techniques, this method based on rapidly biodegradable 
nanoparticles may serve as a formulation approach for “difficult” substances, clinical 
application of which is hampered by low solubility.   
 
Paclitaxel-loaded poly(butyl cyanoacrylate) nanoparticles showed no improvement in the 
increasing survival times of glioblastoma implanted rats.  Increasing the dose or combining it 
with other potent anticancer formulations could be beneficial. 
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6.3 Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to 
albumin nanoparticles enables drug transport into the brain 
The present investigation demonstrates that the delivery of drugs to the brain with 
nanoparticles is at least partly associable with the apolipoprotein E and B pathway.  The drug 
delivery to brain may also be augmented by the interaction of apolipoprotein A-I covalently 
attached to these nanoparticles with the scavenger receptor SR-BI located at the blood-brain 
barrier. 
Consequently, these results demonstrate the existence of more than one possible interaction 
mechanism of nanoparticles with the brain endothelium and the followed by delivery of 
drugs to the CNS. 
 
6.4 Thalidomide bound to human serum albumin nanoparticles 
The thalidomide content in the aqueous phase was increased 8-fold as compared to its 
aqueous solution due to the drug binding to the nanoparticles.  However, the in vivo response 
to thalidomide HSA-NP formulation against glioblastoma multiforme of orally administered 
thalidomide was not improved, as compared to an equal dose.  It is known that thalidomide 
has no immediate antiangiogenic or antiproliferative effect.  Higher dosing parallel to early 
administration of thalidomide in combination with other potent cytostatic agents such as 
doxorubicin may be a new strategy for the glioblastoma treatment. 
 
6.5 Encapsulation of diindolylmethane in poly(lactide-co-glycolide) 
nanoparticles 
The preparation of DIM-loaded nanoparticles by precipitation yielded nanoparticles with a 
narrow size distribution.  The encapsulation of DIM in PLGA-NP appears to be a suitable 
formulation approach that enables a >600-fold increase of DIM content in aqueous media 
and can prevent DIM from unfavourable colour changing in the formulation.   Summary 
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7 Summary 
Many highly active antitumour agents are currently not employable for the systemic 
chemotherapy of brain tumours since their entrance into the brain is blocked by the BBB.  
Obviously, the development of a strategy allowing effective delivery of these agents across 
the BBB would enormously extend the potential of the systemic chemotherapy.  
 
Chemotherapy of rat glioblastoma using nanoparticle-bound doxorubicin  
Doxorubicin bound to polysorbate-coated nanoparticles had been previously shown to 
significantly enhance survival in the orthotopic rat 101/8 glioblastoma model.  The objective 
of this study was to investigate the therapeutic effects of this formulation by morphometric, 
histological and immunohistological methods. 
The 101/8 glioblastoma was implanted intracranially into the male Wistar rats.  The animals 
were randomly divided into 3 groups; one group served as untreated control (n = 20).  The 
second group received doxorubicin in solution (Dox-sol, n = 18), and the third group 
received doxorubicin bound to PBCA nanoparticles coated with PS 80 (Dox-NP + PS 80, n = 
18).  The treatment regimen was 3 × 1.5 mg/kg on days 2, 5, and 8 after tumor implantation.  
The formulations were injected into the tail vein.   
The untreated control animals were sacrificed on days 6, 8, 10, 12, and 14 after the 
implantation.  The animals that had received chemotherapy were sacrificed on day 10, 14 
and 18 after the implantation.  The brains were investigated by morphometrical, 
histochemical, and immunohistochemical methods such as the measurement of the tumor 
size, proliferation of tumor cells, vessel density, expression of glial fibrillary acidic protein 
(GFAP), expression of vascular endothelial growth factor (VEGF), incidence and dimension 
of necrosis, and microvascular proliferation. 
Tumours showed signs of malignancy including invasion to brain tissue and brisk mitotic 
activity.  The tumor proliferation remained stable at high levels throughout the host survival 
time.  Overall, the tumor showed a reproducible growth pattern and temporal development 
that is comparable to human glioblastoma.  Furthermore, the 101/8 glioblastoma had 
infiltrated diffusely the surrounding host brain at the edge of the solid tumor mass showed no 
signs of encapsulation.  Thus the 101/8 glioblastoma fulfills the most criteria for an adequate 
glioma model and can be qualified as a reliable model. 
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Dox-NP + PS 80 produced a pronounced antitumour effect which exhibited as a reduced 
tumour size, lower proliferation, and a decreased necrotic area compared to Dox-sol and to 
untreated control groups.  This result correlates with the results of the earlier study (Steiniger 
2004) where more than 20% of the animals treated with the same nanoparticles showed a 
long-term remission in the same glioblastoma model.  The treatment effect of the 
nanoparticles was also exhibited as impaired vascular density, decrease in the expression of 
the VEGF and lack of microvascular proliferation in the 101/8 glioblastoma model when 
compared to the solution of doxorubicin (Dox-sol) and the untreated animals (control).  A 
drastic effect of Dox-NP + PS 80 on vascularisation was presumably mediated by 
antiangiogenic or cytotoxic effects of doxorubicin. 
 
Encapsulation of water-insoluble drugs in poly(butyl cyanoacrylate) nanoparticles 
Development of the parenteral formulations of the poorly water soluble drugs is considered 
to be a challenging task.  These drugs can be solubilized in non-aqueous solutions composed 
entirely of organic solvent(s), which are usually but not always diluted prior to 
administration  (Strickley 2004).  Many of these currently used excipients are not inert 
vehicles and could exert a range of intrinsic adverse effects and have the potential to cause 
clinically significant drug interactions.  
The nanoparticle technology represents a promising approach to enhance the content of these 
drugs in the aqueous media and may optimize their in-vivo performance.  
In this study, the effectiveness of this approach was investigated using poly(butyl 
cyanoacrylate) nanoparticles and two hydrophobic drugs, loperamide and paclitaxel.  For this 
purpose, the standard method of the preparation of these particles was modified so that the 
drug-loaded PBCA nanoparticles were produced in aqueous media containing 10% (v/v) of 
the organic solvents.  The type of solvent was chosen depending on the drug solubility.   
The nanoparticles were produced by anionic polymerization of n-butyl-2-cyanoacrylate in 
aqueous-organic media in the presence of a drug.  The particles were stabilized by dextran 
70,000 and poloxamer 188 or by 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-5000] sodium salt.  The polymerization media consisted of a 
solution of stabilizers/surfactants in a mixture of 0.01 N HCl and an appropriate organic 
solvent (1 : 9).  The presence of the organic solvents in the polymerization medium did not   Summary 
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considerably influence the physicochemical parameters of the empty nanoparticles.  It was 
shown that in the presence of dichloromethane, methanol, or ethanol the encapsulation 
efficiency of loperamide in the nanoparticles reached 80%.  The loperamide-loaded 
nanoparticles were coated additionally with 1% polysorbate 80.  The analgesic effect of these 
formulations (with or without PS 80 coating) was measured in vivo using the tail-flick test, 
as described in the paper of Alyautdin et al. (Alyautdin 1997).  The loperamide solution was 
chosen as a control formulation. Loperamide is a substrate of P-glycoprotein (Pgp), its lack 
of central opioid effects is due to the efflux activity of the Pgp at the blood-brain barrier 
(Upton 2007).   
As expected, the loperamide solution was ineffective of exerting the central analgesic effect, 
whereas the polysorbate 80-coated nanoparticles as well as the non-coated nanoparticles 
produced considerable analgesia, providing the evidence of the CNS activity.  However, the 
central analgesic effect of the nanoparticles without coating did not last as long as with the 
coated nanoparticles.  Similar results were obtained in the study of Alyautdin et al. 
(Alyautidin 1997) and Petri et al. (Petri 2007).  Obviously, this result suggests that the 
presence of poloxamer 188 in nanoparticles also enabled the drug delivery of across the 
blood-brain barrier thus inducing the CNS effect of loperamide.  
 
The paclitaxel loading in the PBCA-NP in the presence of dextran/poloxamer 188 as a 
mixture of stabilizers, was low (~ 25%).  The maximum loading was achieved in the 
presence of the lipid (~ 45%) which lead to an encapsulation efficacy of 55 µg/mg PBCA.  
This result correlated with the results of Mitra and Lin et al. (Mitra and Lin 2003) and is due 
to more efficient solubilisation of paclitaxel within PEG-PE micelles and/or the affinity of 
these micelles to the growing nanoparticle matrices.   
Paclitaxel also is a substrate of Pgp and, therefore, its penetration into the CNS after 
systemic administration is not efficient.  The objective of this study was to investigate if the 
PBCA-NP coated with polysorbate 80 (PS 80) or poloxamer 188 (F68) were able to deliver 
paclitaxel across the BBB.  As shown by the previous studies, these NP could efficiently 
transport doxorubicin (also a Pgp substrate) across the BBB (Steiniger 2004, Ambruosi 2006, 
Petri 2007).  Moreover, in the case of brain tumour, the penetration of the nanoparticles into 
the tumour could be enhanced due to a higher permeability of the BBB at the tumour site.    Summary 
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Therefore, the antitumour efficacy of three formulations of paclitaxel including: paclitaxel 
bound to PBCA nanoparticles (PXL-NP), PXL-NP coated with polysorbate 80 (PXL-NP + 
PS 80) and PXL-NP coated with poloxamer 188 (PXL-NP + F68) was tested in glioblastoma 
101/8-bearing rats.  Untreated glioblastoma-bearing rats and the animals treated with the 
paclitaxel solution (PXL) were used as controls.  
Due to the low loading of paclitaxel in the nanoparticles, the recommended dose of 
paclitaxel against glioblastoma, which is 17.80 mg/kg (Fetell 1997, FDA), could not be 
administered.  Therefore, the paclitaxel formulations were administered in the same dose 
regimen as doxorubicin: 3 x 1.5 mg/kg on days 2, 5, and 8 post tumour implantation.  None 
of the formulations containing paclitaxel could improve the survival time compared to the 
control groups.  This lack of efficiency is thought to be due to the low drug dosage and the 
short duration of the treatment course. 
 
Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin 
nanoparticles enabled drug transport into the brain 
Apolipoproteins A-I and B-100 were covalently attached to the HSA nanoparticles via the 
NHS-PEG-Mal 3400 linker.  Loperamide as a model drug was bound to these nanoparticles, 
and the antinociceptive reaction of these preparations was recorded after intravenous 
injection in mice by the tail-flick test.  After 15 min, both nanoparticle preparations with the 
coupled apolipoproteins A-I and B-100 yielded considerable antinociceptive effects which 
lasted over 1 h.  The maximally possible effects (MPE) of these preparations reached 65% 
and 50%, respectively, and were statistically different from the controls (loperamide loaded 
to unmodified nanoparticles and loperamide solution).  The loperamide solution achieved no 
effect.  This result demonstrates that more than one mechanism is involved in the interaction 
of nanoparticles with the brain endothelial cells and the resulting delivery of drugs to the 
central nervous system: while Apo B can transport the drug across the BBB via binding to 
the lipoprotein receptor expressed at the BBB, Apo A-I enables this transport via the 
scavenger receptor SR-BI also located at the BBB. 
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Thalidomide bound to human serum albumin nanoparticles 
Thalidomide, an antiangiogenic drug, has poor solublity in water and, so far, is administered 
only orally, although parenteral administration would be desirable in certain clinical 
situations such as impaired intestinal absorption or chemotherapy-induced nausea hampering 
drug intake. 
The objective of the present study was to develop an injectable formulation of thalidomide 
based on the HSA nanoparticles (HSA-NP).  As previously reported, the solubility of the free 
drug (a mixture of enantiomers) in water and 5% glucose solution was only 52 and 70 μg/ml, 
respectively  (Eriksson 2000).  It was shown that binding of thalidomide to these 
nanoparticles enabled a 8-fold increase of the drug content in the water phase which reached 
400 µg Thal/ml NP suspension.  
In this study, the influence of water soluble organic solvents/surfactants on the solubility of 
thalidomide also has been studied  The solvents included 5% glucose solution, 10% 
polysorbate 80, 10% poloxamer 188, Cremophor
® EL - ethanol (51:49).  Thalidomide was 
used in a form of racemate (a mixture of two enantiomers).  In neither of the above 
mentioned solvents, the solubility of thalidomide could exceed the content of thalidomide in 
the nanoparticle formulation. 
The antitumour efficacy of the unmodified thalidomide-loaded HSA-NP (Thal-HSA-NP) and 
Thal-HSA-NP coated with 1% polysorbate 80 (Thal-HSA-NP + PS 80) was evaluated in the 
glioblastoma 101/8-bearing rats.  The effect of these formulations was compared to orally 
administered thalidomide.  Untreated animals were used as control.  The nanoparticle 
formulations were injected into the tail caudal vein.  Thalidomide bound to HSA 
nanoparticles exerted no effect on the prolongation of the survival times in the rats bearing 
the glioblastoma, as compared to the untreated animals.  There was also no improvement in 
the group treated with the polysorbate 80-coated nanoparticles.  The poor results in the 
thalidomide groups treated orally suggest that the dose level and the dosing regimen were not 
adequate. 
 
Encapsulation of diindolylmethane in poly(lactide-co-glycolide) nanoparticles 
3,3’-Diindolylmethane (DIM) is a cruciferous indole which exhibits a potential 
cancerprotective effect especially in estrogen-related conditions (Chen 1998).  The   Summary 
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disadvantage of DIM is its very low solubility in water.  Moreover, this substance is sensitive 
to light and forms highly coloured degradation products that, however, do not affect the 
efficacy of the final formulation but are unfavorable for the appearance.  The objective of the 
present study was to investigate the feasibility of increasing DIM contents in the aqueous 
phase as well as its photostability by encapsulation in poly(lactide-co-glycolide) 
nanoparticles (PLGA-NP). 
Encapsulation of DIM in PLGA-NP appeared to be a suitable formulation approach that 
enabled a > 600 fold increase of the DIM content in aqueous media and could prevent DIM 
from unfavorable color changing in the formulation. 
 
   Results 
 
   
127   
  
8 References 
•  Abbott NJ, Romero A. Transporting therapeutics across the blood-brain barrier. Mol 
Med Tod. 2, 106 - 113 (1996). 
•  Alyautdin R, Gothier D, Petrov V, Kharkevich D, Kreuter J. Analgesic activity of the 
hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated 
poly(butylcyanoacrylate) nanoparticles. Eur J Pharm Biopharm. 41, 44 - 48 (1995). 
•  Alyautdin R, Petrov VE, Langer K, Berthold A, Kharkevich DA, Kreuter J. Delivery 
of loperamide across the blood-brain barrier with polysorbate 80-coated 
polybutylcyanoacrylate nanoparticles, Pharm. Res. 14, 325 - 328 (1997). 
•  Alyautdin RN, Tezikov EB, Ramge P, Kharkevich DA, Begley DJ, Kreuter J. 
Significant entry of tubocurarine into the brain of rats by absorption to polysorbate 
80-coated polybutyl-cyanoacrylate nanoparticles: an in situ brain perfusion study, J. 
Microencapsul. 15, 67 - 74 (1998). 
•  Alyautdin R, Reichel A, Loebenberg R, Ramge P, Kreuter J, Begley D. Interaction of 
poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in 
vitro. J Drug Targeting. 9, 209 - 221 (2001). 
•  Ambruosi A, Yamamoto H, Kreuter J.  Body distribution of polysorbate-80 and 
doxorubicin-loaded [14C] poly(butyl cyanoacrylate) nanoparticles after i.v. 
administration in rats, J Drug Target. 13, 535 - 42 (2005). 
•  Ambruosi A, Gelperina S, Khalansky A, Tanski S, Theisen A, Kreuter J. Influence of 
surfactants, polymer and doxorubicin loading on the anti-tumour effect of poly(butyl 
cyanoacrylate) nanoparticles in a rat glioma model. J Microencapsul. 23,582 - 92 
(2006a). 
•  Ambruosi A, Khalansky AS, Yamamoto H, Gelperina SE, Begley DJ, Kreuter J. 
Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl 
cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing 
rats. J Drug Target. 14, 97 - 105 (2006b). 
•  Araujo L, Löbenberg R, Kreuter J. Influence of the surfactant concentration on the 
body distribution of nanoparticles, J Drug Target 5, 373 - 385 (1999).  
   References 
 
   
128   
  
•  Balazs Z, Panzenboeck U, Hammer A, Sovic A, Quehenberger O, Malle E, Sattler W. 
Uptake and transport of high-density lipoprotein (HDL) and HDL-associated alpha-
tocopherol by an in vitro blood-brain barrier model, J Neurochem. 89, 939 - 950 
(2004). 
•  Barraud L, Merle P, Soma E, Lefrancois L, Guerret S, Chevallier M, Dubernet C, 
Couvreur P, Trepo C, Vitvitski L. Increase of doxorubicin sensitivity by doxorubicin-
loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J 
Hepatol.42, 736 - 743 (2005). 
•  Barth RF. Rat brain tumour models in experimental neuro-oncology: The 9L, C6, T9, 
F98, RG2 (D74), RT-2 and CNS-1 gliomas. J Neurooncology. 36, 91 - 102 (1998). 
•  Bart J, Groen HJ, Hendriks NH, van der Graaf WT, Wallburg W, de Vries EG. The 
blood-brain barrier and oncology: new insights into function and modulation. Cancer 
Treat Rev. 26, 449-62 (2000). 
•  Batrakova EV, Li S, Alakhov VY, Miller DW, Kabanov AV. Optimal structure 
requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux 
transporter activity in bovine brain microvessel endothelial cells. Pharm Res. 20, 
1581 - 90 (2003). 
•  Batrakova EV, Li S, Vinogradov SV, Alakhov VY, Miller DW, Kabanov AV.   
Mechanism of pluronic effect on P-glycoprotein efflux system in blood- brain barrier: 
contributions of energy depletion and membrane fluidization. J Pharmacol Exp Ther. 
299, 483–493 (2001). 
•  Beck PH, Kreuter J, Müller W.E.G, Schatton W. Improved Peroral Delivery of 
Avarol with Polybutylcyanoacrylate Nanoparticles, Eur J Pharm Biopharm. 40, 134 - 
137 (1994). 
•  Begely DJ. The blood-brain barrier: principles for targeting peptides and drugs to the 
central nervous system. J Pharm Pharmacol. 48, 136 – 146 (1996). 
•  Begley DJ, Bradbury MW, Kreuter J. The blood-brain barrier and drug delivery to 
the CNS. M. Dekker, New York, 205 - 223 (2000). 
•  Begley DJ. Understanding and circumventing the blood-brain barrier. Acta Paediatr 
Suppl. 92, 83 - 91(2003a).   References 
 
   
129   
  
•  Begley DJ, Brightman MW. Structural and functional aspects of the blood-brain 
barrier. Review, Prog Drug Res.61, 39 - 78 (2003b). 
•  Begely DJ. Delivery of therapeutic agents to the central nervous system: the 
problems and the possibilities, Pharmacol Ther. 104, 29 - 45 (2004). 
•  Benda P, Someda K, Messer J, Sweet WH. Morphological and immunochemical 
studies of rat glial tumours and clonal strains propagated in culture. J Neurosurg. 34, 
310 - 323 (1971). 
•  Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial 
cell proliferation and survival in vitro reveal a selective antiangiogenic window for 
various chemotherapeutic drugs. Cancer Res. 62, 6938 - 6943 (2002). 
•  Bonstelle CT, Kori SH, Rekate H. Intracarotid chemotherapy of glioblastoma after 
induced blood-brain barrier disruption. AJNR Am J Neuroradiol. 4, 810 - 2 (1983).  
•  Bootz A, Vogel V, Schubert D, Kreuter J. Comparison of scanning electron 
microscopy, dynamic light scattering and analytical ultracentrifugation for the sizing 
of poly(butyl cyanoacrylate) nanoparticles, Eur. J. Pharm. Biopharm. 57, 369 - 375 
(2004). 
•  Bootz A, Russ T, Gores F, Karas M, Kreuter J. Molecular weights of poly(butyl 
cyanoacrylate) nanoparticles determined by mass spectrometry and size exclusion 
chromatography, Eur J Pharm Biopharm. 60,391 - 9 (2005). 
•  Borchard G, Audus KL, Shi F, Kreuter J. Uptake of surfactant-coated poly(methyl 
methacrylate)-nanoparticles by bovine brain microvessel endothelial cell monolayers. 
Int J Pharm. 110, 29 - 35 (1994). 
•  Bozikir A, Saka OM. Formulation and investigation of 5-FU nanoparticles with 
factorial design-based studies. Il Farmaco. 60, 840 - 846 (2005).  
•  Brandes AA, Pasetto LM, Monfardini S. New drugs in recurrent high grade gliomas. 
Anticancer Res. 20, 1913 - 20 (2000). 
•  Brigger I, Morizet J, Aubert G, Chacun H, Terrier-Lacombe M-J, Couvreur P, Vassal 
G. Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a 
combined effect for brain tumour targeting. J Pharmacol Exp Ther. 303, 928 - 936 
(2002).    References 
 
   
130   
  
•  Brightman MW, and Reese TS. Junctions between intimately apposed cell 
membranes in the vertebrate brain. J. Cell Biol. 40, 648 - 677 (1969). 
•  Brown VI, Greene MI. Molecular and cellular mechanisms of receptor-mediated 
endocytosis. DNA Cell Biol. 10, 399 - 409 (1991). 
•  Bullock k, Blackwell K. Clinical efficacy of taxane-trastuzumab combination 
regimens for HER-2-positive metastatic breast cancer. Oncol. 13, 515 - 525 (2008). 
•  Calvo P, Gouritin B, Chacun H, Desmaele D, D’Angelo J, Noel J-P, Georgin D, 
Fattal E, Andreux JP, Couvreur P. Long-circulating PEGylated polycyanoacrylate 
nanoparticles as new drug carrier for brain delivery. Pharm Res. 18, 1157 - 1166 
(2001).  
•  Chen DB, Yang TZ, Lu WL, Zhang Q. In vitro and in vivo study of two types of 
long-circulating solid lipid nanoparticles containing paclitaxel. Chem Pharm Bull. 49, 
1444 - 1447 (2001). 
•  Chen H, Gaul F, Guo D, Maycock A.  Determination of loperamide in rat plasma and 
bovine serum albumin by LC,  J. Pharm. Biomed. Anal. 22, 555 - 561 (2000). 
•  Chen I, McDougal, Wang F, Safe S. Aryl hydrocarbonreceptor-mediated 
antiestrogenic and antitumorigenic activity of diindolylmethane. Carcinogenesis. 19, 
1631-1639 (1998). 
•  Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, 
Bertino JR. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial 
cells at blood-brain barrier sites. Proc Natl Acad Sci. 86, 695 - 8 (1989). 
•  Couvreur P, Kante B, Roland M, Guiot P, Bauduin P, Speiser P. Polycyanoacrylate 
nanocapsules as potential lysosomotropic carriers: preparation, morphological and 
sorptive properties, J. Pharm. Pharmacol. 31, 331 - 332 (1979). 
•  Couvreur P, Kante B, Grislain L, Roland M, Speiser P. Toxicity of 
polyalkylcyanoacrylate nanoparticles II: Doxorubicin-loaded nanoparticles. J Pharm 
Sci, 71, 790 - 792 (1982).  
•  Couvreur P, Grislain L, Lenaerts V, Brasseur F, Guiot P, Biernacki A. Biodegradable 
polymeric nanoparticles as drug carrier for antitumour agents. In: Polymeric 
Nanoparticles and Microspheres, Guiot P, Couvreur P (Eds), CRC Press, Boca Raton, 
27 - 93 (1986).     References 
 
   
131   
  
•  Croy J. E, Brandon T, Komives E. A. Two apolipoprotein E mimetic peptides, ApoE 
(130 - 149) and ApoE (141 - 155)2, bind to LRP1, Biochemistry. 43, 7328 - 7335 
(2004). 
•  Cucullo L, Aumayr B, Rapp E, Damir J. Drug delivery and in vitro models of the 
blood-brain barrier, Curr Opin Drug Discov Devel. 8, 89 - 99 (2005). 
•  Damascelli B, Cantu G, Mattavelli F, Tamplenizza P, Bidoli P, Leo E, Dosio F, 
Cerrotta AM, Di Tolla G, Frigerio LF, Garbagnati F, Lanocita R, Marchiano A, 
Patelli G, Spreafico C, Ticha V, Vespro V, Zunino F. Intraarterial chemotherapy with 
polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles 
(ABI-007): Phase II study of patients with squamous cell carcinoma of the head and 
neck and anal canal: preliminary evidence of clinical activity. Cancer. 92, 2592 - 
2602 (2001). 
•  Damascelli B, Patelli GL, Lanocita R, Di Tolla G, Frigerio LF, Marchiano A, 
Garbagnati F, Spreafico C, Ticha V, Gladin CR, Palazzi M, Crippa F, Oldini C, Calo 
S, Bonaccorsi A, Mattavelli F, Costa L, Mariani L, Cantu G. A novel intraarterial 
chemotherapy using paclitaxel in albumin nanoparticles to treat advanced squamous 
cell carcinoma of the tongue: preliminary findings. AJR Am J Roentgenol. 181, 253 - 
260 (2003). 
•  Davis SS, Illum L. Colloidal delivery systems. Opportunities and challenges. In 
Tomlinson, E and Davis S S Eds. Site –Specific Drug delivery, Wiley, 93 - 110 
(1986).  
•  De Angelis LM. Brain tumours. N Engl J Med. 344, 114 - 23 (2001).  
•  De Loof H, Rosseneu M, Brasseur R, Ruysschaert JM. Use of hydrophobicity 
profiles to predict receptor binding domains on apolipoprotein E and the low density 
lipoprotein apolipoprotein B-E receptor,  Proc. Natl. Acad. Sci. 83, 2295 - 2299 
(1986). 
•  Dehouck B, Fenart L, Dehouck M.P, Pierce A, Torpier G, Cecchelli R. A new 
function for the LDL receptor: Transcytosis of LDL across the blood-brain barrier, J. 
Cell Biol. 138, 877 - 889 (1997).   References 
 
   
132   
  
•  Dergunov AD. Apolipoprotein E structure and substrate and receptor-binding 
activities of triglyceride-rich human plasma lipoproteins in normo- and 
hypertriglyceridemia. Biochemistry. 69, 720 - 737(2004). 
•  Donelli MG, Zucchetti M, D’Incalci M. Do anticancer agents reach the trumor target 
in the human brain? Cancer Chemother Pharamcol. 30, 251 - 60 (1992). 
•  Dreis S, Rothweiler F, Michaelis M, Cinatl J Jr, Kreuter J, Langer K.  Preparation, 
characterisation and maintenance of drug efficacy of doxorubicin-loaded human 
serum albumin (HSA) nanoparticles. Int J Pharm. 341, 207 - 14 (2007). 
•  Duchene D, Ponchel G, Wouessidjewe D. Cyclodextrins in targeting. Application to 
nanoparticles. Adv. Drug Deliv. Rev. 36, 29 - 40 (1999). 
•  Duncan R, Dimitrijevic S, Evagorou EG. The role of polymer conjugated in the 
dignosis and treatment of cancer, STP Pharma Sci. 6, 237 - 263 (1996). 
•  Eleutherakis-Papaiakovou V, Bamias A, Dimopoulos MA. Thalidomide in cancer 
medicine, Annals of Oncology. 15, 1151 - 1160 (2004). 
•  Eriksson T , Bjoerkman S, Roth B, Hoeglund P. Intravenous Formulations of the 
Enantiomers of thalidomide: Pharmacokinetic and Initial Pharmacodynamic 
Characterization in Man.  J. Pharm. Pharmacol. 52, 807 - 817 (2000). 
•  European Pharmacopoeia. 5
th Edition, Chapter 5.4. Residual Solvents, 507 - 510 
(2005). 
•  Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, 
Graeff C, Farber L, Gschaidmeier H, Busschauer A, Fricker G. Transport of 
paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo, J Clin Invest. 
110, 1309 - 1318 (2002). 
•  Fenart L, Casanova A, Dehouck B, Duhem C, Slupek S, Cecchelli R, Betbeder D. 
Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to 
cross an in vitro model of the blood-brain barrier. J Pharmacol Exp Ther. 291, 1017 - 
22 (1999). 
•  Fetell MR, Grossman SA, Fisher JD, Erlanger B, Rowinsky, Stockel J, Piantadosi S. 
Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and 
drug interactions. New Approaches to Brain Tumour Therapy Central Nervous 
System Consortium. J.Clin.Oncol. 15, 3121 - 3128 (1997).    References 
 
   
133   
  
•  Friese A, Seiler E, Quack G, Lorenz B, Kreuter J.  Enhancement of the duration of 
the anticonvulsive activity of a novel NMDA receptor antagonist using 
poly(butylcyanoacylate) nanoparticles as a parenteral controlled release delivery 
system,  Eur. J. Pharm. Biopharm. 49, 103 - 109 (2000b). 
•  Friese A. Kleinpartikulaere Traegersysteme (Nanopartikel) als ein parenterales 
Arzneistofftransportsystem zur Verbesserung der Bioverfuegbarkeit ZNS-aktiver 
Substanzen dargestellt am Beispiel der NMDA-Rezeptor-antagoisten MRZ 2/576 und 
MRZ 2/596. PhD. Thesis, J.W.G Universitaet Frankfurt, (2000a). 
•  Fundaro A, Cavalli R, Bargoni A, Vighetto D, Zara GP, Gasco MR. Non-stealth and 
stealth solid lipid nanoparticles carrying doxorubicin: pharmacokinetics and tissue 
distribution after i.v. administration to rats. Pharm Res. 42, 337 - 343 (2000). 
•  Garber K. Improved paclitaxel formulation: hints at new chemotherapy approach. J 
Natl Cancer Inst. 96, 91 - 92 (2004). 
•  Gelperina SE, Khalansky AS, Skidan IN, Smirnova ZS, Bobruskin AI, Severin SE, 
Turowski B, Zanella FE, Kreuter J. Toxicological studies of doxorubicin bound to 
polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats 
with intracranial glioblastoma. ToxicolLetters. 126, 131 - 141 (2002). 
•  Gessner A, Olbrich C, Schroeder W, Kayser O, Muller RH. The role of plasma 
proteins in brain targeting: species dependent protein adsorption patterns on brain-
specific lipid drug conjugate (LDC) nanoparticles. Int J Pharm. 214, 87 - 91 (2001). 
•  Goossen C, Laing T.J, Plessis J, Goosen TC, Rao TB, Flynn GL. Chemical stabilities 
and biological activities of thalidomide and its N-alkyl analogs. Pharm res. 19, 1232 - 
1235 (2002). 
•  Gref R, Luck M, Quellec P, Marchand M, Dellacherie E, Harnisch S, Blunk T, 
Muller RH. 'Stealth' corona-core nanoparticles surface modified by polyethylene 
glycol (PEG): influences of the corona (PEG chain length and surface density) and of 
the core composition on phagocytic uptake and plasma protein adsorption. Colloids 
Surf B Biointerfaces. 18, 301 - 313 (2000).  
•  Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GYa, Kreuter J. 
Significant transport of doxorubicin into the brain with polysorbate 80-coated 
nanoparticles,  Pharm. Res. 16, 1564 - 1569 (1999).   References 
 
   
134   
  
•  Hamann Pr, Berger MS. Mylotarg: the first antibody-targeted chemotherapy agent. 
In: Page M (eds.) Tumour targeting in cancer therapy, Totowa: Humana Press, 239 - 
254 (2002). 
•  Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK. 
Regulation of transport pathways in tumour vessels: Role of tumour type and 
microenvironment. Proc Natl Acad Sci. 95, 4607 - 4612 (1998). 
•  Hu YP, Jarillon S, Dubernet C, Couvreur P, Robert J. On the mechanism of action of 
doxorubicin encapsulation in nanospheres for the reversal of multidrug resistance. 
Cancer Chemother Pharmacol. 37, 556 - 650 (1996). 
•  Huncharek M, Muscat J, Geschwind JF. Multi-drug versus single agent 
chemotherapy for high grade astrocytoma: results of a metaanalysis. Anticancer 
Res.18, 4693 - 7 (1998).  
•  Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, 
Ring SE, Bedikian A, Hortobagyi GN, Ellerhorst JA. Phase I and pharmacokinetic 
study of ABI-007, a Cremophor-free, protein-stabilised, nanoparticle formulation of 
paclitaxel. Clin Cancer Res. 8, 1038 - 1044 (2002). 
•  Kaaijk P, Troost D, de Boer OJ, Van Amstel P, Bakker PJ, Leenstra S, Bosch DA. 
Daunorubicin and doxorubicin but not BCNU have deleterious effects on organotypic 
multicellular spheroids of gliomas. Br J Cancer. 74, 187 - 193 (1996). 
•  Kattan J, Droz JP, Couvreur P, Marino JP, Boutan-Laroze A, Rougier P, Brault P, 
Vranckx H, Grognet JM, Morge X, Sancho-Garnier H. Phase I clinical trial and 
pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate 
nanoparticles. Invest New Drugs. 10, 191 - 199 (1992). 
•  Kim JH, Pre-purification of paclitaxel by micelle and precipitation, Process Biochem. 
39, 1567 - 1571 (2004). 
•  Kniesel U, Wolburg H. Tight junctions of the blood-brain barrier, Review. Cell Mol 
Neurobiol. 20, 57 - 76 (2000). 
•  Knott TJ, Pease PJ, Powell LM, Wallis SC, Rall Jr. SC, Innerarity TL, Blackhart B, 
Taylor WH, Marcel Y, Milnes R, Johnson D, Fuller M, Lusis AJ, McCarty BJ, 
Mahley RW, Levy-Wilson B, Scott J.  Complete protein sequence and identification 
of structural domains of human apolipoprotein B, Nature. 323, 734 - 738 (1986).   References 
 
   
135   
  
•  Ko L, Koestner A, Wechsler W. Morphological characterisation of nitrosourea-
induced glioma cell lines and clones. Acta Neuropathol. 51, 23 - 31 (1980). 
•  Kornblith PL, Walker M. Chemotherapy for malignant gliomas. J Neurosurg.68, 1 - 
17 (1988). 
•  Koziara JM, Lockman PR, Allen DD, Mumper RJ. In situ blood-brain barrier 
transport of nanoparticles. Pharm Res. 20, 1772 - 1778 (2003). 
•  Kratze F. Albumin as a drug carrier: Design of prodrugs, drug conjagtes and 
nanoparticles. J Control Release (2008). 
•  Kreuter J. Factors influencing the body distribution of polyacrylic nanoparticles. 
Drug Targ. P. Buri and A. Gumma. Amsterdam, Elvier Science Publishers BV, 
(1985). 
•  Kreuter J. Nanoparticles. Swarbrick.J, Boylan Jc (eds.) encyclopedia of 
pharmaceutical technology. 10 Marcel Dekker: New York, pp.165 (1994). 
•  Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of peptides through 
the blood-brain barrier with colloidal polymer particles (nanoparticles), Brain Res. 
674, 171 - 174 (1995). 
•  Kreuter J, Petrov VE, Kharkevich DA, Alyautdin RN. Influence of the type of 
surfactant on the analgesic effects induced by the peptide dalargin after its delivery 
across the blood-brain barrier using surfactant-coated nanoparticles. J Control 
Release. 49, 81 - 87 (1997). 
•  Kreuter J. Nanoparticulate systems for brain delivery of drugs, Adv Drug Deliv Rev. 
47, 65 - 81 (2001). 
•  Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, 
Alyautdin R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across 
the blood-brain barrier, J Drug Target. 10, 317 - 325 (2002a).  
•  Kreuter J. Transport of drugs across the blood-brain barrier by nanoparticles, Curr 
Med Chem Central Nervous Syst Agents. 2, 241 - 249 (2002b).  
•  Kreuter J. Nanoparticles as drug delivery systems, Encyclopedia of nanoscience and 
nanotechnolgy, edited by Nalawa HS., 7, 161 - 180 (2004). 
•  Kreuter J. Nanoparticulate carriers for drug delivery to the brain. In: Nanoparticles as 
Drug Carriers, Torchilin VP (Ed), Imperial College Press, London, 527 - 547 (2006).   References 
 
   
136   
  
•  Kreuter J, Gelperina S. Use of nanoparticles for cerebral cancer. Tumori. 94, 271-277 
(2008).  
•  Krieger M. Charting the fate of the “good cholesterol”: identification and 
characterisation of the high-density lipoprotein receptor SR-BI, Annu. Rev. Biochem. 
68, 523 - 558 (1999).  
•  Krishnadas A, Rubinstein I, Onyuksel H. Sterically stabilised phospholipid mixed 
micelles: in vitro evaluation as a novel carrier for water-insoluble drugs, Pharm. Res. 
20, 297 - 302 (2003). 
•  Langer K, Seegmüller E, Zimmer A, Kreuter J. Characterisation of polybutyl-
cyanoacrylate nanoparticles: I. Quantification of PBCA polymer and dextrans, Int. J. 
Pharm. 110, 21 - 27 (1994). 
•  Langer K, Balthasar S, Vogel V, Dinauer N, Von Briesen H, Schubert D. 
Optimization of the preparation process for human serum albumin (HSA) 
nanoparticles, Int. J. Pharm. 257, 169 - 180 (2003). 
•  Lehne G. P-glycoprotein as a drug target in the treatment of multidrug resistant 
cancer. Curr Drug Targets.1, 85 - 99 (2000). 
•  Liggins R.T, Hunter W. L, Burt H.M. Solid-state characterisation of paclitaxel, J. 
Pharm. Sci. 86, 1458 - 1463 (1997). 
•  Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on 
the World Health Organization Model list of Essential Medicines according to the 
biopharmaceutics classification system, EurJ Pharm Biopharm. 58, 265 - 78 (2004). 
•  Liu S. Lipoproteins as Pharmaceutical Carriers, in: Nanoparticulates as drug carriers 
editor, Vladimir P. Torchilin. 173 - 211 (2006).  
•  Lockman PR, Koziara J, Roder KE, Paulson J, Abbruscato TJ, Mumper RJ, Allen 
DD. In vivo and in vitro assessment of baseline blood-brain barrier parameters in the 
presence of novel nanoparticles. Pharm Res. 20, 705 - 13 (2003). 
•  Lucarelli M, Borelli V, Fiori A, Cucina A, Granata F, Potenza R. L, Scarpa S, 
Cavallaro A, Strom R,  The expression of native and oxidised LDL receptors in brain 
microvessels is specifically enhanced by astrocytes-derived soluble factor(s), FEBS 
Letters. 522, 19 - 23 (2002).   References 
 
   
137   
  
•  Lück M. Plasmaproteinadsorption als möglicher Schlüsselfaktor für eine kontrollierte 
Arzneistoffapplikation mit partikulären Trägern.PhD Thesis, Freie Universität Berlin, 
14 - 24, 137 - 154, (1997). 
•  Maggio WW. Rodent glioma models. In: Perez-Polo JR (eds) Methods in 
neurosciences, Vol. 30, San Diego; Paradigms of neural injury, Acdemic Press Inc. 
81 - 96 (1996). 
•  Mavroudis D, Kouroussis Ch, Kakolyris S, Agelaki S, Kalbakis K, Androulakis N, 
Souglakos J, Samonis G, Georgoulias V. Phase I study of paclitaxel (taxol) and 
pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients 
with advanced solid tumours. Oncology. 62, 216 - 22 (2002).  
•  Merck Index, 13th Edition, Loperamide, 5592 (2001). 
•  Meresse S, Delbart C, Fruchart J. C, Cecchelli R.  Low-density lipoprotein receptor 
on endothelium of brain capillaries, J. Neurochem. 53, 340 - 345 (1989). 
•  Michaelis K, Hoffmann M. M, Dreis S, Herbert E, Alyautdin R. N, Michaelis M, 
Kreuter J, Langer K. Covalent linkage of apolipoprotein E to albumin-nanoparticles 
strongly enhances drug transport into the brain, J. Pharmacol. Exp. Ther. 317, 1246 - 
1253 (2006). 
•  Misra A, Ganesh S, Shahiwala A, Shah S. Drug delivery to the central nervous 
system: a review. J Pharm Pharmaceut Sci. 6, 252 - 273 (2003). 
•  Mitra A, Lin S. Effect of surfactant on fabrication and characterisation of paclitaxel-
loaded polybutylcyanoacrylate nanoparticulate delivery systems, J. Pharm. 
Pharmacol. 55, 895 - 902 (2003). 
•  Mizushima Y, Shiokawa Y, Kashiwazaki S, Ichikawa Y, Hashimoto H, Sakuma A. A 
multicenter double-blind controlled study of lipo-PGE1 incorporated in lipid 
microspheres, in peripheral vascular disease secondary to connective tissue disorders. 
J Pheumatol. 14, 97 - 101 (1987). 
•  Moghimi SM, Hunter AC, Umrray JC. Long-ciculating and target-specific 
nanoparticles: theory to practice, Phartmacol Rev. 53, 283 - 318 (2001). 
•  Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: 
critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog 
Lipid Res. 42, 463 - 78 (2003).   References 
 
   
138   
  
•  Nelson DF, Nelson JS, Davis DR, Chang CH, Griffin TW, Pajak TF. Survival and 
prognosis of patients with astrocytoma with atypical or anaplastic features. J 
Neurooncol. 3, 99 - 103 (1985). 
•  Nerurkar MW, Burto PS, Borchardt. The use of surfactants to enhance the 
permeability of peptides through Caco-2 cells by inhibition of an apically polarised 
efflux system. Pharm Res. 13, 528 - 534 (1996). 
•  Nomura T, Inamura T, Black KL. Intracarotid infusion of bradykinin selectively 
increases blood-tumour permeability in 9L and C6 brain tumours. Brain Res. 659, 62 
- 6 (1994).  
•  Oldendorf WH, Cornford ME, Brown WJ. The large apparent work capability of the 
blood-brain barrier: a study of the mitochondrial content of capillary endothelial cells 
in brain and other tissues of the rat. Ann Neurol. 1, 409 - 17 (1977). 
•  Olivier JC, Fenart L, Chauvet R, Pariat C, Cecchelli R, Couet W. Indirect evidence 
that drug brain targeting using PS 80-coated polybutylcyanoacrylate nanoparticles is 
related to toxicity. Pharm Res. 16, 1836 - 1842 (1999). 
•  Owens DE 3rd, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of 
polymeric nanoparticles. Review, Int J Pharm. 307, 93 - 102 (2006). 
•  Panzenboeck U, Balazs Z, Sovic A, Hrzenjak A, Levak-Frank S, Wintersperger A, 
Malle E, Sattler W. ABCA1 and scavenger receptor class B, type I, are modulators of 
reverse sterol transport at an in vitro blood–brain barrier constituted of porcine brain 
capillary endothelial cells, J. Biol.Chem. 277, 42781 - 42789 (2002). 
•  Pardridge WM. Non-invasive drug delivery to the human brain using endogeneous 
blood-brain barrier systems. Pharm Sci Technolo Today. 2, 49 - 59 (1999). 
•  Peracchia MT, Vauthier C, Passirani C, Couvreur P, Labarre D. Complement 
consumption by poly(ethylene glycol) in different conformations chemically coupled 
to poly(isobutyl 2-cyanoacrylate) nanoparticles. Life Sci. 61, 749 - 761 (1997). 
•  Pereverzeva E, Treschalin I, Bodyagin D, Maksimenko O, Langer K, Dreis S, 
Asmussen B, Kreuter J, and Gelperina S. Influence of the formulation on the 
tolerance profile of nanoparticle-bound doxorubicin in healthy rats: Focus on cardio- 
and testicular toxicity. Int. J. Pharm. 337, 346 - 356 (2007).   References 
 
   
139   
  
•  Pereverzeva E, Treschalin I, Bodyagin D, Maksimenko O, Kreuter J, Gelperina S. 
Intravenous tolerance of a nanoparticle-based formulation of doxorubicin in healthy 
rats. Toxicol Letters, (2008).  
•  Peterson DL, Sheridan PJ, Brown WE. Animal models for brain tumours: historical 
perspectives and future directions. J Neurosurg. 80, 865 - 876 (1994). 
•  Petri B, Bootz A, Khalansky A, Hekmatara T, Muller R, Uhl R, Kreuter J, Gelperina 
S. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated 
poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. J Control 
Release. 117, 51 - 58 (2007). 
•  Pluen A, Boucher Y, Ramanujan S, McKee TD, Gohongi T, di Tomaso E, Brown 
EB, Izumi Y, Campbell RB, Berk DA, Jain RK. Role of tumour-host interactions in 
interstitial diffusion of macromolecules: cranial vs. subcutaneous tumours. Proc Natl 
Acad Sci. 98, 4628 - 4633 (2001). 
•  Poste GR, Kirsh R. et al. The challenge of liposome targeting in vivo. Liposome 
technology Vol III: targeted drug delivery and biological interactions. G 
Gregoriardis. Boca Rton, FL, CRC Press: 1 - 28 (1984).  
•  Ramge P, Kreuter J, Lemmer B. Circadian phase-dependent antinociceptive reaction 
in mice after intravenous injection of dalargin-loaded nanoparticles determined by the 
hot-plate test and the tail-flick test. Chronobiol Int. 17, 767 - 777 (1999). 
•  Ramge P, Unger RE, Oltrogge JB, Zenker D, Begley D, Kreuter J, von Briesen H. PS 
80-coating enhances uptake of polybutylcyanoacrylate (PBCA) nanoparticles by 
human, bovine and murine primary brain capillary endothelial cells. Eur J Neurosci. 
12, 1931 - 1940 (2000). 
•  Reese TS and Kamovsky MJ. Fine structural localization of a blood-brain barrier to 
exogenous peroxidase. J. Cell Biol. 34, 207 - 217 (1967). 
•  Regina A et al., Antitumour activity of ANG1005, a conjugate between paclitaxel 
and the new brain delivery vector Angiopep. Br J Pharmacol, (2008). 
•  Roberts HC, Roberts TP, Bollen AW, Ley S, Brasch RC, Dillon WP. Correlation of 
microvascular permeability derived from dynamic contrast-enhanced MR imaging 
with histologic grade and tumour labeling index: a study in human brain tumours. 
Acad Radiol. 8, 384 - 91 (2001).   References 
 
   
140   
  
•  Roullin VG, Deverre JR, Lemaire L, Hindre F, Venier-Julienne MC, Vienet R, 
Benoit JP. Anit-cancer drug diffusion within living rat brain tissue: An experimental 
study using [(3)H](6)-5-fluorouracil-loaded PLGA microsphere. Eur J Pharm 
Biopharm 53, 293 - 299 (2002).  
•  Sanchez de Juan B, von Briesen H, Gelperina SE, Kreuter J. Cytotoxicity of 
doxorubicin bound to poly(butyl cyanoacrylate) nanoparticles in rat glioma cell lines 
using different assays. J Drug Target 14, 614 - 622 (2006). 
•  Schaller B. Usefulness of positron emission tomography in diagnosis and treatment 
follow-up of brain tumours. Neurobiol Dis 15, 119 - 124 (2004). 
•  Schlageter KE, Molnar P, Lapin GD, Groothuis DR. Microvessel organization and 
structure in experimental brain tumours: microvessel populations with distinctive 
structural and functional properties. Microvasc Res. 58, 312 - 328 (1999). 
•  Schoch G, Seeger H, Bogousslavsky J, Tolnay M, Janzer RC, Aguzzi A, Glatzel M. 
Analysis of prion strains by PrPSc profiling in sporadic Creutzfeldt-Jakob disease. 
Plos Med. 3, e14 (2006). 
•  Schroeder U, Sabel BA. Nanoparticles, a drug carrier system to pass the blood-brain 
barrier, permit central analgesic effects of intravenous dalargin injections. Brain Res.  
710, 121 - 124 (1996). 
•  Schroeder U, Sommerfeld P, Ulrich S, Sabel BA. Nanoparticles technology for 
delivery of drugs across the blood-brain barrier, J Pharm Sci. 87, 1305 - 1307 (1998). 
•  Schuck P, Rossmanith P. Determination of the sedimentation coefficient distribution 
by least-squares boundary modeling, Biopolymers, 54, 328 - 341 (2000). 
•  Sharma US, Sharma A, Chau RI, Straubinger RM. Liposome-mediated therapy of 
intracranial brain tumours in a rat model. Pharm Res. 14, 992 - 998 (1997). 
•  Soma CE, Dubernet C, Bentolila D, Benita S, Couvreur P. Reversion of multidrug 
resistance by co-encapsulation of doxorubicin and cyclosporin A in 
polyalkylcyanoacrylate nanoparticles. Biomaterials. 21, 1 - 7 (2000). 
•  Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, Beals B, Figg 
WD, Hawkins M, Desai N. Comparative preclinical and clinical pharmacokinetics of 
a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel 
formulated in Cremophor (Taxol). Clin Cancer Res.11, 4136 - 4143 (2005).   References 
 
   
141   
  
•  Stan AC, Casares S, Radu D, Walter G.F, Brumeanu T.D. Doxorubicin-induced cell 
death in highly invasive human gliomas, Anticancer Res. 19, 941 - 950 (1999). 
•  Steiniger S, Zenker D, von Briesen H, Begley D, Kreuter J. The influence of PS 80-
coated nanoparticles on bovine brain capillary endothelial cells in vitro. Proc Int 
Symp Control Release Bioact Mater. 26, 789 - 790 (2000). 
•  Steiniger SC, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, Smirnova ZS, 
Severin SE, Uhl R, Kock M, Geiger KD, Gelperina SE. Chemotherapy of 
glioblastoma in rats using doxorubicin-loaded nanoparticles, Int. J. Cancer. 109, 759 - 
767 (2004).  
•  Stehle G, Sinn H, Wunder A, Schrenk H.H, Stewart JC, Stewart G, Hartung W, 
Maier-Borst D, Heene L. Plasma protein (albumin) catabolism by the tumour itself 
implications for tumour metabolism and the genesis of cachexia. Crti.Rev.Oncol. 26, 
77 - 100 (1997).  
•  Straubinger RM, Arnold RD, Zhou R, Mazurchuk R, Slack JE. Antivascular and 
antitumour activities of liposome-associated drugs. Anticancer Res; 24, 397 - 404 
(2004). 
•  Strickley RG. Solubilising Excipients in Oral and Injectable Formulations. Pharm. 
Res.  21(2), 201 - 230 (2004). 
•  Sun W, Xie C, Wang H, Hu Y. Specific role of PS 80 coating on the targeting of 
nanoparticles to the brain. Biomaterials. 25, 3065 - 3071 (2004).   
•  Tamai I, Tsuji A. Transport-mediated permeation of drug across the blood-brain 
barrier, J pharm Sci. 89, 1371 - 1388 (2000).  
•  Tröster SD, Müller U, Kreuter J. Modification of the body distribution of 
poly(methyl methacrylate) nanoparticles in rats by coating with surfactants, Int J 
pharm. 61,85 - 100 (1990). 
•  Tröster SD, Kreuter J. Influence of the surface properties of low contact angle 
surfactants on the body distribution of 14C-poly(methyl methacrylate) nanoparticles, 
J Microencapsulation. 9, 19 - 28 (1992).  
•  Upton R.N. Cerebral uptake of drugs in humans, Clin. Exp. Pharmacol. Physiol. 34, 
695 - 701 (2007).   References 
 
   
142   
  
•  Uriely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, Libson E, 
Muggia FM, Gabizon S. Liposomal doxorubicin: antitumour activity and unique 
toxicities during two complementary phase I studies. J Clin Oncol. 13, 1777 - 1785 
(1995). 
•  Vajkoczy P, Menger MD. Vascular microenvironment in gliomas. Cancer Treat Res. 
117, 249 - 62 (2004). 
•  Van Waarde A, Shiba K, de Jong JR, Ishiwata K, Dierckx RA, Elsinga PH. Rapid 
reduction of sigma1-receptor binding and 18F-FDG uptake in rat gliomas after in 
vivo treatment with doxorubicin. J Nucl Med. 48, 1320 - 1326 (2007). 
•  Vasile E, Simionescu M, Simionescu N.  Visualization of the binding, endocytosis, 
and transcytosis of low-density lipoprotein in the arterial endothelium in situ, J. Cell 
Biol. 96, 1677 - 1689 (1983). 
•  Vauthier C, Dubernet C, Chauvierre C, Brigger I, Couvreur P.  Drug delivery to 
resistant tumours: the potential of poly(alkyl cyanoacrylate) nanoparticles. J Control 
Release. 93, 151 - 160 (2003a). 
•  Vauthier C, Dubernet C, Fattal E, Pinto-Alphandary H, Couvreur P. 
Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. 
Adv Drug Delivery Rev. 55, 519 - 548 (2003b). 
•  Venne A, Li S, Mandeville R, Kabanov A, Alakhov V. Hypersensitizing effect of 
pluronic L61 on cytotoxic activity, transport, and subcellular distribution of 
doxorubicin in multiple drug-resistant cells. 56, 3626-9 (1996). 
•  Verdiere AC, Dubernet C, Nemati F, Soma E, Appel M, Ferte J, Bernard S, Puisieux 
F, Couvreur P. Reversion of multidrug resistance with  polyalkylcyanoacrylate 
nanoparticles: towards a mechanism of action, Br. J. Cancer. 76, 198 - 205 (1997).  
•  Vinogradov SV, Bronich TK, Kabanov AV. Nanosized cationic gels for drug 
delivery: preparation, properties and interactions with cells. Adv Drug Delivery Rev. 
54, 135 - 147 (2002).Vinogradov SV, Batrakova EV, Kabanov AV. Nanogels for 
oligonucleotide delivery to the brain. Bioconjugate Chem. 15, 50 - 60 (2004). 
•  Vogel V, Langer K, Balthasar S, Schuck P, Mächtle W, Haase W, Van den Broek 
J.A, Tziatios C, Schubert D. Characterisation of serum albumin nanoparticles by   References 
 
   
143   
  
sedimentation velocity analysis and electron microscopy, Progr. Colloid Polym. Sci. 
119, 31 - 36 (2002).  
•  von Holst H, Knochenhauer E, Blomgren H, Collins V.P, Ehn L, Lindquist M, Noren 
G, Peterson C. Uptake of adriamycin in tumour and surrounding brain tissue in 
patients with malignant gliomas, Acta Neurochir, 104, 13 - 6 (1990).  
•  Vorbrodt AW, Lossinsky AS, Dobrogowska DH, Wisniewski HM. Cellular 
mechanisms of the blood-brain barrier (BBB) opening to albumin-gold complex. 
Histol Histopathol. 8, 51 - 61 (1993). 
•  Walter KA, Tamargo RJ, Olivi A, Burger PC, Brem H. Intratumoural chemotherapy, 
Neurosurgery. 37, 1128 - 45 (1995).  
•  Weber C, Coester C, Kreuter J, Langer K.  Desolvation process and surface 
characterisation of protein nanoparticles, Int. J. Pharm. 194, 91 - 102 (2000a). 
•  Weber C, Kreuter J, Langer K. Desolvation process and surface characteristics of 
HSA-nanoparticles, Int. J. Pharm. 196, 197 - 200 (2000a). 
•  Weizsacker M, Deen DF, Rosenblum ML, Hoshino T, Gutin PH, Barker M. The 9L 
rat brain tumour: description and application of an animal model. J Neurol. 224, 183 - 
192 (1981).  
•  Widder KJ, Senyei AE, Ranney DF. Magnetically responsive microspheres and other 
carriers for the biophysical targeting of antitumour agents. In S Garattini, A Goldin, F 
Howking, IJ Kopin and RJ Schnitzer (Eds). Adv. Pharmacol. Chemother. Academic 
Press, New York. 16, 213 - 271 (1979).  
•  Woodcock DM, Jefferson S, Linsenmeyer ME, Crowther PJ, Chojnowski GM, 
Williams B, Bertoncello I. Reversal of multidrug resistance phenotype with 
Cremophor EL, a common vehicle for water-insoluble vitamins and drugs, Cancer 
Res. 50,4199 - 4230 (1990). 
•  Woodock DM, Linsenmeyer ME, Chojnowski GM, Kriegler AB, Nink V, Webster 
LD, Sawyer WH. Reversal of mutidrug reistance by surfactants, Br J Caner. 66, 62 - 
68 (1992).  
•  Xu Z et al. In vitro and in vivo evaluation of actively targetable nanoparticles for 
paclitacel delivery, Int J Pharm 288, 361 - 368 (2005).   References 
 
   
144   
  
•  Yablonovskaya L, Spryshkova NA. Morphologic and biologic characteristics of 
experimental tumours of the cerebellum in rats. Arkh Patol. 33, 50 - 53 (1970). 
•  Yokoyama M. Drug targeting with nano-sized carrier system, J Artif Organs. 8, 77 - 
84 (2005). 
•  Youssef M, Fattal E, Alonso M.J, Roblot-Treupel LSauzieres, J, Tancrede C, Omnes 
A, Couvreur P, Andremont A. Effectiveness of nanoparticle-bound ampicillin in the 
treatment of Listeria monocytogenes infection in athymic nude mice, Antimicrob. 
Agents Chemother. 32, 1204 - 1207 (1988). 
•  Zagzag D, Nomura M, Freidiander DR, Blanco CY, Gagner JP, Nomura N, 
Newcomb EW. Geldanamycin inhibits migration of glioma cells in vitro: A potential 
role for hypoxia inducible factor (HIF-lalpha) in glioma cell invasion. J Cell Physiol 
196, 394 - 402 (2003). 
•  Zara GP, Cavalli R, Bargoni A, Fundaro A, Vighetto D, Gasco MR. Intravenous 
administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid 
nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and 
distribution of doxorubicin in brain and other tissues. J Drug Target. 10, 327 - 335 
(2002). 
•  Zhou R, Mazurchuk R, Straubinger RM. Antivasculature effects of doxorubicin-
containing liposomes in an intracranial rat brain tumour model. Cancer Res. 62, 2561 
- 2566 (2002). 
•  Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative 
disorders. 57, 178 - 201 (2008). 
•  Zordan-Nudo, Linge V, Liv ZL, Geroges E. Effects of nonionic detergents on P-
glycoprotein drug binding and reversal of multidrug resistance. Cancer Res. 55, 5994 
- 6000 (1993).  
•  www.fda.gov./cder/cancer/animalframe.htm 
   Results 
 
   
145   
  
9 Curriculum Vitae 
 
 
Personal  Date of Birth: 21/09/1977 
Place of Birth : Tehran 
 
Education 
11/2004- 
Ph.D. student in Pharmaceutical Technology Department, 
University of Frankfurt, Germany 
Dissertation: Nanoparticle formulations for new cytostatic agents 
against glioblastoma 
Advisor: Prof. Dr. Jörg Kreuter 
 
09/1995-07/2000 
 
Master of Pharmacy. Faculty of Pharmacy, University of Szeged, 
Hungary  
English Curriculum  
Thesis: Active ingredients of Hypericum Perforatum and their 
variations 
Advisor: Prof. Imre Máthé D.Sc. 
 
1990-1995 Aboureihan  High  school, Tehran, Iran 
Diploma in Natural Science  
 
Research Experience  Doctoral Research:  
Institute of Pharmaceutical Technology, University of Frankfurt 
Nanosystem LTD, Moscow, Russia 
Institute of Neuropathology, Hamburg-Eppendorf-University 
Development of nanoparticles for the lipophilic  
chemotherapeutics against glioblastoma 
 
Study of active drug transport across the blood brain barrier and 
the receptor-drug interaction 
 
Immunohistochemistry study of glioblastoma in Rats 
   
   Results 
 
   
146   
  
12/2003-1/2004  Research: 
Department of Pharmaceutical Technology, University of Szeged 
Microparticle formulation of chitosan 
Adviser: Prof. Dr. Hódi Klara 
 
09/2000-03/2002  Research: 
Department of Drug and Food Control, Tehran University, Iran 
Measuring of selenium plasma concentration differences between 
age related macular degeneration patients by differential pulse 
cathodic stripping voltammetry 
Adviser: Asst. Prof. Dr. M. R. Oveisi 
 
Professional Training  Institute of Pharmaceutical Technology, University of Frankfurt 
Teaching assistant in Good Manufacturing Practices (GMP) 
12/2003-11/2004  Department of Pharmaceutical Technology, University of Szeged 
Teaching assistant in preparation of dispensary dosage form-
laboratory practice 
Parenteral dosage form-laboratory practice 
 
Working Experience 
06/2006- 
Receptura Pharmaproduktion, Frankfurt am Main 
Consultant and manager analytical quality control 
Preparation of HRT-formulations under GMP regulation 
03/2002-11/2003  Clinical pharmacy department, Pars Hospital, Tehran 
Pharmacist 
 
Membership  Hungarian Pharmacist Society (licensed) 
Iranian Pharmacist Society (licensed) 
Controlled Release Society (CRS) 
Arbeitsgemeinschaft für   
Pharmazeutische Verfahrenstechnik (APV) 
Deutsche Pharmazeutische Gesellschaft (DPHG) 
 
Certification  
03/2006-03/2007 
Frankfurt Innovation Zentrum (FIZ)- Frankfurt 
ZAFES-Curriculum on Drug Research and Development 
for Postgraduates and Graduates 
 
Extracurricular 
Activities 
1998-2000 
Member of EPSU (English Program Students Union), Szeged 
University, Hungary 
 
Language Skills  English: excellent in writing and speaking 
German: very good in writing and speaking 
Hungarian: certified by University of Szeged 
Farsi: mother tongue 
 
   Results 
 
   
147   
  
10 Patent and Publications 
Patent  LTS LOHMANN THERAPIE-SYSTEME AG, University of 
Frankfurt 
Agent enriched nanoparticles based on hydrophilic proteins, 
(WO/2007/104422) 
Publications & 
Presentations 
accepted 
 
 
Article: Efficient systemic therapy of rat glioblastoma by 
nanoparticle-bound doxorubicin is due to antiangiogenic effects 
First author, Neuropathology 
09/2008  Article: Transferrin- and transferrin-receptor-antibody-modified 
nanoparticles enable drug delivery across the blood-brain barrier 
(BBB); co-author. Eur J Pharm Biopharm. 
accepted 2008  Article: Encapsulation of water-insoluble drugs in poly(butyl 
cyanoacrylate) nanoparticles- first author, 
 Journal of Nanoscience and Nanotechnology 
03/2007  Article: Covalent attachment of Apolipoprotein A-I and 
Apolipoprotein B-100 to albumin-nanoparticles enables drug 
transport into the brain; co-author. J Controlled Release 
01/2007  Article: Chemotherapy of brain tumour using doxorubicin bound 
to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: 
Revising the role of surfactants; co-author. J Controlled Release 
06/2008  Poster: Nanoparticle-based formulation approach for the poorly 
soluble drug substances; co-author 
IC-CCPCM 2008, Moscow Russia 
04/2008  Poster: Encapsulation of diinodolylmethane (DIM) in poly(DL-
Lactide-Co-Glycolide) nanoparticles 
PBP 6
th world meeting, Barcelona, Spain 
09/2006  Poster: Development of a paclitaxel formulation based on 
poly(butyl cyanoacrylate) nanoparticles; DPHG, Nürnberg 
07/ 2006  Poster: Thalidomide bound to human serum albumin 
nanoparticles; Controlled Release Society, Vienna, Austria 
03/ 2006  Poster: Doxorubicin-loaded poly(butyl cyanoacrylate) 
nanoparticles: Influence of stabilizer and drug-to-polymer ratio 
on size, polymerization yield, and drug loading; co-author 
Poster: Chemotherapy of brain tumour using doxorubicin loaded 
in surfactant-coated poly(butyl cyanoacrylate) nanoparticles: 
Towards mechanism of action; co-author 
PBP 5
th world meeting, Geneva, Switzerland 
 
  Acknowledgment 
 
   
148   
  
Acknowledgment 
I have worked with a great number of people whose contribution in assorted ways to the 
research and the making this thesis possible and an enjoyable experience for me. It is a 
pleasure to convey my gratitude to them all in my humble acknowledgment.  
 
In the first place I would like to express my deepest gratitude to   
Professor Dr. Jörg Kreuter, for accepting me as a PhD student and also for his supervision, 
advices, and guidance whole through my work. He made the way possible and I will always 
be thankful to him.  
 
I am also thankful to Dr. Svetlana Gelperina for her supervision from the very early stage of 
this study. I also thank Dr. Alexander Khalansky for his professional work for the in vivo 
experiments. It was a pleasant time working with him.  
 
I am also indebted to Professor Dr. Jennifer Dressman for the opportunity to work in the 
Institute of Pharmaceutical Technology at Goethe University. I had a chance to join in her 
GMP laboratory team which became a precious experience for me.  
 
I am thankful to PD Dr. Klaus Langer who was abundantly helpful and offered important 
scientific support and guidance through my research.  
 
I also benefited by outstanding works from Professor Dr. Markus Glatzel and his supportive 
team, specially Dr. Christian Bernreuther at Institute of Neuropathology, University Medical 
Center Hamburg-Eppendorf. 
 
I acknowledge the financial support by the LTS Lohmann Therapie-Systeme for providing 
the financial means and laboratory facilities.  
 
I would like to thank the Goethe University Frankfurt am Main for permiting this thesis in 
the first instance, doing the necessary research work and benefiting from all the university 
facilities such as the workshops and the libraries.  
 
My sincere appreciation goes to Professor Dr. Mihály Kata and Professor Dr. Klára Pintye-
Hodi at Univeristy of Szeged in Hungary who with their support my PhD study was 
enormously facilitated. 
 
My thanks go in particular to the following people; Dr. Vitali Vogel (Institute of Biophysics, 
Goethe University), Dr. Ekarat Jantratid, Elisabeth Herbert, Sylvia Niederdorf, Birgit Johann 
(Institute of Pharmaceutical Technology, Goethe University), Dr. Shang-Ray Yang (Institute 
  Acknowledgment 
 
   
149   
  
of Inorganic and Analytical Chemistry, Goethe University), Manfred Ruppel (Botanical 
Institute, Goethe University), Dr. Alf Theisen (Zentrale Forschungseinrichtung, Klinikum 
Goethe-University), Dr.Weissenberger (Neuro Science Center, Exp. Neurochirurgie Goethe 
University) and Dr. M. Zelig (Bioscience, USA) and Dr. Irwin Jacobs (St.Louis, USA). Their 
presence and generous support was the best thing that could happen to me and my thesis. 
 
I am grateful to the all members of the Pharmaceutical Technology Institute at Goethe 
University for their support and their comradeship; especially to Karsten Ulbrich, Jörgen 
Kufleitner, Sonja Arnold, Melisander Holzer, Stefanie Wohlfart, Anja Zensi, Mathias 
Wacker, Thomas Knobloch, Karim Sempf for sharing the literature and great assistance. My 
thanks go as well to my former colleagues Dr. Hiro Yamamoto, Dr. Alessandra Ambrousi, 
Dr. Berta Sanchez de Jaun, Dr. Alexander Bootz and Dr. Sebastian Dreis who guided this 
work and helped whenever I was in need. 
 
I am grateful in every possible way to my friends Desiree Argott, Efthimia Athanasia dou, 
Isabella Béke Sandorné, Laura Rangel-Ordonez, Marion Weisser, Hedieh Arab, Dr. Hooman 
Arab, Dr. Parya Reisi-Nassab, Marziyeh Maoussavi, Dr. Rana Al Kurdi, Dr. Heidrun 
Wartlick, Emil Magyar and Sarolta Papai for their endless emotional support and being 
always there for me. 
 
I would like to express my eternal gratitude to my parent Dr. Mohammad Hossein 
Hekmatara and Manijeh Rabbani for their everlasting love and indescribable support. I am 
thankful to my sisters Dr. Anali Hekmatara and Dr. Nazli Hekmatara for their constant 
support and understanding. I thank Dr. Hamed Bateni, Marlies Wagner, Hans Wagner and 
Baran Bateni. 
 
Finally, I would like to deeply thank my soul-mate Dr. Maik Wagner for his endless love and 
constant motivation whole through this work.  